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ABSTRACT 
 Thirty percent of individuals with autism spectrum disorder (ASD) have 
recurrent spontaneous seizures (SS). The relationship between the etiology of 
ASD and epilepsy is an active area of study and one that our laboratory is 
interested in pursuing as evidence points to a shared disturbance in brain 
inhibitory systems using the neurotransmitter g-aminobutyric acid (GABA). Most 
patients suffer from temporal lobe epilepsy and although many molecular changes 
have been ascribed to its etiology, why certain individuals are at high risk and 
others are spared is unknown. Temporal lobe epilepsy can be modeled in animals 
through use of chemically induced prolonged seizures, called status epilepticus. 
After status epilepticus there is a seizure-free latent period, where ongoing 
molecular changes occur, followed weeks later by SS, a hallmark of epilepsy. Our 
laboratory has shown that major changes occur in the composition of GABA-A 
receptors (GABARs) during the latent period that impairs the function of synaptic 
		 x 
receptors in the dentate gyrus, a gatekeeper of excitation in the hippocampus. In 
my thesis research I demonstrate for the first time that specific changes in 
GABAR expression are also present during the chronic period of SS, suggesting 
that altered GABAR composition is preserved throughout the disease process. A 
major molecular feature of ASD, and one that is seen in multiple ASD models, is 
marked disruption in development of GABAergic interneurons emerging from their 
birthplace in ganglionic eminence (GE), and the altered expression of GABARs. In 
my thesis research using RNA-sequencing I identified that GE expresses almost 
all of the genes coding for GABAR subunits laying the foundation for future 
studies on the role of GABARs during development. In addition, using sequencing 
of chromatin immunoprecipitated fragments containing binding sites for Engrailed 
2, a major ASD candidate gene, I show that En2 may be a master regulator of 
multiple genes in the SFARI database; and, using mouse in utero electroporation, 
we provide the first evidence that En2 may control the fate of neurons emanating 
from GE at E12.5. Taken together, my thesis research has uncovered two major 
areas for future investigation into the overlapping fields of epilepsy and ASD. 
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CHAPTER I: INTRODUCTION 
 
A. INHIBITORY PROCESSES IN THE BRAIN 	
1. GABAA Receptors 
a. Overview of GABAA receptors 
γ-aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the 
brain. There are three types of GABA receptors (GABRs); the ionotropic GABAA 
and GABAC receptors, and the G-protein coupled GABAB receptor. The GABAA 
(GABAR) mediates the majority of fast synaptic inhibition in the brain through the 
conductance of chloride (Cl-) ions through its central pore upon GABA binding. 
Cl- ion influx hyperpolarizes the postsynaptic neuronal membrane and dampens 
neuronal excitability. The GABAR is a heteropentameric receptor composed of 
five subunits from 16 available subunits (α1-6, β1-3, γ1-3, δ, ε, Φ, and π) (J. 
Simon, Wakimoto, Fujita, Lalande, & Barnard, 2004). Receptor subunit 
composition determines the pharmacological properties of the channel including 
GABA affinity, rate of desensitization, allosteric modulation, and subcellular 
distribution (Vicini, 1991), and varies across brain regions and developmental 
stages (Laurie, Seeburg, & Wisden, 1992). GABARs are modulated by many 
therapeutic agents and drugs including benzodiazepines (BZs), barbiturates, 
steroids, anesthetics, and ethanol (Rabow, Russek, & Farb, 1995). BZs bind 
GABARs at the interface between α and γ subunits and function as positive 
		 2	
allosteric modulators by increasing GABA-mediated current (Sigel & Buhr, 1997). 
The most common receptor conformation is composed of 2α, 2β, and 1 γ or δ 
subunit (Macdonald & Olsen, 1994). α1-containing receptors typically contain a γ 
subunit, are located synaptically, are BZ-sensitive, mediate phasic inhibition, and 
desensitize rapidly. The interaction of the γ2 subunit with synaptic scaffolding 
proteins, such as gephryin, targets receptors to the synapse. α4-containing 
receptors typically contain a δ subunit, are located extrasynaptically, are BZ-
insensitive, mediate tonic inhibition, desensitize slowly, and have a higher affinity 
for GABA than α1-containing receptors. Changes in GABAR subunit composition 
have been implicated in several diseases including epilepsy and schizophrenia. 
 
b. GABARs in development 
GABA is the one of the earliest neurotransmitters detected in the central 
nervous system and functions as an excitatory neurotransmitter and trophic 
factor in embryonic and early postnatal development due to the delayed 
expression of the chloride exporter, KCC2. GABA-mediated calcium signaling 
has been shown to regulate neuronal proliferation, migration, differentiation, and 
synaptic connectivity (Kriegstein & Owens, 2001). It has also been suggested 
that defects in expression or function of GABARs may lead to under-
representation of many important neural connections (Hughes, 2007), perhaps 
coming from its regulation over stem cell proliferation independent of neural 
differentiation (Andäng et al., 2008). Given the multiple functions of GABA 
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signaling during development, it is not surprising how disruption of GABAergic 
signaling can result in widespread neuropathology, as is seen in 
neurodevelopmental disorders such as autism and epilepsy.  
 
2. GABA Interneurons  
a. Interneuron Classification 
Neurons are broadly divided into two main categories, excitatory 
projection neurons (glutamatergic pyramidal cells) and inhibitory local circuit 
neurons (GABAergic interneurons). In general, projection neurons facilitate 
information transfer across brain regions, while interneurons gate the flow of 
information. Although interneurons constitute a small population (20%) of all 
neurons in the brain, each interneuron can contact hundreds to thousands of 
excitatory pyramidal neurons, giving them incredible power to modulate neural 
activity. Interneurons have an astounding diversity, with over 20 distinct classes 
of interneuron populations in the adult cortex alone. A large interneuron diversity 
is also present in the striatum and amygdala, brain regions relevant to multiple 
psychiatric conditions (Marin, 2012). Each interneuron subtype serves a unique 
function in the neural network by differential modulation of pyramidal cell activity, 
which is dictated by their intrinsic firing properties and their ability to innervate 
different regions of the neuron (Kepecs & Fishell, 2014). Thus, neural network 
activity can be impacted in various ways depending on which class of interneuron 
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is disrupted. 
The extensive diversity of interneuron populations in the brain has 
complicated their classification. Despite extensive debate, the method of 
interneuron classification remains controversial based on overlapping 
characteristics and a lack of consensus on the necessary criteria to define a cell 
type. Currently, interneurons are classified based on cell morphology, 
connectivity patterns, gene expression, and intrinsic physiological properties (Fig. 
1). Interneurons are also classified based on their neurotransmitter content. The 
most abundant cortical interneurons are GABA-containing, and can be further 
classified based on the expression of calcium-binding proteins (parvalbumin; PV, 
calbindin; CB, and calretinin; CR) and neuropeptides (somatostatin; SST, 
vasoactive intestinal peptide; VIP, neuropeptide Y; NPY, cholecystokinin; CCK). 
A small population of interneurons contain a neurotransmitter other than GABA, 
including dopaminergic interneurons in the olfactory bulb and cholinergic 
interneurons in the striatum (Marin & Rubenstein, 2001).  
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Figure 1. Multiple Dimensions of Interneuron Diversity. Interneuron cell types 
are usually defined using a combination of criteria based on morphology, 
connectivity pattern, synaptic properties, marker expression and intrinsic firing 
properties. The highlighted connections define fast-spiking cortical basket cells. 
Adapted from (Kepecs & Fishell, 2014). 
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b. Development of Interneurons  
Glutamatergic pyramidal neurons are generated in the proliferative 
ventricular zone of the neocortex, or pallium, and migrate radially to the overlying 
developing cortical plate. Interneurons are generated in the ventricular zone of 
the ventral telencephalon, or subpallium, in a structure called the ganglionic 
eminence (GE) (S. A. Anderson, Eisenstat, Shi, & Rubenstein, 1997). The GE is 
a transitory proliferative structure present in the embryonic brain and consists of 
three main regions; the medial GE (MGE), lateral GE (LGE) and caudal GE 
(CGE). The pre-optic area (POA) of the subpallium also contributes to a small 
subset of cortical interneuron populations (Gelman et al., 2011). These 
proliferative regions are defined by both anatomical and molecular features and 
give rise to distinct interneuron subtypes that migrate tangentially to several brain 
regions including the cortex (neocortex and hippocampus), striatum, amygdala, 
and olfactory bulb (Brazel, Romanko, Rothstein, & Levison, 2003; Flames et al., 
2007; Marin & Rubenstein, 2001).  
The majority of GABAergic interneurons in the telencephalon are derived 
from the MGE and CGE, with the LGE and POA contributing minor 
subpopulations (Fig. 2). In the cortex, PV- and SST-expressing interneurons are 
derived from the MGE, and VIP-expressing interneurons originate from the CGE. 
The CGE also contributes interneuron populations to several structures of the 
limbic system including the hippocampus and amygdala (Nery, Fishell, & Corbin, 
2002). The LGE is the main source of striatal GABAergic projection neurons 
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(medium spiny neurons) and olfactory bulb interneurons, but also contributes to 
cortical interneuron populations in later stages of migration (T. Ma et al., 2012; 
Marin & Rubenstein, 2001; Olsson, Björklund, & Campbell, 1998). The majority of 
neurons in the striatum are medium spiny projection neurons (90-95%), with the 
remaining 5-10% consisting of interneurons with diverse characteristics (Olsson 
et al., 1998). Striatal interneurons originate from the MGE and are comprised of 
four major classes; cholinergic interneurons, CR-expressing GABAergic 
interneurons, PV-expressing GABAergic interneurons, and SST-, NPY-, and 
nitric oxide synthase (NOS)-expressing GABAergic interneurons (Marin, 
Anderson, & Rubenstein, 2000).  
Genetic programs established in progenitor cells play a major role in 
specifying interneuron identity and diversity through the expression of various 
transcription factors which regulate the expression of proteins that determine the 
intrinsic functional properties of an interneuron, including ion channel 
composition, migration, and integration into neural networks (Marin, 2012). While 
cortical pyramidal neuron specification is mainly determined by genetic programs 
in the precursor cells, interneuron specification and diversity is regulated by a 
combination of gene expression and local environmental cues encountered 
throughout the long migratory route from the GE (O'Leary & Borngasser, 2006).  
Both excitatory and inhibitory signals have been shown to affect 
interneuron migration and morphological maturation necessary for incorporation 
into neural networks (Bortone & Polleux, 2009; Cancedda, Fiumelli, Chen, & Poo, 
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2007). In early brain development, ambient GABA functions as a trophic factor 
working through GABARs, and has been shown to regulate tangential migration 
in the developing mouse brain (Cuzon, Yeh, Cheng, & Yeh, 2006). Migrating 
interneurons from the MGE to the cortex express functional GABARs (Cuzon 
Carlson & Yeh, 2011), suggesting that regulation of GABAR number or kind 
might play an important role in interneuron development, even in the absence of 
functional synapses.  
 
c. Interneurons and Disease 
The genetic specification of interneurons is highly relevant to 
developmental neuropsychiatric disorders. Mutations in genes involved in the 
early development of interneurons can alter the total number or location of 
interneurons, while mutation in genes necessary for later stages of interneuron 
development can affect connectivity and integration into neural networks (Marin, 
2012). Several neuropsychiatric disorders including ASD, schizophrenia, and 
epilepsy are associated with a loss of specific interneuron populations and a 
disruption in the balance of excitation and inhibition in the brain (Marin, 2012). 
Several animal models of ASD have a loss of specific interneuron populations 
(Peñagarikano et al., 2011; Sgadò et al., 2013; Tripathi et al., 2009). A loss of 
interneurons has also been observed in the prefrontal and cingulate cortex in 
schizophrenia patients (Benes, McSparren, Bird, SanGiovanni, & Vincent, 1991). 
Human epilepsy patients and animal models of temporal lobe epilepsy have a 
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loss of inhibitory interneurons in the CA1 region and dentate gyrus of the 
hippocampus (Dinocourt, Petanjek, Freund, Ben-Ari, & Esclapez, 2003; 
Kobayashi et al., 2003). However, the mechanisms underlying the loss of specific 
interneuron populations in disease is not understood. 
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Figure 2. Interneuron subtypes are generated from discrete proliferative 
regions within the subpallium. The progressive development of the 
telencephalon from an undifferentiated epithelium into discrete proliferative zones 
that produce particular interneuron populations and the specific genes involved at 
each stage. On the right are more anatomically accurate cross-sections of the 
progenitor zones from embryonic day 8 to 11, and a schematic of interneuron 
diversity in the cortex. Interestingly, although common proliferative zones 
produce the entire diversity of interneurons across all telencephalic structures, 
unique cell types and gene expression are seen in interneuron populations that 
reside in particular telencephalic structures. CCK, cholecystokinin; CR, calretinin; 
CGE, caudal ganglionic eminence; LGE, lateral ganglionic eminence; LTS, low 
threshold spike; MGE, medial ganglionic eminence; NGF, nerve growth factor; 
NOS, nitric oxide synthase; OLM, oriens/lacunosum moleculare; POA, pre-optic 
area; VIP, vasointestinal peptide. Adapted from (Kepecs & Fishell, 2014). 
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d. Developmental biology of progenitors  
 The ventricular zone (VZ) of the GE is the proliferative region lining the 
ventricle that contains the neural progenitor radial glial (RG) cells. In early brain 
development, RG cells mainly undergo proliferative, symmetric cell divisions, to 
produce two identical daughter RG cells to amplify their population. Later in 
development, RG cells increase their neurogenic, asymmetric cell divisions to 
produce one RG cell and one neuron or intermediate progenitor (IP) cell (Fig. 3). 
Neurons and IP cells subsequently detach from the ventricular surface and 
mobilize to the sub-ventricular zone (SVZ) before migrating to their final 
destination in the brain. IP cells mainly undergo symmetric, neurogenic cell 
division to produce two neurons; thus the use of IPs serves to generate more 
neurons from the same number of progenitors (Götz & Huttner, 2005). A balance 
between self-renewal and the generation of differentiated progeny is important to 
generate the proper number of neurons, and is attained through the regulation of 
asymmetric divisions (Gómez-López, Lerner, & Petritsch, 2014). A disruption in 
this balance can result in the early depletion of the progenitor pool or excessive 
growth.  
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Figure 3. Symmetric versus asymmetric division of neuroepithelial and 
radial glial cells. This figure summarizes the relationship between apical-basal 
polarity, cleavage-plane orientation and the symmetric, proliferative versus 
asymmetric, neurogenic division of neuroepithelial and radial glial cells. For the 
apical-basal polarity of the plasma membrane, please refer to the key. a. Vertical 
cleavage results in a symmetric, proliferative division. b. Horizontal cleavage 
results in an asymmetric, neurogenic division. C. Vertical cleavage results in an 
asymmetric, neurogenic division. Adapted from (Götz & Huttner, 2005).  
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Figure 4. Lineage trees of neurogenesis. The lineage trees shown provide a 
simplified view of the relationship between neuroepithelial cells (NE), radial glial 
cells (RG) and neurons (N), without (a) and with (b) basal progenitors (BP) as 
cellular intermediates in the generation of neurons. They also show the types of 
cell division involved. Adapted from (Götz & Huttner, 2005). 
 
  
		 17	
 
 
 
 
 
 
 
		 18	
B. GABAERGIC DYSFUNCTION AND DISEASE 
 
1. Autism Spectrum Disorders 
a. Overview and Significance 
Autism spectrum disorder (ASD) was first described in 1943 by Dr. Leo 
Kanner, an Austrian-American psychiatrist and physician, in his seminal 
publication “Autistic Disturbances of Affective Contact" in which he reported the 
case histories of eleven children with a set of common clinical characteristics that 
comprised a unique syndrome not previously described (Kanner, 1943). Later 
termed “early infantile autism”, the main unifying feature of these children was 
their “inability to relate themselves in the ordinary way to people and situations 
from the beginning of life” (Kanner, 1949). In addition to extreme withdrawal, 
these children also had an insistence of sameness and routines, obsessive 
spinning of objects, and severe language impairments. These children were 
frequently misdiagnosed with schizophrenia and were often placed in special 
schools for the feebleminded.  
Currently, ASD is defined in the Diagnostic and Statistical Manual of 
Mental Disorders, 5th edition (DSM-5; Am. Psychiatr. Assoc. 2013) as a 
“persistent deficit in social communication and interaction with restricted 
repetitive patterns of behavior, interests, or activities that manifest in early 
development and cannot be explained by intellectual disability”. With the 
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prevalence of ASD sharply on the rise, it is currently estimated that ASD affects 
an estimated 1 in 68 children in the United States across all racial, ethnic, and 
socioeconomic groups, and affect males approximately five times more than 
females for reasons that are currently unknown (Centers for Disease Control and 
Prevention, CDC; 2014). Symptoms typically emerge before the age of three and 
persist into adulthood with 90 percent of autistic patients requiring long term care 
throughout their lifetime (Howlin, Goode, Hutton, & Rutter, 2004). In the majority 
of ASD cases, behavioral symptoms gradually emerge within the first few years 
of life, but a substantial subset of patients (15%-47%) undergo behavioral 
regression after a period of normal development in which they lose previously 
attained language and social abilities (Stefanatos, 2008). 
Despite the dramatic increase in ASD diagnoses and awareness over the 
past few decades, there is no cure for this devastating disorder. Current 
therapies only treat the symptoms associated with ASD, which highlights the 
importance of elucidating the underlying mechanisms of this disorder in order to 
develop more effective therapeutics.  
 
b. Clinical Diagnosis 
Diagnosis of ASD has been complicated by the widely heterogeneous 
behavioral symptomology and lack of a diagnostic biomarker (G. M. Anderson, 
2014). Previously, the DSM-IV (1994) categorized several clinical subtypes under 
the larger umbrella diagnosis of pervasive development disorders (PDDs) which 
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included autistic disorder, Asperger’s Syndrome (AS), Childhood Disintegrative 
Disorder (CDD), Pervasive Developmental Disorder-Not Otherwise Specified 
(PDD-NOS), and Rett Syndrome (RS). All of these syndromes shared some core 
clinical features but had defined clinical discriminants. The attempt to 
compartmentalize the vastly heterogeneous population of PDDs into discrete 
categories proved to be unreliable and inconsistent across clinicians and 
researchers (Lord et al., 2012). To address this problem, the DSM-5 consolidated 
all existing PDD categories into a single diagnosis of Autism Spectrum Disorder 
(ASD). 
 
c. Prevalence 
The prevalence of ASD was first reported in 1976 at 1 in 2,500 children 
and has dramatically increased over the past several decades (Wing, Yeates, 
Brierley, & Gould, 1976). In the past decade alone, the prevalence has increased 
from 1 in 150 in the year 2000, to 1 in 68 in the year 2010 (1 in 42 boys, and 1 in 
189 girls) according to the most recent data from the CDC’s Autism and 
Developmental Disabilities Monitoring (ADDM) network. The increase in 
prevalence has received substantial attention and is not well understood. It 
remains controversial to whether the increase in prevalence reflects a true 
increase in ASD incidence or is due to other factors including the broadening of 
the diagnostic criteria in the DSM over time (M. King & Bearman, 2009), 
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increased awareness and reporting by both physicians and parents, or increased 
exposure to environmental toxins (Geschwind, 2009). 
 
d. Co-morbities  
ASD is associated with several co-morbidities with an estimated 95% of 
autistic children diagnosed with three or more co-morbid psychiatric or medical 
disorders (G. Joshi et al., 2010). Epilepsy is one of the most frequently 
diagnosed co-morbid conditions. 30% of autistic children suffer from epilepsy 
compared to 2% of healthy children (Tuchman & Rapin, 2002). The high 
concordance rate likely reflects a shared pathophysiological mechanism 
underlying the two disorders. An estimated 50-75% of autistic children are also 
diagnosed with intellectual disability having a nonverbal IQ score below 70 
(Kaufman, Ayub, & Vincent, 2010). ASD patients also have a higher prevalence 
of obsessive-compulsive disorder (OCD), anxiety, attention deficit hyperactivity 
disorder (ADHD), depression, sleep disorders, and gastrointestinal dysfunction 
(Zafeiriou, Ververi, & Vargiami, 2007).  
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Table 1. Diagnostic criteria for ASD defined in the DSM-5 (2013) 
Autism Spectrum Disorder (299.00) 
A. Persistent deficits in social communication and social interaction across 
multiple contexts, as manifested by the following, currently or by history 
(examples are illustrative, not exhaustive): 
1. Deficits in social-emotional reciprocity, ranging, for example, from abnormal social 
approach and failure of normal back-and-forth conversation; to reduced sharing of 
interests, emotions, or affect; to failure to initiate or respond to social interactions. 
2. Deficits in nonverbal communicative behaviors used for social interaction, ranging, for 
example, from poorly integrated verbal and nonverbal communication; to abnormalities 
in eye contact and body language or deficits in understanding and use of gestures; to a 
total lack of facial expressions and nonverbal communications. 
3. Deficits in developing, maintaining, and understand relationships, ranging, for example, 
from difficulties adjusting behavior to suit various social contexts; to difficulties in 
sharing imaginative play or in making friends; to absence of interest in peers. 
B. Restricted, repetitive patterns of behavior, interests, or activities, as 
manifested by at least two of the following, currently or by history (examples 
are illustrative, not exhaustive): 
1. Stereotyped or repetitive motor movements, use of objects, or speech (e.g., simple 
motor stereotypes, lining up toys or flipping objects, echolalia, idiosyncratic phrases). 
2. Insistence on sameness, inflexible adherence to routines, or ritualized patterns of 
verbal or nonverbal behavior (e.g., extreme distress at small changes, difficulties with 
transitions, rigid thinking patterns, greeting rituals, need to take same route or eat 
same food everyday). 
3. Highly restricted, fixated interests that are abnormal in intensity or focus (e.g., strong 
attachment to or preoccupation with unusual objects, excessively circumscribed or 
preservative interests). 
4. Hyper- or hyporeactivity to sensory input or unusual interest in sensory aspects of the 
environment (e.g., apparent indifference to pain/temperature, adverse response to 
specific sounds or textures, excessive smelling or touching of objects, visual 
fascination with lights or movement). 
C. Symptoms must be present in the early developmental period (but may not 
become fully manifest until social demands exceed limited capabilities, or 
may be masked by learned strategies in later life). 
D. Symptoms cause clinically significant impairment in social, occupational, or 
other important areas of current functioning. 
E. These disturbances are not better explained by intellectual disability 
(intellectual development disorder) or global developmental delay. 
Intellectual disability and autism spectrum disorder frequently co-occur; to 
make comorbid diagnoses of autism spectrum disorder and intellectual 
disability, social communication should be below that expected for general 
developmental level. 
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e. Etiology 
The etiology of ASD is widely heterogeneous and complex and consists of 
a strong genetic predisposition combined with environmental risk factors (Pardo 
& Eberhart, 2007). The clinical heterogeneity of ASD likely reflects the diverse 
genetic variability across patients. It has been estimated that there may be 
hundreds of etiologies responsible for ASD development (Lord & Bishop, 2015). 
 
Genetics of ASD 
ASD is currently considered the most heritable neuropsychiatric disorder 
with an estimated heritability of 90% (A Bailey Le Couteur, n.d.). Evidence 
supporting a strong genetic basis of autism is indicated by a significantly higher 
concordance rate in monozygotic twins (60-92%) than in dizygotic twins (0-10%) 
with the range in percentage varying based on the use of a narrow versus broad 
diagnostic criteria, respectively (Devlin & Scherer, 2012). Additional family 
studies reveal a child is 25 times more likely to be diagnosed with autism if they 
have a sibling with ASD (Constantino, Zhang, Frazier, Abbacchi, & Law, 2010).  
Syndromic autisms account for 10% of all ASD cases and are associated 
with known genetic disorders or chromosomal abnormalities including Fragile X 
syndrome, Rett syndrome, tuberous sclerosis, neurofibromatosis, Angelman 
syndrome, and Prader-Willi syndrome (Bailey et al., 1998). Non-syndromic 
autism accounts for the remaining 90% of ASD cases in which the etiology is 
unknown (Benvenuto, Moavero, Alessandrelli, Manzi, & Curatolo, 2009). A 
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polygenic model of ASD has been proposed implicating the number of ASD 
susceptibility genes between 5 and 15 loci (Folstein & Rosen-Sheidley, 2001). 
The occurrence of de novo chromosomal abnormalities is more frequent in 
ASD patients suggesting a causal relationship between specific chromosomal 
defects and the ASD. Chromosomal abnormalities detected in ASD include 
duplications, deletions, and translocations. Duplication of chromosome 15q11-
q13 is the most common chromosomal abnormality in ASD occurring in 1-3% of 
all ASD cases, while deletion of this region results in Angelman syndrome and 
Prader-Willi syndrome, both of which display ASD behavioral phenotypes (Losh, 
Sullivan, Trembath, & Piven, 2008). This region contains multiple GABAR subunit 
genes including GABRA5, GABRB3, and GABRG3 (Cook et al., 1998; Dykens, 
Sutcliffe, & Levitt, 2004). Deletions in chromosomal regions 2q, 7q, 13q, and 22q 
are also commonly detected in ASD patients (Lukusa, Vermeesch, Holvoet, 
Fryns, & Devriendt, 2004; Manning et al., 2004; J. B. Vincent et al., 2000). 
Copy number variants (CNVs) occur in 10-20% of all ASD cases, and is 
defined as a DNA segment that is 1 kb or larger and present at a variable copy 
number in comparison with a reference genome (Feuk, Marshall, Wintle, & 
Scherer, 2006). CNVs can alter gene dosage, coding sequences, and the 
expression of nearby genes (Lou et al., 2011). Chromosomal rearrangements are 
detected in approximately 6% of ASD cases.  
ASD susceptibility genes are often initially identified by linkage and 
association studies are further investigated with gene expression studies and 
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animal models. Linkage analysis studies identify the chromosomal locations of 
disease-associated genes based on the tendency of genes and other genetic 
markers to be inherited together based on their close proximity to one another on 
the same chromosome. Association studies test for a correlation between genetic 
variants and disease phenotype to identify disease-associated genes or genomic 
regions. Collectively, genetic studies support a heterogeneous polygenic 
inheritance of ASD with regions of every chromosome in the genome associated 
with ASD. However, the most frequently identified ASD-associated loci include 
chromosome 7q which contains the ASD candidate gene En2 and chromosome 
15q which contains multiple GABAR subunit genes (Zager, 2005).  
AutDB is a manually curated publicly available database created to 
catalogue and centralize all genetic findings associated with ASD, and is 
currently licensed to the Simons Foundation Autism Research Initiative (SFARI) 
as SFARI gene (Basu, Kollu, & Banerjee-Basu, 2009). AutDB is continuously 
updated and currently contains over 700 genes in the database associated with 
ASD.  
 
Environmental factors 
Environmental factors play a critical role in ASD susceptibility in 
combination with genetic risk factors, which is supported by a monozygotic twin 
concordance rate of less than 100% (Herbert et al., 2006). Vaccines are the most 
extensively researched and highly controversial environmental risk factor of 
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autism after a study reported an increase in the incidence of autism following 
administration of the measles, mumps and rubella (MMR) vaccine (Wakefield et 
al., 1998). The publication was later formally retracted and the authors stated “no 
causal link was established between the MMR vaccine and autism as the data 
were insufficient” (Murch et al., 2004). The initial findings were also discredited 
due to a lack of reproducibly by many studies (Fombonne & Chakrabarti, 2001; 
Fombonne, Zakarian, Bennett, Meng, & McLean-Heywood, 2006; Honda, 
Shimizu, & Rutter, 2005; Schechter & Grether, 2008).  
 Exposure to bisphenol-A (BPA), a plasticizer commonly found in food and 
beverage containers has been linked to autism. A recent study demonstrated 
children with ASD have a decreased ability to metabolize and eliminate BPA from 
the body as compared to healthy controls (Stein, Schluter, Steer, Guo, & Ming, 
2015). The authors of the study suggest their results do not prove that BPA 
causes ASD, but rather highlight their findings as an example of how an 
environmental exposure may interact with a genetic predisposition to influence 
ASD risk. BPA has been shown to have modulatory effects on GABARs, 
potentiating GABA currents at low doses, and inhibiting GABA currents at higher 
doses (Aoshima, Hossain, Imamura, & Shingai, 2001; I.-S. Choi et al., 2007). It is 
hypothesized that the actions of BPA on GABARs may disrupt neurotrophic 
GABA signaling in early brain development. 
Additional environmental risk factors proposed to increased autism risk 
include advanced paternal age, in utero exposure to valproic acid, air pollution, 
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thalidomide, alcohol, and maternal medical issues including stress, autoimmune 
disease, depression, schizophrenia, and hypothyroidism (C. R. King, 2011; Volk, 
Lurmann, Penfold, Hertz-Picciotto, & McConnell, 2013). 
 
f. Animal Models of ASD 
Given the complex heterogeneous etiology of ASD, there is no single 
animal model of autism. An animal model of autism is defined as an animal in 
which either expression of an autism-associated gene or genetic locus has been 
manipulated, or chemical/biological agents (environmental factor) linked to 
autism were administered (Kumar et al., 2011). A useful animal model of ASD 
needs to display a combination of behavioral, neuropathological, biochemical, 
and genetic similarities to the disorder (Murcia, Gulden, & Herrup, 2005). The 
En2 knockout mouse is considered “a window into autism” because of the 
striking similarities with human ASD patients based on neuroanatomical and 
behavioral deficits that are the core features of ASD (Cheh et al., 2006).  
 
g. Neurobiology of ASD 
Post-mortem analysis of the autistic brain has revealed several 
neuroanatomical defects of the cerebellum, corpus callosum, basal ganglia, and 
limbic system (Bauman & Kemper, 1985). Cerebellar hypoplasia and a decrease 
in the number of purkinje cells (PCs) is the most consistent neuropathological 
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observation in ASD (Bailey et al., 1998; Fatemi, Halt, Realmuto, et al., 2002a; 
Ritvo et al., 1986). PCs have an extensive dendritic arbor that receives over 
200,000 synaptic connections and are the sole output of the cerebellum. In 
addition to controlling motor functions, the cerebellum plays a role in learning, 
memory, and language (Desmond & Fiez, 1998). Abnormalities in limbic system 
(hippocampus, entorhinal cortex, and amygdala) have been reported including a 
decrease in cell size, increased cell packing density, and limited dendritic arbors 
of neurons, suggestive of a premature arrest in neuronal development (Bauman 
& Kemper, 1994) 
The synapse hypothesis of autism was first proposed by in 2003 after the 
discovery of neuroligin 4 mutations in in two Swedish brothers with ASD (Jamain 
et al., 2003). Neuroligins are postsynaptic cell adhesion proteins that bind to 
presynaptic neurexins to facilitate synapse formation, trigger post-synaptic 
differentiation and control the balance of excitatory and inhibitory inputs (Graf, 
Zhang, Jin, Linhoff, & Craig, 2004; Prange, Wong, Gerrow, Wang, & El-Husseini, 
2004). Subsequent studies have shown that a large number of ASD candidate 
genes play a critical role in synaptic transmission. Mutations in neurexins, 
SHANK3, and contactin-associated protein-like 2 (CNTNAP2) were identified in 
ASD patients. SHANK3 is a scaffolding protein that can bind neuroligins at 
excitatory synapses and has been shown to be a master organizer of the 
postsynaptic density (Meyer, Varoqueaux, Neeb, Oschlies, & Brose, 2004). 
Dysfunction of CNTNAP2, a member of the neurexin family, disrupts neuronal 
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dendritic and spine development resulting in disrupted synaptic transmission. 
Dendritic defects have also been reported in ASD. Decreased dendritic 
branching in the CA1 and CA4 regions of the hippocampus was observed in the 
one of the earliest neuropathological findings in the ASD brain (Raymond, 
Bauman, & Kemper, 1996). 
The impaired connectivity hypothesis of ASD proposes abnormalities in 
global information integration caused by a reduction in the connectivity between 
neural networks and an overconnectivity within isolated individual neural 
assemblies (Rippon, Brock, Brown, & Boucher, 2007). Additional studies have 
reported a decrease in the size of the corpus callosum, which facilitates 
information transfer between the cerebral hemispheres. A consistent finding in 
ASD is abnormalities in brain growth. MRI studies of autistic patients ranging 
from one to fifty years old reveal early brain and head overgrowth within the first 
three years of life followed by a decrease in brain size and neuronal loss of 
starting in adolescence and declining over time (Courchesne, 2004; Courchesne, 
Campbell, & Solso, 2011). Brain overgrowth occurs primarily in the frontal and 
anterior temporal lobes which are essential for the development of higher 
cognitive functions including social and language skills, which are impaired in 
ASD patients (Geschwind, 2009). It is hypothesized that early brain overgrowth 
disrupts the normal developmental trajectory of cortical connectivity resulting in 
underconnectivity between key areas of the brain (Courchesne & Pierce, 2005). 
Additional evidence suggests that ASD may be the result of an insult during brain 
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development in utero. Evidence of minicolumn disorganization in the cortex 
suggests the pathogenesis of ASD may occur in the first and second trimester of 
gestation (Pardo & Eberhart, 2007). 
 
h. GABA dysfunction in ASD 
Altered expression of several components of the GABAergic system have 
been documented in post-mortem brain tissue from patients diagnosed with 
autism. Significant changes in messenger RNA (mRNA) and protein levels for the 
GABA-synthesizing glutamic acid decarboxylase (GAD) enzymes GAD65 and 
GAD67 (Fatemi, Halt, Stary, et al., 2002b), GABARs (Cook et al., 1998; Fatemi 
et al., 2010; Oblak, Gibbs, & Blatt, 2011; Shao et al., 2003), and GABABRs 
(Oblak, Gibbs, & Blatt, 2010) have been reported in ASD patients compared to 
age-matched controls in multiple brain regions. Decreased GAD expression in 
the hippocampus is hypothesized to reduce GABA levels possibly contributing to 
seizure activity (Blatt et al., 2001). Inversions and duplications in the GABAR 
subunit gene cluster on chromosome 4, which contains GABRA4 (Russek, 
1999), are associated with autistic siblings (Kakinuma, Ozaki, Sato, & Takahashi, 
2008; J. B. Vincent et al., 2006). However, the most compelling evidence linking 
GABARs to ASD comes from family-based association tests and genotype-
pedigree disequilibrium tests that identified genetic linkage to single nucleotide 
polymorphisms (SNPs) in two GABAR subunit genes using 470 Caucasian 
families with autism; one SNP is located in the α4 subunit gene (GABRA4) and 
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one in the β1 subunit gene (GABRB1) (D. Q. Ma et al., 2005). The β1 SNP is 
only associated with autism in the presence of the α4 SNP, while the α4 SNP 
alone shows significant association confirmed using additional Caucasian 
families and extended to the African American population (Collins et al., 2006). 
Interestingly, our laboratory identified that the ASD associated SNPs in GABRA4 
and GABRB1 alter transcription factor binding sites for EN2, a homeobox 
transcription factor important in the developing brain, which is also an ASD 
candidate gene. 
 Chronic changes in the expression of inhibitory neurotransmitter receptors 
have already been associated with diseases of the nervous system, including 
epilepsy (Brooks-Kayal et al., 1999; Lund et al., 2008; YogendraSinh H Raol et 
al., 2006; Roberts, Hu, Lund, Brooks-Kayal, & Russek, 2006; Roberts et al., 
2005), where we have shown a relationship between increased Gabra4 and 
decreased Gabra1 upon status epilepticus (SE) using a rat model. The high 
incidence of seizure activity (especially during sleep) and of epilepsy in autistic 
patients (Rossi, Parmeggiani, Bach, Santucci, & Visconti, 1995) also suggests 
that a change in GABAR function could be an ASD contributing factor.  
 
i. Treatment 
While there is no cure for ASD, combinations of various behavioral and 
pharmacological therapies have shown to be effective at improving some 
behavioral and psychological problems experienced by ASD patients. Research 
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has shown that early behavioral intervention is key to a successful outcome. 
Medications including antipsychotics, antidepressants, benzodiazepines, and 
anticonvulsants are often prescribed as adjunctive therapy to improve the 
disabling symptoms of ASD including aggression, hyperactivity, self-injury, and 
repetitive behaviors. 
 
2. Epilepsy  
a. Overview and Significance 
Epilepsy is one of the most prevalent neurological disorders in the world 
affecting between 1-3% of the population worldwide. This disorder affects 
approximately 3 million people in the United States alone with estimated annual 
medical related costs reaching $15.5 billion dollars (Epilepsy foundation, 2015). 
Epilepsy patients suffer from the spontaneous recurrence of seizures, which is 
characterized by episodes of abnormal synchronous neuronal discharge of the 
brain (Shneker & Fountain, 2003). During seizure activity, neurons experience a 
sudden and prolonged depolarization resulting in the firing of action potentials 
and a subsequent hyperpolarization, known as a paroxysmal depolarizing shift 
(PDS). An estimated 30% of cases are the result of a genetic predisposition or a 
brain insult such as head trauma, stroke, or brain tumor (Shneker & Fountain, 
2003). However, the development of epilepsy in the remainder of epileptic 
patients is of unknown etiology.  
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b. Classification 
 Epilepsy syndromes are classified based on several factors including 
seizure type, age of onset of seizure, family history, physical examination, EEG 
testing, and neurologic imaging studies (Shneker & Fountain, 2003). Seizure type 
can be classified as a partial or generalized. Partial seizures, also known as 
localized seizures, arise from a small focal region of the brain, although activity 
can spread to involve the entire brain. Partial seizures are further categorized as 
simple or complex based on the presence or absence of cognitive deficits. 
Simple partial seizures involve a small region of brain hemisphere or lobe and do 
not result in the loss of consciousness. The types of symptoms experienced 
depend on what region of the brain is affected. Complex partial seizures involve 
a greater area of a hemisphere and often result in an alteration of consciousness. 
Temporal lobe epilepsy (TLE) is the most common complex partial epilepsy. 
 Unlike partial seizures, generalized seizures involve both cerebral 
hemispheres and appear to begin in several parts of the brain simultaneously. 
Seizures in this class include absence, myoclonic, and tonic-clonic seizures. 
Absence seizures are common in children and typically present as a blank stare 
with decreased consciousness or responsiveness. Awareness is fully restored 
after an absence seizure and a person is usually unaware that they experienced 
a seizure. Myoclonic seizures involve brief muscle contractions and commonly 
occur between wake and sleep.  Tonic-clonic seizures, or grand mal seizures, 
are the most severe type of seizure and consist of sustained periods of muscle 
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contractions followed by periods of muscle relaxation. These seizures often result 
in injury and produce a deep state of sleepiness and confusion afterwards. 
Status epilepticus (SE) is a dangerous condition requiring immediate medical 
attention and is defined as seizures lasting more than 30 minutes, or three 
consecutive seizures without intermission, and can lead to permanent brain 
damage or death if untreated. 
 
c. Temporal Lobe Epilepsy 
TLE is a complex partial epilepsy defined by the recurrence of 
spontaneous seizures originating from the temporal lobe, including the 
hippocampus, entorhinal cortex, and amygdala. While no single causative factor 
has been discovered, TLE is often the result of a brain injury or lesion. The initial 
brain insult is followed by a seizure-free latent period, which can last from months 
to years in human patients before the onset of spontaneous seizures or chronic 
epilepsy (Engel, 1993). TLE is frequently unresponsive to anticonvulsant therapy 
and is often progressive with symptoms worsening over time. Many 
neuropathological changes have been observed in the brains of TLE patients and 
animal models, including changes in cell number and neural connectivity. These 
changes are hypothesized to contribute to epileptogenesis, or the development 
of epilepsy.  
Neuronal loss in the epileptic brain has been observed in several regions 
of the hippocampus, including the dentate gyrus, CA1, and CA3 regions 
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(Bartolomei et al., 2005). Seizure-induced neurogenesis of dentate granule cells 
(DGCs) and glial cell proliferation has been reported in animal models of TLE, 
although it is unclear if this is a protective response to cell death or contributes to 
seizure activity (Hansen, Jørgensen, Bolwig, & Barry, 1990; Parent et al., 1997). 
Mossy fiber sprouting in the hippocampus has been hypothesized to contribute to 
epileptogenesis. Axons of glutamatergic DGCs, or mossy fibers, normally 
synapse onto hilar neurons of the hippocampus. Seizure activity can cause 
mossy fibers to “sprout” and aberrantly synapse onto apical dendrites of DGCs, 
resulting in an excitatory feedback loop, and potential network hyperexcitability 
(Sutula, 2002; Tauck & Nadler, 1985). 
 
d. Animal models of TLE 
Several animal models have been created to study the process of 
epileptogenesis in TLE, which use various methodologies to produce an initial 
brain insult including the chemoconvulsants kainic acid (KA) and pilocarpine 
(PILO), hyperthermia, traumatic brain injury, and electrical kindling. The 
chemoconvulsant and kindling animal models are frequently used because they 
most accurately represent the neuropathology and progression of 
epileptogenesis as it occurs in humans.  
 PILO is a M1 muscarinic acetylcholine receptor agonist and has been 
shown to increase levels of glutamate in the brain using microdialysis (Smolders 
et al., 1997). Systemic administration of PILO in rats recapitulates the main 
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features of TLE including epileptic foci in the limbic system, an initial precipitating 
injury, the presence of a seizure-free “latent period”, and hippocampal sclerosis 
and reorganization of neural networks (Curia, Longo, Biagini, Jones, & Avoli, 
2008; W. A. Turski, Czuczwar, Kleinrok, & Turski, 1983). Intraperitoneal (IP) 
PILO administration is followed by status epilepticus (SE), or a period of 
sustained seizure activity that can last for over an hour. Diazepam is usually 
administered after one hour of SE to reduce the mortality rate. The subsequent 
latent period can last anywhere from days to weeks before the development of 
recurrent spontaneous seizures, which is the main feature of chronic epilepsy. 
EEG monitoring is used to characterize and record seizure activity in epileptic 
animals. 
 
e. Catamenial Epilepsy 
Catamenial epilepsy is characterized by the exacerbation of seizures in 
females during menstruation when levels of progesterone and its metabolite 
allopregnanolone decrease (Scharfman, 2003). Allopregnanolone, a neuroactive 
steroid, is a potent positive allosteric modulator of the GABAR (Herzog & Frye, 
2003; Macdonald & Olsen, 1994). The clinical administration of progesterone or 
the synthetic allopregnanolone analog Ganaoxolone significantly decreases 
seizure frequency in women with catamenial epilepsy (Herzog, 1999; Monaghan, 
McAuley, & Data, 1999). Neuroactive steroids modulate GABARs by binding to 
sites located within the transmembrane domains of α and β subunits, which is 
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distinct from the binding sites for benzodiazepines, barbiturates, and GABA 
(Hosie, Wilkins, & Smart, 2007). Sensitivity to allopregnanolone is decreased in 
α4 (S. S. Smith et al., 1998) and δ (Zhu, Wang, Krueger, & Vicini, 1996) subunit-
containing GABRs, which are located extrasynaptically and mediate tonic 
inhibition in the brain. Thus, changes in GABAR subunit composition that occur in 
the epileptic brain can influence the response to steroid therapies. 
 
f. GABAR dysfunction in epilepsy 
Mutations and variants in multiple GABAR subunits have been associated 
with several epilepsy syndromes including the α1, β3, γ2, and δ subunits (Kang & 
Macdonald, 2009). These mutations have been shown to impair receptor function 
by several mechanisms including decreasing subunit mRNA transcription and 
stability, disrupting subunit protein folding, stability, or oligomerization, and by 
disrupting receptor trafficking (Macdonald, Kang, & Gallagher, 2010). 
 
3. Autism and Epilepsy 
Autism and epilepsy are neurological disorders frequently diagnosed in 
children and have a high co-morbidity rate. It is estimated that 30% of children 
with autism have epilepsy, and 30% of children with epilepsy have autism 
(Tuchman, Moshé, & Rapin, 2009). Although all seizure types have been 
observed in ASD patients, partial complex seizures or generalized tonic-clonic 
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seizures occur more frequently (Kang & Barnes, 2012). Children with ASD and 
epilepsy often have intellectual disability, motor impairments, and sleep 
disturbances (Tuchman, Cuccaro, & Alessandri, 2010). The high co-occurrence 
rate of these disorders suggests they may share common pathological 
mechanisms. Disruptions in GABAergic signaling is the most frequently reported 
pathology in ASD and epilepsy, including altered expression of GABARs (Kang & 
Barnes, 2012). Several studies suggest that early life seizure activity may 
increase the risk of developing ASD through changes in GABA-A, N-methyl-D-
aspartate (NMDA), and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
(AMPA) receptor expression and function, which alters synaptic plasticity and the 
balance of excitation and inhibition in the brain (Brooks-Kayal, 2010; 
YogendraSinh H Raol et al., 2006; G Zhang, Raol, Hsu, Coulter, & Brooks-Kayal, 
2004). Several genetic disorders with impairments in GABAergic signaling are 
associated with a dual diagnosis of ASD and epilepsy including Fragile-X 
syndrome, Rett syndrome, and tuberous sclerosis (Kang & Barnes, 2012). 
 
C. TRANSCRIPTION FACTORS THAT REGULATE GABRs IN AN ANIMAL 
MODEL OF TLE 
Epileptogenesis, or the process of epilepsy development, is associated 
with numerous changes in gene expression. One of the primary goals of epilepsy 
research is to identify which changes are causative in epileptogenesis, and which 
changes are compensatory, in order to identify novel therapeutic targets for the 
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treatment of epilepsy. Our laboratory has identified changes in GABAR subunit 
expression and function that occur immediately after status epilepticus, and also 
in the chronic epileptic state, as a potential contributory factor in epileptogenesis. 
Specifically, a decrease in α1 subunit and an increase in α4 subunit mRNA and 
protein expression occurs after sustained seizure activity (Brooks-Kayal et al., 
1999; Brooks-Kayal, Shumate, Jin, Rikhter, & Coulter, 1998b; Lund et al., 2008). 
Co-immunoprecipitation studies revealed an increase in α4γ2-containing 
receptors, and a decrease in α1γ2-containing receptors localized to the synapse 
24 hours after SE (Lund et al., 2008). A switch in receptor composition from 
α1βγ2 to α4βγ2, which desensitizes rapidly, may contribute to the development 
of epilepsy. Supporting this hypothesis, increasing α1 subunit levels in the DG of 
adult rats through viral delivery is protective against the development of epilepsy 
(YogendraSinh H Raol et al., 2006).  
 
1. Regulation of GABRA1 by CREB and ICER  
 Previous work in our laboratory has described BDNF-mediated regulation 
of the GABRA1 subunit through activation of the Janus kinase-signal transducer 
and activators of transcription (JAK-STAT) pathway that occurs after SE. Seizure 
activity results in massive increases in brain-derived neurotrophic factor (BDNF) 
levels, which acting at the tropomysin related kinase B (TrkB) receptor, results in 
the transphosphorylation of JAK kinases, which in turn phosphorylates tyrosine 
residues in the STAT3 protein. Activated pSTAT3 proteins dimerize and 
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translocate to the nucleus where it binds to the STAT recognition site in the 
inducible cAMP early repressor (ICER) promoter, and dramatically increases its 
transcription. ICER and phosphorylated cAMP response element binding protein 
(pCREB) heterodimerize and bind to the cyclic AMP response element (CRE) 
site in the GABRA1 promoter, decreasing its transcription. Our laboratory has 
reported prolonged increases in pCREB and ICER in the DG of the 
hippocampus, lasting from 1-48 hours after pilo-induced SE. Using ChIP and 
DNA pulldown studies, increased pCREB and ICER binding at the CRE site of 
GABRA1 subunit gene are also demonstrated after pilo-induced SE. 
Furthermore, in-vivo administration of the JAK kinase inhibitor pyridone 6 (P6) 
into the DG prior to the onset of SE blocks the induction of ICER as well as the 
decreased transcription of GABRA1 (Lund et al., 2008). 
 
2. Regulation of GABRA4 by EGR3 
Our laboratory has also described the BDNF-mediated upregulation of the 
GABRA4 subunit through activation of the protein kinase C and mitogen 
activated protein kinase (PKC-MAPK) pathway, which increases the expression 
of the transcription factor early growth response factor 3 (Egr3). We 
demonstrated increases in Egr3 protein levels, as well as increased binding of 
Egr3 to the GABRA4 promoter in the DG of the hippocampus 24 hours after 
PILO-induced SE (Roberts et al., 2005).  
		 41	
Figure 5. Differential expression of GABAR α-subunits via brain-derived 
neurotrophic factor (BDNF)-stimulated signal transduction pathways. 
Whether a GABAR has an α1- or α4-subunit in its complex may have dramatic 
effects on brain inhibition. The results of our research show that BDNF may be 
responsible for flipping the switch in α-subunit expression, with a decreased α1 
and increased α4, all in response to the activities of one signaling molecule, 
BDNF. Dramatic increases in the levels of BDNF associated with status 
epilepticus (SE) may drive distinct changes in gene expression through activation 
of at least three pathways: protein kinase C-mitogen activated protein kinase 
(PKC-MAPK); RAS-MAPK; and Janus kinase-signal transducer and activator of 
transcription (JAK-STAT). CREB = cAMP-response element binding protein; 
Egr3 = early growth response factor 3; ICER = inducible cAMP early repressor; P 
= phosphate. Evidence to support this model comes from a variety of in vitro, ex 
vivo, and in vivo studies. Adapted from (Brooks-Kayal, Raol, & Russek, 2009). 
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D. TRANSCRIPTION FACTORS THAT REGULATE BRAIN DEVELOPMENT 
1. En2 Overview 
The engrailed gene was first discovered in Drosophila in the laboratory of 
Reidar Eker in Norway in 1926 as a spontaneous mutation resulting in a notched 
thorax disrupted wing development (Eker, 2010). It was named after the French 
word “engraile” which translates to “dented by hail” (Gibert, 2002). Subsequent 
studies identified Engrailed as a developmental patterning gene expressed in the 
central nervous system (CNS) and posterior compartments of body and wing 
segments (Dinardo, Kuner, Theis, & O'Farrell, 1985; Garcia-Bellido, Ripoll, & 
Morata, 1973). Molecular analysis mapped engrailed to chromosome 2, and also 
identified a neighboring paralogue of high sequence homology termed invected 
(inv) (Coleman, Poole, Weir, Soeller, & Kornberg, 1987; Poole, Kauvar, Drees, & 
Kornberg, 1985). Engrailed and invected homologues were identified in the 
mouse and human genomes based on a high sequence homology, and were 
named Engrailed 1 (En1) and Engrailed 2 (En2) (Joyner, 1985). En1 and En2 
map to chromosomes 1 and 5 in the mouse genome, and to chromosomes 2 and 
7 in the human genome, respectively (Joyner & Martin, 1987; Logan, Willard, 
Rommens, & Joyner, 1989; Poole, Law, Kao, & Lau, 1989). En2 is a multi-
functional protein, with known roles as a transcription factor, translation factor, 
and secreted factor for axon guidance.  
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Figure 6. The functional domains within the En protein. En homology (EH) 
regions 1-5 contain a high degree of conservation at the protein level across 
species. The DNA-binding homeodomain (EH4) contains the highest level of 
conservation. The EH1 and EH5 domains mediate transcriptional repression. The 
EH2 and EH3 domains bind Pbx, a transcription factor that modifies En DNA 
binding specificity and affinity. En can also mediate translation through its 
interaction with the eukaryotic translation initiation factor 4E through a sequence 
located near the N-terminus. Adapted from (Morgan, 2006). 
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2. En2 function 
2a. Transcription factor 
Engrailed belongs to a large family of transcription factors that share a 60 
amino-acid DNA binding domain termed the homeobox. The homeobox is 
evolutionarily conserved across species, and transcription factors in this class 
regulate gene expression by binding to AT-rich DNA elements. In addition to the 
homeobox domain, these proteins contain additional regions of conservation 
termed engrailed homology (EH) domains (Logan et al., 1992) . The EH1 and 
EH5 domains mediate engrailed repressor activity through binding of the co-
repressor groucho (Jiménez, Paroush, & Ish-Horowicz, 1997; S. T. Smith & 
Jaynes, 1996). Transcriptional repression is achieved either from blocking the 
function of activators bound to nearby DNA sequences (Jaynes & O'Farrell, 
1991), or by preventing the formation of the pre-initiation complex by competing 
with transcription factor IID binding (Ohkuma, Horikoshi, Roeder, & Desplan, 
1990). Engrailed can also act as a transcriptional activator through the interaction 
with a specific set of co-factors including Pbx1 and Meis (Alexandre & Vincent, 
2003). Thus different contexts and the availability of various co-factors can 
determine the transcriptional activity of Engrailed at different target genes. The 
EH2 and EH3 domains bind the Pbx family of homeodomain transcription factors 
that modulates the DNA binding specificity and affinity of engrailed (Peltenburg & 
Murre, 1997; van Dijk & Murre, 1994). The EH4 domain, the DNA-binding 
homeodomain, also contains a conserved 11 amino-acid nuclear export signal 
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(Maizel, Bensaude, Prochiantz, & Joliot, 1999). The mammalian targets of En2 
are largely unknown. However, one study in drosophila identified target genes 
involved in axon guidance, development, cell adhesion, and signal transduction 
(Solano et al., 2003).  
 
2b. Secreted and Internalized Factor 
In addition to its functions in the nucleus as a transcription factor, 
engrailed protein is located in the cytoplasmic and membrane fractions and 
associates with caveolae-like vesicles suggesting it is released (Joliot et al., 
1997). Approximately 5% of Engrailed proteins are secreted and internalized by 
nearby cells which is dependent on the penetration sequence located in the 
homeodomain (Cosgaya, Aranda, Cruces, & Martin-Blanco, 1998; Joliot et al., 
1998). In vitro studies have shown that En2 is endocytosed by growth cones of 
retinal axons to function as a guidance factor. Once endocytosed, engrailed 
interacts with eukaryotic initiation factor 4E (eIF4E) through a sequence located 
on the N-terminus of the protein and regulates local protein translation and axon 
turning (Brunet et al., 2005; Nédélec et al., 2004).  
 
2c. Midbrain-Hindbrain Development 
In vertebrate development, Engrailed plays an essential role in patterning 
the mesencephalic region of the developing neural tube, most notably the 
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midbrain-hindbrain boundary (MHB). The isthmic organizer (IsO) of the MHB is 
formed at the interface between anterior (otx2-expressing) and posterior (gbx2-
expressing) neural tissue, and is an important source of signals required for the 
specification of the mesencephalon and rostral metencephalon, and for the 
formation and maintenance of the MHB. MHB maintenance is dependent on the 
interaction of engrailed with additional patterning genes including members of the 
Wnt and Pax families forming a complex regulatory loop (Joyner, 1996).  
 En2 promotes cell cycle exit in granule neuron precursors in the postnatal 
cerebellum (Rossman et al., 2014). However, En2 is widely expressed by all cells 
in the prenatal cerebellum, when all cells are proliferating, so it has been 
proposed that En2 has opposite effect on neurogenesis in the prenatal and 
postnatal cerebellum. 
 
3. Developmental expression patterns and functions of En2 
3a. Midbrain-Hindbrain Region (mouse studies) 
Initial studies of the developmental patterns of Engrailed were performed 
with situ hybridization analysis in lacZ knock-in mice. En2 expression is first 
detected at E8.5 (the 5-somite stage) in the region of the neural tube 
corresponding to the midbrain-hindbrain region. Several structures emerge from 
this region including the cerebellum, the dorsal midbrain colliculi, and ventral 
neurotransmitter structures including the raphe nucleus (RN) and locus coeruleus 
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(LC). Throughout development, En2 expression becomes increasingly restricted 
with adult expression limited to the granule cells of the cerebellum, pons, 
periaqueductal gray (PAG), and midbrain dopaminergic neurons (mDA) of the 
substantia nigra (SN) and ventral tegmental area (VTA) (Davis & Joyner, 1988; 
Davis, Noble-Topham, Rossant, & Joyner, 1988; Di Nardo et al., 2007). 
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Table 2. En2 expression patterns and functions in the mid/hindbrain  
Developmental Stage En2 Expression Function 
E8.0-E12.5 Midbrain-Hindbrain Junction 
A-P patterning, 
neurotransmitter 
development 
E12.5-E15.5 
Developing cerebellum, 
colliculi, ventral mid-
hindbrain nuclei including 
LC and RN, and PAG 
Retinal-tectal mapping, 
neurotransmitter 
development 
E15.5-P0 Developing cerebellum, colliculi 
Retinal-tectal mapping, 
cerebellar connectivity 
P0-P12 Differentiating granule cells of the cerebellum 
Cell cycle and 
differentiation 
Adult 
Granule cells of 
cerebellum, pons, PAG, 
mDA neurons in the SN 
and VTA 
mDA cell survival 
Adapted from (J. Choi, Millonig, Matteson, Kamdar, & Rahman, 2011)  
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En1 expression precedes En2 expression by a few hours at the 1-somite 
stage (Joyner, 1996). En1 and En2 expression largely overlap until embryonic 
day 12 (E12.0) when En1 expression begins to decrease in the developing 
midbrain and cerebellum. By adulthood, En1 is no longer expressed in the 
cerebellum but remains in the pons, PAG, SN, and VTA. In contrast to En2, En1 
is expressed outside the central nervous system in the spinal cord, vertebral 
bodies, limb buds, and tail bud (Davis & Joyner, 1988). 
 En1 and En2 expression (collectively termed En) is necessary for the 
development of mDA neurons, which is the principle source of dopamine (DA) in 
the adult brain. Continued En expression into adulthood is required for the 
survival and maintenance of mature mDA neurons (H. H. Simon, Saueressig, 
Wurst, Goulding, & O'Leary, 2001). En1/En2 double knockout mice have a 
deletion of the entire midbrain/hindbrain region and die shortly after birth. mDA 
neurons are generated, differentiate into post-mitotic tyrosine hydroxylase (TH)-
expressing neurons, and then rapidly undergo caspase 3-mediated apoptosis, 
resulting in the loss of the entire population of mDA neurons by E14 (Alberi, 
Sgadò, & Simon, 2004). Interestingly, mutations in both En1 and En2 have been 
associated with Parkinson’s Disease (PD) which is marked by the progressive 
loss mDA neurons of the substantia nigra pars compacta (SNpc) (Haubenberger 
et al., 2011; Rissling, Strauch, Höft, Oertel, & Möller, 2009).  
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3b. Forebrain Regions (mouse studies) 
Several recent studies suggest that En2 is important for the development 
of the telencephalon. Low levels of En2 expression have been reported in 
mulitple adult mouse forebrain structures relevant to ASD including the 
hippocampus, somatosensory cortex, and amygdala (Brielmaier et al., 2012; J. 
Choi et al., 2011; Tripathi et al., 2009). Furthermore, En2 knockout mice display 
an anterior shift in the lateral, basolateral, central, and medial nuclei of the 
amygdala in (Kuemerle, Zanjani, Joyner, & Herrup, 1997).  
 
3c. Human studies of En2 expression  
Studies of En2 expression in the human brain are limited. Two studies in 
human embryonic brains have reported the abundant expression of En1 and En2 
in the midbrain-hindbrain regions at 18 and 40 post-conception weeks (pcw) 
(Logan et al., 1992; Zec, Rowitch, Bitgood, & Kinney, 1997). A microarray study 
of the adult human brain by the Allan Institute for Brain Science reports high En2 
expression in brain regions implicated in ASD pathogenesis including the 
cerebellum and several forebrain and midbrain structures including the 
amygdala, basal ganglia, thalamus, and brain stem, and reports that human En2 
expression is more widespread than in the mouse brain. 
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4. En2 Genetic Analysis  
4a. ASD-associated mutations 
EN2 was first identified as an ASD susceptibility gene in 167 families 
(Gharani, Benayed, Mancuso, Brzustowicz, & Millonig, 2004) has been replicated 
in multiple pedigrees (Benayed et al., 2005; Brune et al., 2008; Sen et al., 2010; 
L. Wang et al., 2008; Yang et al., 2008; Yang, Shu, Hallmayer, & Lung, 2010). 
The A-C haplotype of two intronic SNPs (rs1861972 and rs1861973) is over-
transmitted to affected individuals, and under-represented in unaffected siblings. 
The population attributable risk (PAR) estimates the ASD-associated haplotype 
may contribute to 40% of the autistic population (Benayed et al., 2005). 
Additional studies demonstrated that these SNPs confer a gain of function 
mutation increasing the expression of En2 and alter binding sites for the 
transcription factors cut-like homeobox 1 and nuclear factor I/B (Benayed et al., 
2009; J. Choi, Ababon, Matteson, & Millonig, 2012). Studies of post-mortem 
cerebellar tissue from ASD patients reveal a significant increase in EN2 mRNA 
and protein levels when compared to controls which may be regulated by 
epigenetic factors (J. Choi et al., 2014; James, Shpyleva, Melnyk, Pavliv, & 
Pogribny, 2013). 
 
4b. En2 mouse models  
Two En2 mouse models have been generated. The traditional knockout 
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mouse has a deletion of the homeobox coding sequences of En2 (Joyner, 
Skarnes, & Rossant, 1989). The En2 knockout mouse (En2 (-/-)) is considered “a 
window into autism” because of the striking similarities with human ASD patients 
based on neuroanatomical and behavioral deficits that are the core features of 
ASD (Cheh et al., 2006). Similar to ASD patients, En2 (-/-) mice display 
cerebellar hypoplasia, with a 33% reduction in total cerebellar volume, and a 30-
40% loss of all cells in the cerebellum, including purkinje, granule, deep nuclear, 
and inferior olive cells (Kuemerle, Gulden, Cherosky, Williams, & Herrup, 2007; 
Millen, Hui, & Joyner, 1995; Millen, Wurst, Herrup, & Joyner, 1994). Interestingly, 
loss of engrailed results in learning and memory deficits, supporting the role for 
engrailed in the hippocampus (Cheh et al., 2006). Additional studies in the EN2 
knockout mouse have identified a novel role for EN2 in maintaining the 
excitatory-inhibitory balance in the brain. Engrailed is expressed in postnatal 
GABAergic neurons (Sgadò et al., 2013) and En2 (-/-) mice have a significant 
decrease in PV and SST-positive inhibitory interneurons in the CA3 pyramidal 
layer and stratum lacunosum moleculare (SLM) region of the hippocampus, and 
are subsequently more susceptible to kainic acid induced seizures (Tripathi et al., 
2009). However, the mechanism behind the loss of interneuron populations 
remains unknown. 
The second animal model is a transgenic mouse in which En2 expression 
is maintained in purkinje cells after birth when it is normally downregulated. 
Interestingly, maintained En2 expression in purkinje cells after birth results in a 
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similar cerebellar phenotype to the knockout animal including hypoplasia and a 
significant loss of purkinje cells and other cerebellar cell types, suggesting that 
the level of En2 is critical for normal development (Baader, Sanlioglu, Berrebi, 
Parker-Thornburg, & Oberdick, 1998).  
Knockout of En1 is more severe than En2 and results in a complete 
deletion of the midbrain-hindbrain region and death shortly after birth due to the 
earlier onset of En1 expression (Wurst, Auerbach, & Joyner, 1994). Knock-in of 
the En2 coding region into the En1 locus rescues the En1 knockout phenotype, 
suggesting the Engrailed proteins are functionally equivalent but differ in their 
temporal and spatial expression patterns (Hanks, Wurst, Anson-Cartwright, 
Auerbach, & Joyner, 1995). 
 
5. Engrailed and Cancer 
Homeobox transcription factors have well established roles in many 
developmental processes including cell specification, growth, differentiation, and 
proliferation (Benayed et al., 2005; Jankowski, Holst, Liebig, Oberdick, & Baader, 
2004; McGrath, Michael, Pandha, & Morgan, 2013). In the adult, En2 expression 
is restricted to the CNS. Ectopic expression of En2 outside of the CNS is 
associated with tumor development in adults, suggesting it may be involved in 
cancer pathogenesis. En2 has been implicated as a potential oncogene due to its 
ectopic expression in breast, prostate, melanoma and ovarian cancers (McGrath 
et al., 2013). Expression of En2 has been detected in several breast cancer cell 
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lines, and downregulation of En2 was shown to significantly reduce cellular 
proliferation. Ectopic overexpression of En2 in non-cancerous mammary cell 
lines increased their malignant features and caused mammary tumors when 
transplanted into mammary glands in mice (N. L. Martin, Saba-El-Leil, Sadekova, 
Meloche, & Sauvageau, 2005). En2 expression has also been detected in 
several prostate cancer cell lines, and downregulation of En2 was shown to 
decrease cellular proliferation (Bose, Bullard, & Donald, 2008). En2 expression is 
also detected in human prostate cancer tissue but not in normal prostate tissue 
(Morgan et al., 2011).  
En2 is currently being investigated for its utility as a diagnostic biomarker 
in prostate cancer due to the secretory ability of En2. Two independent studies 
detected En2 protein in the urine of approximately 70% of prostate cancer 
patients, but not in healthy controls (Morgan et al., 2011; Pandha et al., 2012). 
Taken together, this data supports a role for En2 as a possible cancer biomarker 
and a novel target of cancer therapeutics.  
 
E. Major Hypothesis and Specific Aims of Thesis 
Results of two research areas are presented in my thesis document 
reflecting my strong interest in both ASD and chronic epilepsy. The first set of 
projects are presented in Chapter 3 where we hypothesize that expression of the 
ASD candidate gene Engrailed 2 in the ganglionic eminence is critical for the 
development of neuronal populations that originate from this brain region and the 
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subsequent formation of key inhibitory neural circuitry that is disrupted in brain 
disorders. 
The specific objectives of the work presented in this chapter are: 1) To 
determine whether the homeobox factor En2 plays a role in the birth of neurons 
that originate in the GE of the developing brain; and 2) To identify genome-wide 
targets of En2 and their enrichment in gene regulatory networks relevant to 
neurodevelopment and autism. 
The second set of studies are presented in Chapter 4, which build upon 
the research of my laboratory that identified BDNF-mediated changes in GABAR 
subunit expression in the dentate gyrus of the hippocampus following status 
epilepticus, and the signal transduction cascades (PKC/MAPK, and JAK-STAT) 
that mediate these changes. The work presented in this chapter is centered 
around the hypothesis that similar changes in GABAR subunit expression occur 
after spontaneous seizures in chronic epilepsy, and are regulated by activation of 
signal transduction pathways similar to those that are activated after SE.  
The specific objectives of the work presented in this chapter are: 1) To 
investigate whether GABRA4 and GABRA1 subunit expression is altered 
following recent spontaneous seizures in chronically epileptic rats; and 2) To 
identify the signal transduction pathways activated after recent spontaneous 
seizures. 
 
 
		 58	
CHAPTER II: MATERIALS AND METHODS 
 
SECTION I: MATERIALS AND METHODS OF CHAPTER III 
A. MATERIALS 
1. Plasmids 
a. pCAX vector 
The pCAX vector directs gene expression under the CAG (cytomegalovirus 
enhancer/chicken β-actin promoter) promoter as previously described (Saffary & 
Xie, 2011) and was generously provided by Dr. Zhigang Xie (Boston University, 
Boston, MA). 
 
b. MMLV retroviral vector 
An MMLV-based retroviral vector directs eGFP gene expression under the CAG 
promoter was generously provided by Dr. Victor Borrell (Instituto de 
Neurociencias, Alicante, Spain) and originated in the laboratory of Dr. Ed 
Calloway (Salk Institute for Biological Sciences, La Jolla, CA). 
 
c. Pbx1 expression construct in pCMV6 vector 
Mouse pre-B cell leukemia transcription factor 1 (Pbx1) cDNA plasmid which 
directs Pbx1 gene expression under the CMV promoter was purchased from 
Origene (catalog number MC200105; accession number: BC002244).  
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2. Antibodies 
Primary antibodies (Abs) used in this study were as follows: rabbit anti-En2 Ab 
(Santa Cruz, SC-66877X), mouse monoclonal anti-V5 Ab (Life Technologies, 
R960-25), rabbit anti-GFP Ab (Sigma, G1544); rabbit anti-GABRA4 Ab (Novus, 
NB300-194), rabbit anti-GABRA1 Ab (Millipore, 06-868), rabbit anti-Egr3 Ab 
(Santa Cruz, SC-191X), and anti-β-actin Ab (Sigma, A2228) chicken anti-GFP Ab 
(Aves Lab, GFP-1010); and mouse anti-BIII tubulin (Covance, 801201). 
Secondary antibodies used in this study were as follows: anti-rabbit HRP-
conjugated Ab (Santa cruz), anti-mouse HRP-conjugated Ab (Vector Labs), 
Alexa Fluor® 488 anti-chicken (Life Technologies), and Alexa Fluor® 555 anti-
mouse (Jackson Labs). Normal Rabbit IgG (Santa Cruz) and normal Mouse IgG 
(Millipore) were used as negative controls for Chromatin immunoprecipitation 
(ChIP) experiments. 
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Table 3. Antibody dilution factors  
1° Antibody 2° Antibody 
Antigen Dilution factor Diluent Antigen 
Dilution 
factor 
WESTERN BLOT 
Rb-αEn2 1:1000 5% milk Goat-αRb-HRP 1:2000 
Ms-αV5 1:5000 5% milk Hs-αMs-HRP 1:2000 
Rb-αGFP 1:2000 TBS-T Goat-αRb-HRP 1:2000 
Rb-αGABRA4 1:500 2% milk Goat-αRb-HRP 1:2000 
Rb-αGABRA1 1:1000 5% milk Goat-αRb-HRP 1:2000 
Rb-αEgr3  1:1000 2% milk Goat-αRb-HRP 1:2000 
Ms-α β-actin 1:30K TBS-T Hs-αMs-HRP 1:15000 
IHC 
Ch-αGFP 1:1000  αCh-Alexafluor 488 1:200 
Ms-αBIII-tubulin 1:150   αMs-Alexafluor 555 1:200 
Rb=rabbit; Ms=mouse; Ch=chicken; Hs=horse; Gt=Goat; IHC=immunohistochemistry 
 
B. METHODS 
1. Cell Culture 
a. Human Embryonic Kidney (HEK293) cells 
HEK293 cells were maintained in Dulbecco’s Modified Eagle Medium (high 
glucose/L-glutamine) containing 0.1mM non-essential medium and 10% fetal 
bovine serum. Cells were incubated at 37°C and 5% CO2. At 80-90% confluency, 
cells were trypsinzed and centrifuged for 5 min, followed by a wash and 
trituration with HEK media. Cells were split 1:5-1:10 into 35 mm or 100 mm cell 
culture dishes (Nunc). 
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b. Primary neuronal culture 
Primary midbrain, hippocampal and neocortical neurons were dissected from 
embryonic day 18 (E18) Sprague-Dawley rats (Charles River Laboratories). 
Pregnant dams were euthanized by exposure to 95% CO2 and embryos were 
harvested. Embryonic brains were removed and placed in ice-cold Ca2+/Mg2+ free 
(CMF) media [Ca2+/Mg2+ free Hank’s BSS, 4.2 mM sodium bicarbonate, 1 mM 
pyruvate, 20 mM HEPES, 3 mg/ml BSA, pH7.25-7.3]. Relevant brain regions 
were dissected, homogenized, and centrifuged in plating media [Neurobasal 
media (Invitrogen), 10% fetal bovine serum (Gibco), 100 U/ml penicillin, 100 
µg/ml streptomycin, 200 mM glutamine]. Neurons were plated on poly-L-lysine 
(0.1 mg/mL) coated dishes, placed in an incubator (37°C/ 5% CO2) for one h, 
after which plating medium was removed and replaced with defined medium 
[Neurobasal media (Invitrogen), B27 serum-free supplement (Gibco), 100 U/ml 
penicillin, 100 µg/ml streptomycin, 200 mM glutamine]. Cultures were returned to 
the incubator for approximately 7 days until further use. 
 
2. Transient transfection of HEK293 cells 
HEK cells were plated in 35mm or 100mm dishes such that their confluency was 
approximately 60% on the day of transfection. Cells were transfected with 
Xtreme Gene HP transfection reagent (Roche). All reagents were warmed to 
room temperature before use. Xtreme Gene transfection reagent was added to 
reduced-serum Opti-MEM media. DNA was then added to the transfection 
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mixture and incubated for 15 minutes at room temperature. DNA-lipid complexes 
were then added dropwise on to the cells, gently swirled, and returned to the 
incubator (37°C/5% CO2) for 24 hrs. 
 
3. Molecular subcloning 
a. Subcloning of En2 in V5-His TOPO® vector 
The expression construct for mouse En2 (accession number: NM_010134.3) was 
generously provided by Dr. Alexandra Joyner (Memorial Sloan Kettering Cancer 
Center, New York, New York) and was previously subcloned into the pcDNA3 
vector (Life Technologies) by Sabita Bandyopadhyay (Russek laboratory). A full-
length amplicon was created by PCR for subcloning of the En2 transcript 
upstream of a V5-His fusion gene (pcDNA3.1/V5-His TOPO® vector, Life 
Technologies). The forward primer was designed to add a Kozak sequence 
(ACC) before the start codon. The reverse primer was designed to mutate the 
stop codon by introducing a nucleotide substitution from TAG (stop codon) to 
GAG (Glutamic Acid). Primer sequences are reported in Table 4. Care was taken 
to ensure that the tag was cloned in frame. Successful cloning was validated with 
direct sequencing and Western blot analysis.  
 
Table 4. En2 V5-His TOPO® vector subcloning primers and their sequences  
Primers Sequence 
En2-V5 sense 5’- ACC ATG GAG GAG AAG GAT TCC AAG -3’ 
En2-V5 antisense 5’- CTC CTC GCT GTC CGA CTT GCC -3’ 
Red letters indicate mutated nucleotides, underlined letter indicate added sequences 
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b. Subcloning of shRNAs into the pSilencer™ vector 
The pSilencer™ siRNA expression vector system was used to express hairpin 
siRNA (shRNA) under control of the human U6 RNA polymerase III promoter 
(Life Technologies). Multiple sets of En2 and GABRA4 shRNAs were designed 
using the siRNA design tool from Ambion and blasted against the mouse 
genome to ensure target specificity. shRNAs were designed to contain a 19-mer 
or 29-mer sequence targeting the coding region of mouse En2 or GABRA4 
mRNA and a common hairpin loop sequence (TTCAAGAGA). Constructs 
containing shRNAs were generated by inserting annealed oligonucleotides 
(oligos) into the pSilencer 2.0-U6 vector using BamH1 and HindIII restriction sites 
and screened for knockdown efficiency in HEK293 cells. The pSilencer vector 
expressing a random sequence (RS) shRNA, which has limited homology to any 
known sequence in the mouse genome, served as a negative control and was 
provided with the kit for the pSilencer siRNA expression vector system. The oligo 
sequences and targeting regions are reported in Table 5. The most effective 
shRNAs in vitro were subsequently tested in vivo using in utero electroporation.  
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Table 5. shRNA oligonucleotides and targeting sequence  
Name Sequence 
En2 shRNA #1 
sense 
5’- GAT CCG GAG GTT CCA AGA CGC TAT TTC AAG AGA 
ATA GCG TCT TGG AAC CTC CTT TTT TGG AAA -3’ 
En2 shRNA #1 
antisense 
5’- AGC TTT TCC AAA AAA GGA GGT TCC AAG ACG CTA  
TTC TCT TGA AAT AGC GTC TTG GAA CCT CCG -3’ 
En2 shRNA #1 
targeting sequence 5’- GGA GGT TCC AAG ACG CTA T -3’ 
En2 shRNA #2 
sense 
5’- GAT CCG ACG CTA TCA CTT CAC GGT TTC AAG AGA 
ACC GTG AAG TGA TAG CGT CTT TTT TGG AAA -3’ 
En2 shRNA #2 
antisense 
5’- AGC TTT TCC AAA AAA GAC GCT ATC ACT TCA CGG 
TTC TCT TGA AAC CGT GAA GTG ATA GCG TCG -3’ 
En2 shRNA #2 
targeting sequence 5’- GAC GCT ATC ACT TCA CGG T -3’ 
En2 shRNA #3 
sense 
5’- GAT CCG CCA AAG AAG AAG AAC CCT ATT CAA GAG 
ATA GGG TTC TTC TTC TTT GGT TTT TTG GAA A -3’ 
En2 shRNA #3 
antisense 
5’- AGC TTT TCC AAA AAA CCA AAG AAG AAG AAC CCT  
ATC TCT TGA ATA GGG TTC TTC TTC TTT GGC G -3’ 
En2 shRNA #3 
targeting sequence 5’- CCA AAG AAG AAG AAC CCT A -3’ 
En2 shRNA #4 
sense 
5’- GAT CCA GAA GAA GAA CCC TAA CAA TTC AAG AGA 
TTG TTA GGG TTC TTC TTC TTT TTT TGG AAA -3’ 
En2 shRNA #4 
antisense 
5’- AGC TTT TCC AAA AAA AGA AGA AGA ACC CTA ACA  
ATC TCT TGA ATT GTT AGG GTT CTT CTT CTG -3’ 
En2 shRNA #4 
targeting sequence 5’- AGA AGA AGA ACC CTA ACA A -3’ 
En2 shRNA #5 
sense 
5’- GAT CCG AAG AAC CCT AAC AAA GAG TTC AAG AGA 
CTC TTT GTT AGG GTT CTT CTT TTT TGG AAA -3’ 
En2 shRNA #5 
antisense 
5’- AGC TTT TCC AAA AAA GAA GAA CCC TAA CAA AGA  
GTC TCT TGA ACT CTT TGT TAG GGT TCT TCG -3’ 
En2 shRNA #5 
targeting sequence 5’- GAA GAA CCC TAA CAA AGA G-3’ 
En2 shRNA #6 
sense 
5’- GAT CCG AAC CCT AAC AAA GAG GAC TTC AAG AGA 
GTC CTC TTT GTT AGG GTT CTT TTT TGG AAA -3’ 
En2 shRNA #6 
antisense 
5’- AGC TTT TCC AAA AAA GAA CCC TAA CAA AGA GGA  
CTC TCT TGA AGT CCT CTT TGT TAG GGT TCG -3’ 
En2 shRNA #6 
targeting sequence 5’- GAA CCC TAA CAA AGA GGA C -3’ 
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En2 shRNA #7 
sense 
5’- GAT CCG CCC TAA CAA AGA GGA CAA GTT CAA GAG 
ACT TGT CCT CTT TGT TAG GGT TTT TTG GAA A -3’ 
En2 shRNA #7 
antisense 
5’- AGC TTT TCC AAA AAA CCC TAA CAA AGA GGA CAA  
GTC TCT TGA ACT TGT CCT CTT TGT TAG GGC G -3’ 
En2 shRNA #7 
targeting sequence 5’- CCC TAA CAA AGA GGA CAA G -3’ 
En2 shRNA #8 
sense 
5’- GAT CCG GCT GAG TTT CAG ACC AAC TTC AAG AGA 
GTT GGT CTG AAA CTC AGC CTT TTT TGG AAA -3’ 
En2 shRNA #8 
antisense 
5’- AGC TTT TCC AAA AAA GGC TGA GTT TCA GAC CAA  
CTC TCT TGA AGT TGG TCT GAA ACT CAG CCG -3’ 
En2 shRNA #8 
targeting sequence 5’- GGC TGA GTT TCA GAC CAA C -3’ 
En2 shRNA #9 
sense 
5’- GAT CCG CGA GTC TCA GAT CAA GAT TCT CAA GAG  
AAA TCT TGA TCT GAG ACT CGT TTT TTG GAA A -3’ 
En2 shRNA #9 
antisense 
5’- AGC TTT TCC AAA AAA CGA GTC TCA GAT CAA GAT  
TTC TCT TGA GAA TCT TGA TCT GAG ACT CGC G -3’ 
En2 shRNA #9 
targeting sequence 5’- CGA GTC TCA GAT CAA GAT T -3’ 
En2 shRNA #10 
sense 
5’- GAT CCG TCA AGA AAG CCA CGG GCA ATT CAA GAG 
ATT GCC CGT GGC TTT CTT GAT TTT TTG GAA A -3’ 
En2 shRNA #10 
antisense 
5’- AGC TTT TCC AAA AAA TCA AGA AAG CCA CGG GCA  
ATC TCT TGA ATT GCC CGT GGC TTT CTT GAC G -3’ 
En2 shRNA #10 
targeting sequence 5’- TCA AGA AAG CCA CGG GCA A -3’ 
GABRA4 shRNA #1 
sense  
5’- GAT CCT TGG AAT AAC CAC AGT CCT CAC  
GAT GAC CTT CAA GAG AGG TCA TCG TGA GGA CTG 
TGG TTA TTC CAA TTT TTT GGA AA -3’ 
GABRA4 shRNA #1 
antisense 
5’- AGC TTT TCC AAA AAA TTG GAA TAA CCA 
 CAG TCC TCA CGA TGA CCT CTC TTG AAG GTC ATC 
GTG AGG ACT GTG GTT ATT CCA AG -3’ 
GABRA4 shRNA #1 
targeting sequence 5’- TTG GAA TAA CCA CAG TCC TCA CGA TGA CC -3’ 
GABRA4 shRNA #2 
sense  
5’- GAT CCT ACA CAA TGA GAC TCA CCA TAA 
 GTG CGG ATT CAA GAG ATC CGC ACT TAT GGT GAG 
TCT CAT TGT GTA TTT TTT GGA AA -3’ 
GABRA4 shRNA #2 
antisense 
5’- AGC TTT TCC AAA AAA TAC ACA ATG AGA  
CTC ACC ATA AGT GCG GAT CTC TTG AAT CCG CAC TTA 
TGG TGA GTC TCA TTG TGT AG -3’ 
GABRA4 shRNA #2 
targeting sequence 5’- TAC ACA ATG AGA CTC ACC ATA AGT GCG GA -3’ 
GABRA4 shRNA #3 
sense  
5’- GAT CCT GCT GCT GTC AAC TAT TTC TTC AAG AGA 
GAA ATA GTT GAC AGC AGC ATT TTT TGG AAA -3’ 
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GABRA4 shRNA #3 
antisense 
5’- AGC TTT TCC AAA AAA TGC TGC TGT CAA CTA TTT  
CTC TCT TGA AGA AAT AGT TGA CAG CAG CAG -3’ 
GABRA4 shRNA #3 
targeting sequence 5’- TGC TGC TGT CAA CTA TTT C -3’ 
GABRA4 shRNA #4 
sense  
5’- GAT CCT GCT CGT ATT CTC TTT CCA TTC AAG AGA 
TGG AAA GAG AAT ACG AGC ATT TTT TGG AAA -3’ 
GABRA4 shRNA #4 
antisense 
5’- AGC TTT TCC AAA AAA TGC TCG TAT TCT CTT TCC  
ATC TCT TGA ATG GAA AGA GAA TAC GAG CAG -3’ 
GABRA4 shRNA #4 
targeting sequence 5’- TGC TCG TAT TCT CTT TCC A -3’ 
RS shRNA targeting 
region 5’-ACT ACC GTT GTT ATA GGT G-3’ 
 
 
c. Subcloning of shRNAs into MMLV retroviral vectors 
PCR primers were designed to amplify a product containing the U6 promoter and 
shRNA sequence from the pSilencer shRNA vectors generated previously. BstEII 
restriction enzyme sequences were added to the sense and antisense primers as 
reported in Table 6. The product was subcloned into the BstEII restriction site of 
the MMLV vector upstream of the CAG promoter driving expression GFP. Two 
constructs were generated to co-express either RS shRNA (control) or En2-
specific shRNA and GFP. The same reverse primer was used to generate both 
constructs. Western blot analysis confirmed expression of both GFP protein and 
shRNA as evidenced by En2 protein knockdown.  
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Table 6. MMLV retroviral vector subcloning primers and their sequences  
Primers Sequence 
En2 shRNA sense (BstEII) 5'-AGC TCG GGT CAC CAA GCT TTT CCA AAA AAG GAG G-3' 
RS shRNA sense (BstEII) 5'-AGC TCG GGT CAC CAA GCT TTT CCA AAA AAC TAC C-3' 
shRNA antisense (BstEII) 5'-CTA GTA GGT GAC CAA GGT CGG GCA GGA AGA GGG-3' 
Red letters indicate BstEII sequences 
 
d. Subcloning of shRNA-resistant En2 into the pCAX vector 
An shRNA-resistant En2 cDNA was created by introducing 4 silent mutations into 
the shRNA target region of En2 cDNA using the overlapping PCR-mutagenesis 
method as described previously (Heckman & Pease, 2007). Mutagenic primers 
(B and C) and flanking primers (A and D) were designed to generate 
intermediate PCR products that contain overlapping fragments. Intermediate 
products were denatured and used as template DNA for a second PCR reaction 
in which strands of each product hybridize at their overlapping, complementary 
regions that contain the desired mutations. Amplification of the final product in 
the second PCR was achieved using primers A and D. The final PCR product 
containing 4 silent mutations in the En2 shRNA target region was then 
directionally subcloned into the pCAX expression vector through the addition of 
EcoRI and BamHI restriction sites on the flanking primers. Primer sequences are 
reported in Table 7. shRNA resistance was validated in transfected HEK293 cells 
with Western blot analysis. Nucleotide and protein sequences of WT En2 and 
shRNA-resistant En2 are reported in Table 8. 
		 68	
Table 7. shRNA-resistant En2 subcloning primers and their sequences  
Primers Sequence 
Flanking primer A (EcoRI) 5’- GGT ACG AAT TCA CCA TGG AGG AGA AGG ATT CCA AG -3’ 
Mutagenic primer B 5’- AAG TGA AAG CGT TTT GGT TCC ACC CTC TCC GTC GAC CGC -3’ 
Mutagenic primer C 5’- GAG GGT GGT TCC AAA ACG CTT TCA CTT CAC GGT GGT -3’ 
Flanking primer D (BamHI) 5’- AGC GGA TCC CTA CTC GCT GTC CGA CTT G -3’ 
Red letters indicate mutated nucleotides 
 
Table 8. Nucleotide/protein sequences of WT En2 and shRNA-resistant En2 
Genotype Sequence 
wild-type (WT) En2  GAA GGA GGT TCC  AAG  ACG CTA TCA  
           Glu - Gly - Gln - Ser - Lys - Thr – Leu - Ser  
shRNA-resistant En2  GAG GGT GGT TCC  AAA  ACG CTT TCA 
           Glu - Gly - Gln - Ser - Lys - Thr – Leu - Ser 
Red letters indicate mutated nucleotides 
 
e. Subcloning of GABRA4 into the pCAX vector  
The expression construct for rat GABRA4 (accession number: NM_080587.3) 
was previously subcloned into the pcDNA3 vector (Life Technologies) by Sabita 
Bandyopadhyay in our laboratory. A full-length amplicon was generated to add 
EcoRI and BamHI restriction sites for directional cloning into the pCAX vector. 
Primers are reported in Table 9. Successful cloning and protein expression was 
validated in transfected HEK293 cells with Western blot analysis.  
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Table 9. GABRA4 subcloning primers and their sequences 
Primers Sequence 
GABRA4 sense (EcoRI) 5’- GGT ACG AAT TCA CCA TGG TTT CTG TCC AGA AGG-3’ 
GABRA4 antisense (BamHI) 5’- AGC GGA TCC TTA CAT TAG ACT TTC TGA TTT CTC C -3’ 
Red letters indicate added restriction enzyme sequences 
 
f. Subcloning of Pbx1 
Mouse Pbx1 cDNA expression construct in the pCMV6 vector was purchased 
from Origene (catalog number: MC200105; accession number: BC002244). A 
100-bp fragment missing from the 5’ end of the gene was added by amplification 
of this fragment from total mouse brain cDNA using PCR. Kpn1 and Nhe1 
restriction enzyme sequences were added to the primers to facilitate directional 
subcloning into the construct as reported in Table 10. Expression of full-length 
Pbx1 was confirmed with direct sequencing and Western blot analysis.  
 
Table 10. Pbx1 subcloning primers and their sequences 
Primers Sequence 
Pbx1 sense (Kpn1) 5’-GGG GTA CCA CCA TGG ACG AGC AGC  CGA G -3’ 
Pbx1 antisense (Nhe1) 5’ CTA GCT AGC AGC ATG TTG TCC AGT CGC ATG-3’ 
Red letters indicate added restriction enzyme sequences 
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4. Protein Extraction 
Cells were washed once with ice-cold PBS (pH 7.4) supplemented with 1X 
protease inhibitor cocktail (Roche) and 1X phosphatase inhibitor cocktail 
(Roche), 1mM Na3VO4, 1mM NaF, Cells were scraped and collected in cold 1X 
PBS/EDTA and spun down at 1,500 x RPM for 5 min at 4°C. Supernatant was 
discarded and the cell pellet was resuspended with an appropriate volume of 
RIPA lysis buffer (1X RIPA buffer (Millipore), 1X protease inhibitor cocktail 
(Roche), 1X phosphatase inhibitor cocktail (Roche), 1mM NaF, 1mM 
Phenylmethyl-sulfonyl fluoride (PMSF) and 1mM Na3VO4. Cells were vortexed 
and incubated for 10 min on ice. Cell lysates were centrifuged at maximum 
speed at 4°C for 10 min and the supernatant was collected. Protein sample 
concentrations were determined with the Bradford assay (Bio-Rad Laboratories) 
and stored at -80°C.  
 
5. Western Blot Analysis 
Protein extracts were resolved on 10% Tris-glycine SDS-PAGE gels (Invitrogen) 
under reducing conditions and transferred to nitrocellulose membranes 
(Invitrogen), along with Full-Range Rainbow Molecular Weight Markers (GE). 
Membranes were blocked in 2-5% milk in Tris-buffered saline with 0.05% tween 
(TBS-T) for 1 h at room temperature. Immunoblots were incubated with primary 
antibodies overnight at 4°C, washed 3 times with TBS-T and incubated with 
secondary Ab in conditions described in Table 1 for 1 h at room temperature. 
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Proteins were visualized using enhanced chemiluminescence (ECL; Amersham 
Pharmacia Biotech). Anti-β-actin Ab and anti-GFP Ab were used for protein 
normalization. Immunoblot films were scanned using a densitometer (Molecular 
Dynamics) and the intensity of protein bands of interest were quantified using 
ImageQuantTM TL software (GE).  
 
6. RNA Extraction and Real time quantitative PCR (RT-qPCR) 
a. Rat Primary cultures 
RNA was extracted from primary neuronal culture dishes using the RNeasy Micro 
kit (Qiagen). RNA purity (260/280 ratio) and concentration were determined using 
the NanoDrop spectrophotometer (Thermo-Scientific). A Taqman® expression 
assay for rat En2 (Rn01410380_m1, FAM labeled) and cyclophilin A (cyc), 
(Rn00690933_m1, VIC labeled) was purchased from Life Technologies. Each 
sample was run in duplicate with each 50µL reaction containing 2.5µL of 20X 
En2 Taqman primer/probe kit, 1.25µL of 20X cyc Taqman primer/probe kit, 25µL 
Taqman master mix, 1.25µL enzyme, and 5µL of mRNA diluted to 8 ng/µL. RT-
PCR reactions were performed using the ABI PRISM 7900HT (Applied 
Biosystems). Thermocycling parameters were as follows: 1 cycle of 50 °C for 30 
minutes, 1 cycle of 95 °C for 10 minutes, and then 50 cycles of 95 °C for 15 
seconds and 60 °C for 1 minute. Data were normalized to cyclophilin expression 
in the same sample, and expressed as a En2/cyclophilin ratio.  
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b. Mouse Ganglionic Eminence brain tissue 
Fine dissections of the medial, lateral, and caudal ganglionic eminence from 
E12.5 mouse brains were pooled and immediately immersed in RNAlater reagent 
(Life Technologies). Total RNA was extracted using the RNeasy Lipid Mini RNA 
extraction kit (Qiagen) and analyzed for RNA integrity (RIN) and concentration 
using the BioAnalyzer® (Agilent Technologies, Inc). A Taqman® expression 
assay for mouse En2 (Mm00438710_m1, FAM labeled) was purchased from Life 
Technologies and we designed cyclophilin A primers and probe using Primer 
express software (sense primer: 5’- TGC AGC CAT GGT CAA CCC C– 3’; 
antisense primer: 5’- CCC AAG GGC TCG TCA– 3’; probe: 5’- CCG TGT TCT 
TCG ACA TCA CGG CCG, VIC labeled). Each sample was run in triplicate with 
each 25 µL reaction containing 1.25 µL of 20X En2 Taqman primer/probe kit, 0.5 
µL of cyclophilin forward primer (9 µM), 0.5 µL of reverse primer (9 µM), 0.5 µL of 
Taqman probe (10 µM), 12.5 µL Taqman master mix, 0.625 µL enzyme, and 5µL 
of mRNA diluted to 80 ng/µL. Thermocycling parameters were as follows: 1 cycle 
of 48 °C for 15 min, 1 cycle of 95 °C for 10 min, and then 50 cycles of 95 °C for 
15 sec and 60 °C for 1 min. En2 expression was normalized by subtracting the 
cyclophilin Ct from En2 Ct (Δ Ct method). Error bars represent standard error of 
the mean (SEM) of three technical replicates. 
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7. ChIP followed by deep sequencing (ChIP-seq)  
a. ChIP assay 
ChIP was performed using the iDeal ChIP-seq kit (Diagenode; Denville, NJ). 
HEK293 cells were grown to ~60% confluence and transfected with En2-V5 or 
WT En2 expression vectors. After 24 h, cells were cross-linked with 37% 
paraformaldehyde for 10 min to retain protein-DNA complexes and quenched 
with glycine for 5 min. Cells were washed in PBS, trypsinized, and collected by 
centrifugation for cell counting. Cells were then lysed and resuspended in 
shearing buffer for sonication to generate chromatin fragments between 300-500 
bps as verified by agarose gel electrophoresis. One million cells were used per 
assay with an anti-V5 Ab (5 µgs; Life Technologies) or normal mouse IgG (2 µgs; 
Santa Cruz Biotechnology) to account for non-specific DNA pulldown (mock IP). 
DNA was precipitated using protein A-conjugated magnetic beads. ChIP-
enriched DNA and input DNA (sonicated chromatin not subjected to IP) were 
purified and quantitated using the Qubit machine (Agilent) for subsequent library 
construction. Mock IP with V5 IP in HEK cells transfected with WT En2 did not 
yield sufficient DNA for library construction. 
 
b. ChIP-seq library preparation 
Libraries were prepared with 20 ng of ChIP-enriched and input DNA. DNA was 
repaired to make blunt ended fragments using the NEBNext® ChIP-Seq Sample 
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Prep Reagent Set 1 (NEB; Ipswich, MA).  The Klenow reaction was used to add 
a 3’-dA overhang, which was then prepared for ligation of adapters as specified 
in the ChIP-Seq Sample Prep kit (Illumina; San Diego, CA).  Gel purification 
removed unligated adapters and selected for DNA fragments in the size range of 
300-500 bps. PCR amplification and barcoding of adapter-ligated DNA for 
multiplexing was achieved using the NEBNext® Multiplex Oligos for Illumina kit 
(NEB; Ipswich, MA). The quality of ChIP-seq libraries was assessed using the 
BioAnalyzer® (Agilent Technologies, Inc). Deep sequencing was performed on 
the HiSeq 2000 machine (Illumina). The Illumina platform utilizes the sequencing 
by synthesis (SBS) technology, in which the incorporation of fluorescently labeled 
reversible terminators are imaged as each dNTP is added, and then cleaved to 
allow incorporation of the next base. Validation of En2 target genes identified by 
ChIP-seq was performed using traditional ChIP assayed with qPCR as discussed 
below. 
 
8. Bioinformatic analysis of ChIP-seq datasets 
ChIP-seq data analysis was performed using Strand NGS software package 
(version 2.5, www.strand-ngs.com) under a license held in the laboratory. Pre-
alignment quality control (QC) was performed to remove DNA reads of poor 
sequencing quality. The phred quality score is a metric used to assess the 
accuracy of sequencing, and indicates the probability that a given base is called 
correctly by the sequencer. A phred quality score of 30 indicates the probability 
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of a correct base call is 99.9%, and is the benchmark for quality in next-
generation sequencing. The phred score is calculated by averaging the score of 
each base in the 50 bp read. DNA reads with a phred score of 30 and above 
were aligned to human genome (hg19 build) using the COBWeb algorithm 
(Strand NGS). Post-alignment QC was performed to include only non-redundant, 
uniquely mapping reads with an alignment score of 90 and above in downstream 
analysis. The alignment score represents the number of bases that match to a 
specific genomic location, with an alignment score of 100 representing a 
complete match. Redundant reads were removed as they are usually the result 
of overamplification of ChIP DNA during the PCR step of library construction, and 
likely originate from the same original DNA fragment. Removing redundant reads 
results in more reliable peak identification. Reads that map to more than one 
genomic location were discarded because the original binding site cannot be 
determined. 
Peaks were identified using two different peak-calling algorithms, Model-
based Analysis for ChIP-Seq (MACS, version 2.0; (Feng, Liu, Qin, Zhang, & Liu, 
2012; Yong Zhang et al., 2008)) and Probabilistic Inference for ChIP-Seq (PICS; 
(Xuekui Zhang et al., 2011)). The MACS algorithm was run with a p-value cutoff 
set to 1.0E-05. To increase the confidence of peak detection, only MACS peaks 
that were also detected by PICS were included in our downstream analysis. The 
data reported in our tables corresponds to MACS analysis. Genomic regions with 
read densities that are significantly higher than the control sample that pass this 
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threshold are identified as a peak. The p-value of each peak is reported as the P 
score, which is -log10(p-value). The input sample was set as the control sample 
to estimate the false discovery rate (FDR). The FDR is calculated by identifying 
peaks in the control sample using the same parameters used for the ChIP 
sample. The control sample should not contain any read enrichment, so any 
peak identified by MACS in the control sample is considered to be a false 
positive. For a given p-value threshold, the FDR is calculated as the number of 
control peaks divided by the number of ChIP-seq peaks (Feng et al., 2012). The 
FDR is reported as the Q-score in our tables, which is the -log10(FDR). The fold 
change (FC) value associated with each peak represents the ratio of read 
densities between the input read density and the ChIP-enriched read density for 
a given genomic location. The chromosomal location of each peak is reported, 
including the start, end, and summit of the peak. Peaks were annotated using the 
UCSC gene database with a cutoff distance of 5 kilobases (kbs) using the Strand 
NGS software. The region of the gene in which the peak is located is reported in 
our tables, (i.e., upstream, 5’ untranslated region [UTR], intron, coding-region, 
and 3’UTR). The data associated with each peak is presented in our tables 
(Table 15). 
Motif analysis was performed using the Scan Motif tool in Strand NGS. 
The mouse En2 position weight matrix (PWM) was downloaded from the 
JASPAR database and imported into the Strand software. MACS peak regions 
with a FC over 7 were scanned for the presence of an En2 motif with a p-value 
		 77	
threshold of 0.0035. A significant p-value represents the probability that the 
match between the motif and the DNA sequence in the reference genome is not 
due to chance alone. Only peaks that contained an En2 motif were included in 
downstream analysis. Gene Ontology (GO) enrichment analysis was performed 
using the Strand NGS software package. An adjusted p-value threshold of 0.1 
was chosen using the Benjamini Hochberg multiple testing correction test. 
Network analysis was performed using Ingenuity Pathway Analysis (IPA®, 
QIAGEN Redwood City, www.qiagen.com/ingenuity) knowledge base. En2 
targets genes were imported into the IPA program for functional annotation and 
enrichment of biological functions and canonical pathways. A p-value threshold 
was set at 0.05 to identify significantly enriched functions and pathways using the 
right-tailed Fisher Exact test. See Figures 7 and 8 below for the process of ChIP-
seq sample generation and analysis. 
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Figure 7. A schematic diagram of the ChIP-seq workflow  
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Figure 8: A schematic diagram of strand-specific ChIP-seq peak profiles at 
enriched sites. DNA fragments from a chromatin immunoprecipitation 
experiment are sequenced from the 5’ end. Therefore, the alignment of these 
tags to the genome results in two peaks (one on each strand) that flank the 
binding location of the protein or nucleosome of interest. This strand-specific 
pattern can be used for the optimal detection of enriched regions. To create an 
approximate distribution of all fragments, each tag location can be extended by 
an estimated fragment size in the appropriate orientation and the number of 
fragments can be counted at each position. Adapted from (Park, 2009). 
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9. Chromatin Immunoprecipitation (ChIP) analyzed by qPCR 
Traditional ChIP was used to validate five En2 target genes previously identified 
by ChIP-seq using the Magna ChIP A kit (Millipore; Billerica, MA). HEK293 cells 
were grown to ~60% confluence and transfected with En2-V5 or WT En2 
expression vectors. After 24 h, cells were cross-linked with 37% 
paraformaldehyde for 10 min to retain protein-DNA complexes and quenched 
with glycine for 5 min. Cells were washed in PBS, trypsinized, and collected by 
centrifugation for cell counting. Cells were then lysed and resuspended in 
shearing buffer for sonication to generate chromatin fragments between 300-500 
bps as verified by agarose gel electrophoresis. One million cells were used per 
assay with an anti-V5 Ab (5 µgs; Life Technologies) or normal mouse IgG (2 µgs; 
Santa Cruz Biotechnology) to account for non-specific DNA pulldown (mock IP). 
DNA was precipitated using protein A-conjugated magnetic beads. Quantitative 
real-time PCR (qRT-PCR) was used to determine the enrichment of 
immunoprecipitated DNA relative to input DNA using gene-specific primer sets. 
PCR primers were designed (SciTools, IDT) to flank the En2 binding sites 
identified by ChIP-seq for the following five target genes; lysine demethylase 5C 
(KDM5C), empty spiracles homeobox 2 (EMX2), protein kinase C beta (PRKCB), 
tuberous sclerosis 1 (TSC1), and neurofibromin 1 (NF1) as listed in Table 11. 
Each sample was run in triplicate with each 20 µL reaction containing 1 µL of 
sense primer (9 uM), 1 µL of antisense primer (9 uM), 10 µL Power Up™ SYBR 
green® master mix (Life Technologies; A25741), and 2 µL of ChIP-DNA. 
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Thermocycling was performed using the ABI Prism 7900HT machine and 
parameters were as follows: 1 cycle of 50°C for 2 min, 1 cycle of 95°C for 2 min, 
and 50 cycles of 95°C for 15 s, 55°C for 15 s, and 72°C for 1 min. The triplicate 
CT standard deviation was monitored to ensure tight replicates. Standard curves 
were generated using HEK293 genomic DNA and assessed for correlation 
coefficient (R2) values and reaction efficiencies (R2>0.98 and a slope of 
approximately -3.3, respectively). Melt curve analysis and agarose gel 
electrophoresis confirmed a single PCR product at the expected size. Data were 
normalized to input signal and expressed as fold enrichment (% Input).  
 
 
Table 11. ChIP qPCR primers and their sequences 
Primers Sequence 
KDM5C sense 5’-CGC CGT TGC AAT GAA CTA TT -3’ 
KDM5C antisense 5’- AGG CTG GTA TGG GTT TCT ATT T-3’ 
EMX2 sense 5’- CTT CGG AGG AAG CTG TTT ATG T-3’ 
EMX2 antisense 5’-GCC CTA AGT CCA AGG ACA ATC -3’ 
PRKCB sense 5’-CCT TCA AAG CCA TTC CTC CT -3’ 
PRKCB antisense 5’-CTC TGC TGC ACC TTC CAT TA -3’ 
TSC1 sense 5’-CCA ACC CAC ATC GTC AGT TA -3’ 
TSC1 antisense 5’-CCT TCT CGA AAG GAA GGA TAG AC -3’ 
NF1 sense 5’-AGC GCC AGT CTA GGT GA -3’ 
NF1 antisense 5’-GCC GGC CGG TTT CAT TA -3’ 
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10. RNA deep sequencing (RNA-seq) and transcriptomic analysis 
RNA was extracted from MGE and LGE dissections as described above. 
Amplified cDNA was generated from total RNA using the Ovation RNA-Seq 
System kit (Nugen). Single-ended RNA libraries were constructed using the 
Ovation Ultralow library system (Nugen). The quality of RNA libraries were 
validated using the BioAnalyzer® (Agilent Technologies, Inc). Sequencing was 
performed using the Illumina GAIIx platform (Boston University Core Facility). 
Strand NGS software was used for all downstream analysis. Reads with a quality 
score of 30 and above were aligned to the mouse genome using the COBWeb 
algorithm (Strand NGS). Reads with an alignment score below 90, duplicate 
reads, and reads that mapped to more than region of the genome were removed 
from downstream analysis. RNA quantification was performed by the Strand 
NGS software, which counts the total number of reads that map to each gene 
and exon in the genome, and is reported as raw counts. Normalization of the raw 
counts was achieved using the DESeq method, which accounts for differences in 
the total number of reads between samples and log transforms the data (Anders 
& Huber, 2010). See Tables 14 and 15. 
 
11. In Utero electroporation  
Targeted in utero electroporation of the GE was performed as previously 
described (Borrell, Yoshimura, & Callaway, 2005). Timed-pregnant female mice 
were deeply anesthetized and maintained in 2% isoflurane during surgery. The 
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abdominal cavity was opened, the uterine horns exposed, and 1 µL of DNA 
solutions were injected into the lateral ventricle of E12.5 embryos through the 
uterine wall. pCAG-EGFP expression vector was included in the DNA solution to 
monitor transfection. Plasmid DNA was introduced into telencephalic progenitors 
in the ganglionic eminence by passing electric pulses (5 pulses of 30V, 50 ms 
ON – 950 ms OFF) through the whole head with a CUY21SC electroporator and 
5 mm paddle electrodes (Nepa Gene). Electroporated embryos were fixed 5 days 
later at e17.5, cryosectioned, and processed for GFP immunoreactivity. GFP+ 
cells indicate transfected cells that also contain either En2-specific or control 
shRNA generating plasmids, shRNA-resistant En2 transgene plasmids, or 
GABRA4 transgene plasmids. 
12. In vivo retroviral injections for single progenitor clonal analysis 
Low titer retrovirus (5x105-5x106 pfu/mL) was prepared, concentrated and viral 
titer was estimated. For in utero injections, E12.5 timed-pregnant female mice 
were deeply anesthetized and maintained in 2% isoflurane during surgery. The 
abdominal cavity was opened, the uterine horns exposed, and retrovirus 
solutions were pressure injected into the telencephalic lateral ventricle of the 
embryos through the uterine wall. Injected embryos were fixed 48 h later, 
cryosectioned, and processed for immunohistochemistry.  
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13. Immunohistochemistry  
For histological analysis, embryos were obtained by cesarean section and fixed 
with 4% paraformaldehyde (PFA). Brain sections were cut with a cryostat at 
twenty µm thickness for electroporation experiments and forty µm thickness for 
retrovirus experiments. For immunohistochemistry of frozen brain slices, the 
tissue was incubated with primary antibodies overnight, followed by appropriate 
secondary antibodies. Fluorescent stainings were counterstained with DAPI to 
label nuclei. Primary antibodies were as follows: anti-GFP (1:1000, Aves Inc.); 
anti-βIII tubulin (1:1000, Covance). Secondary antibodies used were as follows: 
Alexa Fluor® 488 anti-chicken (1:200, Life Technologies) and Alexa Fluor® 555 
anti-mouse (1:200, Jackson Labs). 
 
14. Quantification for single progenitor clonal analysis 
a. Cell counts and measurements  
Cell types were identified according to the following criteria: Radial glial cell 
(RGC), a cell with its soma in the VZ, and a single apical process contacting the 
ventricular surface; Intermediate progenitor cell (IPC), a cell with multiple short 
processes extended from the cell soma and absence of Tuj1 expression; Neuron, 
a cell with either multipolar or apico-basal polarity with positive Tuj1 expression. 
These quantifications were done to differentiate the following regions: caudal GE 
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(CGE), lateral GE (LGE), medial GE (MGE) and preoptic area (POA) as 
previously described (Flames et al., 2007). 
b. Double-labeling analyses   
Quantification of cell co-staining was performed by confocal microscopy (Leica) 
through a 40X lens. Images were acquired from sections of 0.5 µm all along the 
thickness of the tissue. 
 
15. General Statistics  
Statistical analyses of all data were performed using Excel or Prism (GraphPad). 
Student’s t-test was used to determine 95% confidence interval between two 
experimental conditions. One-way analysis of variance (ANOVA) was utilized for 
3 or more experimental conditions, followed by Tukey’s post hoc analysis. Chi-
square analysis was used for double labeling experiments in single progenitor 
clonal analysis. See sections 8 and 10 for a discussion of the relevant statistics 
for genomic and transcriptomic analysis of ChIP-seq and RNA-seq datasets, 
respectively.  
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SECTION II: MATERIALS AND METHODS OF CHAPTER IV 
 
1. Pilocarpine injections 
SE was induced in adult Sprague-Dawley rats (Charles-River Labs, Kingston, 
PA) as described previously (Lund et al., 2008) using 385 mg/kg intraperitoneal 
(i.p.) pilocarpine after pretreatment with scopolamine (1mg/kg, i.p), and followed 
by diazepam (6 mg/kg, i.p.) 1 h after onset of SE, with additional 3 mg/kg every 2 
h as needed to ablate persistent motor seizures. Age-matched control rats 
received subconvulsive doses of pilocarpine (38.5 mg/kg i.p.), did not develop SE 
or spontaneous seizures, and were handled and housed identically to the 
epileptic animals. For animal experiments were approved by the institutional 
animal care and use committee at the University of Colorado Anschutz Medical 
Campus, and approved and conducted in accordance with the United States 
Public Health Service’s Policy on Human Care and Use of Laboratory Animals. 
 
2. Surgical implantation of electrodes 
Chronically epileptic rats (4 weeks post-SE) and controls were implanted with two 
stainless steel screws placed 4 mm caudal to bregma and 2.5 mm lateral from 
midline bilaterally, with reference and ground electrodes placed bilaterally behind 
lambda, as described previously (Grabenstatter et al., 2014). Animals were 
allowed to recover from surgery for 1 week before proceeding with any further 
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experimentation. 
3. EEG acquisition and analysis 
Rats subjected to pilocarpine-induced SE and control rats were video-
electroencephalography (EEG) recorded 24 h per day using a Pinnacle digital 
video-EEG system with flexible cables to monitor seizure frequency as described 
previously (Grabenstatter et al., 2014). EEG signals were sampled at 1 kHz, 
amplified by 100x, and band-pass filtered between 0.3 Hz and 600 Hz. Prior to 
inclusion in the study, all pilocarpine-treated SE animals were confirmed to have 
at least two EEG-documented SS and thus meet the criteria for epilepsy. EEG 
records of these chronically epileptic animals were then reviewed daily, and 
animals were sacrificed if they had (1) experienced a seizure with the past 3 h 
(recent SS or <3 h group) or (2) had been seizure free for >24 h (no recent SS or 
>24 h group). After sacrifice and tissue collection, electrographic recordings 
spanning the 7 days prior to sacrifice were examined visually by a trained 
technician blinded to all experimental parameters to determine the number of 
electrographic seizures that had occurred for each animal. 
Electroencephalographic seizures were differentiated from background noise by 
the appearance of large-amplitude (>3 times baseline), high frequency (>5 Hz) 
activity, with progression of the spike frequency lasting > 10 s. Electrographic 
seizures were manually detected in EEG recordings and correlated with 
behavioral manifestations in continuous video recordings utilizing a modified 
Racine scale (described above). Seizure quantification was conducted according 
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to seizure type (convulsive or nonconvulsive). Motor seizures were scored by 
standard behavioral classes (Racine, 1972), with Racine class 3 or greater 
seizures categorized as convulsive seizures and class 2 or below considered 
nonconvulsive.  
 
4. Real-time (RT)-PCR and Western blots (performed by M. Cogswell) 
Epileptic animals (56.21 ± 13.99 days after pilocarpine-induced SE) confirmed to 
have had at least two SS were sacrificed <3 h from the time of an SS or >24 h 
after the last SS. Tissue from age-matched controls was analyzed to assess 
changes in protein and mRNA potentially induced by spontaneous seizure 
activity. RNA was extracted from microdissected hippocampal dentate gyrus 
tissue using RNeasy Mini RNA extraction kit (Qiagen, Venlo, The Netherlands). 
Primers and probe for BDNF (Rn02531967_s1), Gabra4 (Rn00589846_m1), and 
cyclophilin (Rn00690933_m1) were purchased from Applied Biosystems (Foster 
City, CA). Primers and probe for Egr3 were designed using primer express 
software. Primer and probe sequences for Egr3 are reported in Table 12. 
Samples were repeated in duplicate, with each reaction split into two wells in a 
total volume of 20 µL containing 16 ng of RNA using an ABI Prism 7900HT 
machine (ABI Biosystems, Foster City, CA). Polymerase chain reaction (PCR) 
cycling parameters were 50°C for 30 min, 95°C for 10 min, 50 cycles of 95°C for 
15 s, and 60°C for 1 min.  All values were normalized to cyclophilin expression to 
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control for loading variability and expressed as fold change with respect to the 
mean control values (defined as 1). 
 Western blot was performed on protein (25 µg for GABARα4; 30 for Egr3) 
extracted from microdissected DG as previously published (YogendraSinh H 
Raol et al., 2006). Membranes were incubated with rabbit polyclonal antibodies 
raised against GABARα4 (anti-GABARα4, Millipore, Billerica, MA, AB5457; 
Research Research Identifier (RRID): AB_177479; 1:2000) in 1% milk/Tris-
Buffered Saline and Tween 20 (TBS-T) or Egr3 (anti-Egr3 (H-180) N-terminus, 
sc22801; Research Research Identifier (RRID): AB_2097199; 1:400; Santa Cruz, 
Dallas, Texas) in 2% milk/Tris-Buffered Saline and Tween 20 (TBS-T) overnight 
at 4°C. Membranes were then washed and incubated with anti-rabbit secondary 
antibody (1:10,000 in 1% milk/TBS-T for GABAR; GE healthcare, Little Chalfont, 
Buckinghamshire, United Kingdom) or (Veryblot, Abcam, Cambridge, United 
Kingdom, AB131366; 1:500 in 2% milk/TBS-T for Egr3) for 1 h at room 
temperature. Protein bands were detected using chemiluminescent solution 
(Pierce, Rockford, IL), and membranes were stripped and reprobed with rabbit 
polyclonal antibody raised against β-actin (1:40,000, Sigma, St. Louis, MO) in 1% 
milk/TBS-T overnight.  GABARα4 and Egr3 values were normalized to β-actin 
expression in the same samples and expressed as percent change relative to 
mean control values in the same run (defined as 1). Densitometry was performed 
with NIH Image J version 1.42q. Statistical significance was calculated with Prism 
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software using a one-way ANOVA with a Tukey’s test for multiple comparisons or 
an unpaired Student’s t-test as indicated.  
 
Table 12. Real-time RT PCR primers and their sequences 
Primers Sequence 
Egr3 sense 5’- GAG ATC CCC AGC GCG C -3’ 
Egr3 antisense 5’- CAT CTG AGT GTA ATG GGC TAC CG -3’ 
Egr3 probe 5’- CAA CCT CTT CTC CGG CAG CAG TGA C -3’ 
 
5. In vivo ChIP in the pilocarpine model of epilepsy (performed by M. 
Cogswell)  
Rats (provided by Dr. Brooks-Kayal’s laboratory) were perfused with cold 1x 
phosphate-buffered saline (PBS; with 1:1,000 phosphatase inhibitors) followed 
by 4% formaldehyde. Whole brains were immersed overnight in 4% 
formaldehyde and sectioned at 600 µm. Microdissected DG was sonicated to 
produce 300-500 bp fragments of crosslinked protein-DNA complexes and 
precipitated using an Egr3-specific Ab (10 µg; Santa Cruz Biotechnology) or 
normal rabbit immunoglobulin G (IgG; 2 µg; Santa Cruz Biotechnology) to 
account for non-specific DNA pull down. Immunoprecipitated protein-DNA 
complexes were reverse-crosslinked and purified for PCR analysis using the 
protein A-conjugated magnetic bead ChIP kit (Millipore). Quantitative real-time 
RT-PCR was performed using primers and Taqman probe that flank the Egr3 
binding site in the Gabra4 promoter as listed in Table 13. Each sample was run 
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in triplicate with each 20µL reaction containing 1µL of sense primer (9 uM), 1µL 
of antisense primer (9 uM), 1µL of Taqman probe (10 uM), 10µL master mix (Life 
Technologies), and 2µL of ChIP-DNA. Thermocycling was performed using the 
ABI Prism 7900HT machine and parameters were as follows: 50°C for 2 minutes, 
95°C for 10 minutes, 50 cycles of 95°C for 15 sec, and 60°C for 1 minute. The 
triplicate CT standard deviation was monitored when analyzing data to ensure 
tight replicates. Standard curves were generated using rat genomic DNA 
(Clontech) and assessed for satisfactory correlation coefficient (R2) values and 
reaction efficiencies (R2>0.98 and a slope of approximately -3.3, respectively). 
Data were normalized to input signal (Egr3/Input) and expressed as fold change 
with respect to control (defined as 1). Input represents the DNA signal from 
sample preparation prior to immunoprecipitation. 
 
Table 13. ChIP qPCR primers and their sequences 
Primers Sequence 
GABRA4p sense 5’- GAA CAA ACT TGC CTA GCT TCG CGT -3’ 
GABRA4p antisense 5’- TCC TCC AGC CTA GCC GC -3’ 
GABRA4p probe 5’- AAG TTC ACC GGC GAG CAG CGC TTT CA -3’ 
 
 
.
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CHAPTER III: A NOVEL ROLE FOR EN2 IN THE GANGLIONIC EMINENCE 
AND THE DISCOVERY OF NEW GENE TARGETS ENRICHED IN NEURAL 
DEVELOPMENT. 
 
ABSTRACT 
  A major molecular feature of autism spectrum disorder (ASD) in human 
patients, and one that is seen in multiple mouse models that display autism-
suggestive behavioral phenotypes, is the marked disruption in the development 
of GABAergic interneurons that emerge from the ganglionic eminence (GE). 
Although a plethora of ASD genes have appeared since discovery of Engrailed-2 
(En2) mutations in human patients, En2 knockout mice remain an important ASD 
model displaying many of the behavioral, anatomical, and neuropathological 
features (including loss of specific GABAergic interneuron populations and 
increased seizure susceptibility) associated with disease. How removal of a 
homeobox transcription factor specifically responsible for development of the 
midbrain and cerebellum produces a full spectrum of ASD phenotypic changes 
has remained a mystery made more elusive by the lack of knowledge regarding 
specific En2 targets in the genome. Unlike the developing cerebellum and 
midbrain where En2 is highly abundant, low levels of En2 exist in all structures of 
GE. Using in utero electroporation, we show that En2 is required to maintain 
progenitors in the ventricular zone in the lateral GE. Delivery of En2 shRNAs to 
this region results in a 50% reduction of transfected progenitors in the ventricular 
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zone, which is partially rescued by co-delivery of En2 shRNAs with a resistant 
En2. Using retroviral clonal analysis, we show that loss of En2 promotes 
neurogenesis of radial glia progenitor cells specifically in the lateral GE, and 
possibly the caudal GE, relevant to the generation of neurons originating from 
these regions of the brain. Specifically, delivery of En2 shRNAs results in a 
significant decrease in the percentage of radial glial cells per clone (a 10% 
decrease in the lateral GE, and a 45% decrease in the caudal GE) and a 
significant increase in the percentage of neurons per clone (20%) in the lateral 
GE. Using chromatin immunoprecipitation followed by high density sequencing of 
DNA fragments from cells transfected with En2-V5 fusion proteins, our data 
analysis suggests that En2 may be a master regulator of multiple ASD candidate 
genes in the SFARI database including 83 expressed in GE at embryonic day 
12.5. Network analysis using Ingenuity Pathway Analysis identified several 
pathways enriched in our ChIP-seq dataset relevant to our phenotype including 
the proliferation of neuronal cells (p=1.03E-03). Gene ontology analysis identified 
224 functional terms significantly enriched in our dataset, including cell cycle 
(adjusted p-value=3.18E-04) and neurogenesis (adjusted p-value=3.0E-03). Our 
results are the first to show a potential role for En2 dysfunction in GE that could 
negatively impact the development of neural circuitry in the brain and a function 
for low levels of expression of this important transcription factor. 
 
		 95	
INTRODUCTION 
 Genome-wide association studies have identified Engrailed-2 (En2) as an 
ASD candidate gene in multiple pedigrees (Benayed et al., 2005; Brune et al., 
2008; Gharani et al., 2004; Sen et al., 2010; L. Wang et al., 2008; Yang et al., 
2008; 2010). The strength of this association between En2 and ASD is seen in 
the En2 knockout (En2-/-) mouse that displays many of the neuroanatomical and 
neurobehavioral deficits that are the core features of the disorder in humans, 
including cerebellar abnormalities (Kuemerle et al., 1997; Millen et al., 1994), 
learning and memory deficits, and deficits in social interaction (Cheh et al., 
2006). En2 is a homeobox-containing transcription factor that is highly expressed 
in the midbrain and cerebellum where it regulates many aspects of development 
including cerebellar growth, patterning, and connectivity (Millen et al., 1994; 
Sillitoe, Vogel, & Joyner, 2010). More recent studies have shown that En2 is also 
expressed at very low levels in several adult brain structures including the 
hippocampus and cortex, which may explain some of the cognitive and 
behavioral symptoms of ASD patients, although no specific function has yet been 
attributed to En2 presence in these structures (Tripathi et al., 2009; Brielmaier et 
al., 2012).  
Recent studies have identified what may be a novel role for En2 in 
maintaining the excitatory-inhibitory balance in the brain, as it is expressed in 
subsets of GABAergic interneurons in the adult mouse hippocampus and cortex 
(Sgadò et al., 2013; Tripathi et al., 2009). Interestingly, En2-/- mice have a loss of 
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interneurons in these regions that is associated with greater susceptibility to 
kainic acid-induced seizures (Kelsom & Lu, 2013; Sgadò et al., 2013; Tripathi et 
al., 2009). The molecular mechanism(s) behind the loss of interneuron 
populations in these knockout animals still remains unknown.  
Interneuron dysfunction has been implicated in several neuropsychiatric 
disorders including schizophrenia, autism and epilepsy (Marin, 2012) suggesting 
that the proper function of these neurons is key to brain health. GABAergic 
interneurons are widely heterogeneous and are classified based on their 
anatomical, physiological, and molecular signatures (Kepecs & Fishell, 2014). 
They modulate neural circuitry thereby playing a vital role in maintaining the 
delicate balance of excitation and inhibition in the central nervous system (CNS). 
Unlike excitatory pyramidal cortical neurons, inhibitory interneurons are 
generated in the ganglionic eminences of the ventral telencephalon, and migrate 
tangentially to the cortex, hippocampus, striatum, and olfactory bulb (S. A. 
Anderson et al., 1997; Borrell et al., 2005; Marin & Rubenstein, 2001; Wichterle, 
Turnbull, Nery, Fishell, & Alvarez-Buylla, 2001). The ganglionic eminence is a 
transitory structure in embryonic development and consists of three regions 
based on their rostral to caudal location; the medial (MGE), lateral (LGE) and 
caudal ganglionic eminence (CGE), which have unique gene expression 
signatures and give rise to different subtypes of interneurons that migrate to 
discrete brain regions (Flames et al., 2007; Kepecs & Fishell, 2014). 
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The ventricular zone (VZ) of the GE is the proliferative region lining the 
ventricle that contains the neural progenitor cells. In early brain development, 
progenitor cells mainly undergo proliferative, symmetric cell divisions to produce 
two daughter progenitor cells to amplify the pool of dividing cells. Later in 
development, progenitor cells increase their neurogenic, asymmetric cell 
divisions to self-renew and produce neurons or intermediate progenitor cells 
(IPCs). IPCs detach from the ventricular surface and mobilize to the sub-
ventricular zone (SVZ), where they undergo symmetric, neurogenic cell divisions 
to produce two daughter neurons (Götz & Huttner, 2005).  
Identifying the molecular pathways that control the development of 
inhibitory interneurons, i.e. their proliferation, differentiation, and migration in the 
brain is an area of intense research because it has the promise of informing our 
understanding of developmental brain disorders. Multiple transcription factors 
have been identified as key regulators of progenitor cell division. We 
hypothesized that En2 might play a role in the ontogeny of GABAergic 
interneuron progenitor cells based on the phenotype of En2 knockout mice. 
Previous studies also showed that En2 regulates neuronal precursor proliferation 
and differentiation (Benayed et al., 2005; Rossman et al., 2014) consistent with 
our hypothesis that En2 might control aspects of neurogenesis in the GE that 
could impact region-specific brain circuitry after birth.  
We now report for the first time that neural precursor cells in the GE 
express En2 at low levels. To test the biological relevance of En2 expression, 
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En2 shRNAs were delivered into the GE using mouse in utero electroporation, 
and we now report that specific En2 knockdown decreases the number of apical 
progenitors residing in the VZ of the LGE. Single progenitor clonal analysis using 
retroviral En2 shRNA delivery supports this finding and demonstrates that En2 
may promote the self-renewal of neuronal progenitor cells; and, that its absence, 
or decrease, triggers premature cell cycle exit and detachment from the VZ to 
promote neurogenesis. 
Little is actually known regarding the targets of En2 in the developing brain 
mostly due to the lack of specific En2 antibodies for chromatin 
immunoprecipitation (ChIP). We were surprised to find that overexpression of 
En2-V5 fusion proteins in human cell cultures, that were subjected to chromatin 
immunoprecipitation (ChIP) high density sequencing, identified over 80 target 
genes found in the Simons Foundation Autism Research Initiative (SFARI) 
database, a repository of all known human genes associated with ASD. Many of 
these genes are also expressed in the GE at E12.5 along with low levels of En2, 
as previously described in the adult hippocampus (Tripathi et al., 2009). The first 
genome-scale prediction of synthesis rates of mRNAs and proteins indicates that 
a single RNA transcript can generate around 2500 protein molecules in a single 
cell, suggesting that protein levels are most likely controlled by translation for 
many gene products.  These careful studies, along with the datasets coming from 
single cell transcriptomics of multiple cell types, has opened up the possibility 
that low copy mRNAs may play a greater role than originally appreciated 
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(Schwanhäusser et al., 2011). Our results are consistent with this expectation 
and are the first to demonstrate that low levels of En2 transcripts in the GE are 
functional. This finding is especially interesting as the GE has not been 
previously associated with En2 gene regulation and is the birthplace of neurons 
whose function is disturbed in developmental disorders. Moreover, results of our 
gene network analysis of putative En2 gene targets, identified by En2-V5 ChIP-
sequencing, suggests that these targets are also significantly enriched in many 
pathways important to neuronal development including chromatin modification, 
cell cycle, and neurogenesis.  
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RESULTS 
En2 mRNA is expressed at low levels in all regions of the mouse GE. 
To examine a possible role for En2 in the development of progenitor cells 
in the GE, we first measured the expression of En2 messenger RNA (mRNA) 
levels using quantitative real-time PCR (qRT-PCR) analysis. GE progenitors 
were carefully dissected from the VZ of the MGE, LGE, and CGE from E12.5 
mouse embryos and pooled for RNA extraction (Fig. 9A). As shown in the 
representative PCR tracings of Figure 9B, En2 is expressed at low levels in all 
regions of the GE. En2 expression was normalized to the internal control 
reference gene Cyclophilin-A using the ΔCt method [Cyclophilin Ct - En2 Ct] (Fig. 
9C) where a lower ΔCt value represents the detection of higher levels of En2 
mRNAs. Adult mouse cerebellar tissue was used as a positive control to 
represent high levels of En2 expression as reported in the literature (mean ΔCt = 
2.3). All regions of the GE have similar mean ΔCt values; (MGE ΔCt = 13.4, LGE 
ΔCt = 13.1, and CGE ΔCt = 12.7), and at much lower levels than in the 
cerebellum, consistent with recent reports that En2 is expressed at low levels in 
several adult brain regions including the hippocampus and prefrontal cortex 
{Tripathi:2009ey, Brielmaier:2012gc}. Our detection of En2 expression in the 
embryonic GE suggests that it may play a role in the ontogeny of GABAergic 
interneuron progenitor populations, as the GE is the birthplace of all 
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interneurons, as well as the medium spiny projection neurons of the striatum that 
originate from the LGE. 
 To assess the integrity of the GE dissections assayed in Fig. 9B and C, 
RNA-sequencing (RNA-seq) libraries were prepared from the same samples and 
read using Illumina technology followed by downstream data analysis (Strand 
NGS v2.5 software collection). The tables displayed in Figure 9D and E shows 
the raw and normalized gene expression values, respectively, from 
transcriptomic analysis that accurately detect the gene expression markers which 
distinguish between MGE and LGE, as expected if the dissection is true to the 
proposed cell type. Highest in MGE: (Nkx 2-1, Shh, Lhx6), Highest in LGE: 
(Pax6), and genes expressed in both MGE and LGE (Dlx2) were enriched in their 
respective samples. 
 In addition, given that autism has been associated with an alteration in the 
function of the GABAergic signaling pathway, we examined whether there was a 
differential pattern of gene expression specific to certain type A GABA receptor 
(GABAR) subunits in GE, as the majority of hippocampal GABAergic 
interneurons originate specifically from MGE and CGE, and GABARs are known 
to participate in complex gene regulatory networks that underlie region specific 
cellular dynamics. Interestingly, our results show that there is an equal presence 
or absence of almost all GABAR subunit mRNAs in MGE and LGE with the 
exception of Gabra5 that is higher in MGE. Note that there is no detection of 
Gabra6 or Gabrd in either LGE or MGE (Table 14).  
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Figure 9: En2 mRNAs are expressed at low levels in all regions of the 
mouse ganglionic eminence. (A) Schematic representation of specific regions 
(MGE, LGE, and CGE) that were dissected from the ventricular zone of E12.5 
mouse brains and prepared for downstream RNA analysis. A: anterior; P: 
posterior (B) Real-time qPCR amplification curves of En2 mRNA and cyclophilin 
mRNA of adult mouse cerebellum (CER), microdissected E12.5 mouse MGE, 
LGE, and CGE, and no template control (NTC). (C) Delta Ct quantification of 
qPCR analysis shown in panel (B). Average delta Ct values were calculated by 
subtracting Cyclophilin (Cyc) Ct from En2 Ct. A lower delta Ct value represents 
higher gene expression. Columns represent the average of three technical 
replicates. Error bars, mean ± SEM. (D-E) RNA-seq transcriptome profiling 
validates the accuracy of microdissected MGE and LGE tissue samples. Data 
analysis was performed using the Strand NGS software platform. The absolute 
fold change (Abs FC) between MGE and LGE are shown for genes expressed 
only in MGE (Nkx2-1, Shh, Lhx6), or only in LGE (Pax6), or co-expressed in 
MGE and LGE (Dlx2) and are reported as both raw read values (D) and DESeq 
normalized values (E). (Tissue dissections from the mouse GE depicted in panel 
A were performed in the Borrell laboratory in collaboration. RNA extraction and 
all downstream analysis was performed by M. Cogswell) 
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Table 14: RNA-seq transcriptome profiling of GABAR subunit genes 
expressed in the MGE and LGE of E12.5 embryos. Given that a disturbance in 
GABAergic transmission is proposed as a contributory factor in ASD, RNA-seq 
was used to determine which GABAR subunit genes are expressed in this region 
and if expression is specific to either MGE or LGE. “*” marks detection of Gabra5 
that we later identify by En2-V5 ChIP-seq as a potential direct target of En2 (Fig. 
5, En2 motif p-value: 8.8E-4.  Data is expressed as DESeq normalized values. 
MGE: medial ganglionic eminence; LGE: lateral ganglionic eminence. (Performed 
by M. Cogswell) 
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En2 is required to maintain ventricular progenitors in the LGE. 
Given the presence of En2 in GE, we next asked whether En2 expression 
in the GE might be biologically relevant by disrupting En2 expression in neuronal 
progenitors using En2-specific shRNAs. shRNAs were first designed and 
validated as being En2-specific, when compared to a random sequence shRNA 
control, using Western blot analysis (Fig. 10A). To test the specificity of the En2-
shRNA in vivo, a rescue experiment was designed to selectively deliver back an 
shRNA resistant En2 transgene along with En2 shRNA to determine the 
likelihood of an off-target effect being responsible for our finding. An shRNA-
resistant En2 cDNA was generated by introducing 4 silent mutations (shown in 
red) into the shRNA target region of the transgene using a PCR based method. 
The resistance of this mutated En2 transcript to En2 shRNA silencing was 
evidenced by Western blot analysis using transfected HEK293 cells. As shown in 
Fig 10A, shRNA knockdown of WT En2 (lane 3) was abolished by mutating 4 bps 
in the shRNA target region (mutant En2, lane 5). Based on these results, 
targeted IUE was used to deliver control shRNA, En2-specific shRNA, or 
combined En2-specific shRNA and resistant En2 to the ganglionic eminence at 
embryonic day 12.5 as shown in Fig 10B. Five days later embryos were 
harvested and processed for GFP immunoreactivity. (A GFP construct was co-
delivered in all conditions for visualization of individual cells that were 
electroporated.) 
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In control animals, the majority (65%) of electroporated (GFP+, black) 
cells were located in the VZ and contacted the ventricular surface, both features 
typical of VZ radial glial progenitor cells (RGCs, Fig. 10C-E). In animals that 
received En2 shRNA, only about 15% of electroporated cells remained in VZ, 
and the remaining cells were dispersed throughout the sub-ventricular zone 
(SVZ), which are either intermediate progenitor cells (IPCs) or neurons. 
Furthermore, the cells remaining in the VZ were detached from the VZ surface, 
which is atypical of VZ progenitors and may be indicative of these cells being 
IPCs or neurons not yet mobilized to SVZ (Fig. 10F). These findings suggest that 
En2 is important for retaining VZ progenitors attached to the VZ surface, and for 
their self-renewal. An absence or a decrease in En2 levels leads to their 
detachment from the VZ and likely their exit from the cell cycle as they become 
neurons. Furthermore, co-delivery of En2 shRNA and shRNA-resistant En2 
cDNA partially rescues the En2 silencing phenotype. More specifically, 50% of 
electroporated cells are located in the VZ and contact the ventricular surface 
(both features typical of VZ progenitor cells), similar to control. Results of the 
rescue experiment strongly suggest that the En2 shRNA phenotype is in fact due 
to a specific loss of En2 expression, and most likely not an off-target effect.  
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Figure 10: En2 is required to maintain ventricular progenitors in the lateral 
ganglionic eminence. (A) Sequence of the En2 mRNA region targeted by 
selective shRNAs. Four silent mutations (red) were introduced into the shRNA 
target region of the wild-type En2 transgene (WT En2) to confer resistance to 
knockdown by En2 shRNAs (resistant transgene (res. En2), also referred to as r-
En2). Western blot analysis demonstrates that levels of WT En2 protein are 
knocked down by En2-specific shRNAs (lane 3), while res. En2 (r-En2) is 
resistant to knockdown (lane 5). (B) Experimental paradigm used for shRNA 
knockdown and rescue experiments. (C) Coronal sections through the lateral 
ganglionic eminence (LGE) of E17.5 embryos showing GFP (green) and DAPI 
(blue) stain after electroporation with Ctrl shRNA or En2 shRNA at E12.5. Dotted 
lines delineate the VZ border of the LGE, arrowheads indicate the electroporated 
site. Detail images are high magnifications of panoramic views on the left. NCx, 
neocortex; Spt, septum; cc, corpus callossum. Scale bar, 350 µm. (D) LGE of 
E17.5 embryos showing GFP or DAPI stain after electroporation with Ctrl shRNA, 
En2 shRNA, or En2 shRNA + resistant En2 at E12.5. Solid arrowheads indicate 
transfected cells in VZ attached to the ventricular surface (dotted lines); open 
arrowheads indicate GFP+ cells within VZ that have detached from the 
ventricular surface; arrows indicate cells located in the mantle zone (MtZ). 
Dashed lines delineate the border between VZ and MtZ. Scale bar, 175 µm. (E) 
Distribution of GFP+ cells in VZ and MtZ upon transfection with the constructs as 
indicated. Data are mean ± SEM. (n = 524 cells from 4 different embryos, Ctrl 
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shRNA; n = 494 cells, 4 embryos, En2 shRNA; n = 747 cells, 4 embryos, En2 
shRNA + rEn2; chi-square test, ***p < 0.001. (F) High magnification details of 
GFP+ cells in VZ at E17.5 upon electroporation of the indicated constructs at 
E12.5. Solid arrowheads indicate the end feet of apical processes contacting the 
ventricular surface (dotted lines). Open arrowheads indicate the soma of cells 
detached from the ventricular surface. (Panel A performed by M. Cogswell, 
Panels B-F was performed in the Borrell laboratory in collaboration) 
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Loss of En2 promotes neurogenesis of radial glia progenitor cells in the 
LGE. 
Single progenitor clonal analysis was performed to follow the fate of the 
apical progenitors after En2 knockdown. Retroviral vector constructs were 
generated to co-express GFP and En2-specific shRNA or control shRNA. 
Western blot analysis confirms the expression of both GFP and shRNAs as 
evidenced by En2 knockdown (Fig. 11A). Embryos were injected with retrovirus 
into the lateral ventricle at E12.5 and maintained in utero for 2 days to ensure 
faithful identification of cells belonging to a single progenitor (Fig. 11B).  
Transduced progenitors and their daughter cells (GFP+) were analyzed for 
cell type based on cell morphology and expression of the neuronal marker Tuj1 
(red) after delivery of control (left) or En2 shRNA (right). RGCs (indicated by 
arrowheads, Fig. 11 C2 & C4) have their soma in the VZ, a single apical process 
contacting the ventricular surface, and are Tuj1 negative. IPCs (indicated by 
arrowheads, Fig. 11 C2 & C4) have multiple short processes extended from the 
cell soma and are Tuj1 negative. Neurons (indicated by arrows; Fig. 11 C1 & C3) 
have either multipolar or apico-basal polarity and are Tuj1 positive. For each 
clone, the following metrics were quantified: the number of cell divisions (cells 
per clone), the number of apical progenitors (% RGCs per clone), the number of 
IPCs (% Tuj1-negative multipolar progenitors per clone), and the number of 
neurons (% Tuj1+ cells per clone). Data analysis was performed specific to the 
following regions of the GE: MGE, LGE, CGE, and the preoptic area (POA).  
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Interestingly, our dataset suggests that loss of En2 has little to no effect on 
MGE and POA progenitors. However, in the LGE, there is a significant decrease  
in RGCs per clone (12%, p<0.05), and a concomitant significant increase in 
neurons (19%, p<0.05). Thus, RGCs in the LGE transduced with En2 shRNAs 
increase their terminal divisions to give rise to neurons directly, unlike in control 
where RGCs are dividing to self-amplify their population and to produce IPCs, 
and these cells will produce neurons. However, in the CGE, there is a significant 
decrease in RGCs per clone (36%, p<0.05), and although there is a trend 
towards an increase in neurons (21%), it remains to be determined whether this 
is significant (Fig. 11D). (Data shown is mean +/- standard error of the mean 
(SEM)). Taken together, our results demonstrate an important role for En2 on 
progenitor cell dynamics in the LGE as modeled in Fig. 12. In normal 
development, VZ progenitor division is balanced between RGC self-renewal 
(blue arrow), generation of neurogenic IPCs (red arrow), and generation of Tuj1+ 
neurons (green arrows). En2 knockdown biases the VZ progenitor fate towards 
the generation of neurons over self-renewal. 
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Figure 11: Loss of En2 promotes neurogenesis of radial glia progenitor 
cells in LGE but not MGE. (A) Retroviral vectors were generated to co-express 
GFP and En2-specific shRNAs, or control shRNAs. Western blot analysis 
confirms the specificity of the constructs for knocking down En2 but not GFP. (B) 
Experimental paradigm used for progenitor clonal analysis. Embryos were 
injected with retrovirus at E12.5 and maintained in utero until analysis at E14.5. 
(C) Examples of individual progenitor clones in the LGE of E14.5 embryos 
injected with Ctrl shRNAs or En2 shRNAs, as indicated. Individual cells within 
clones (GFP+) were analyzed for Tuj1 immunoreactivity (neurons). Arrowheads 
indicate RGCs and IPCs, negative for Tuj1 (c2, c4); arrows indicate neurons, 
Tuj1+ (c1, c3). High magnification images (c) are single confocal planes to 
demonstrate co-localization (or absence of). (D) Quantification of the total 
number of cells per clone, percent of radial glia cells (RGCs), multipolar cells 
negative for Tuj1 (MPs; presumptive intermediate progenitor cells), and neurons 
(Tuj1+). Data are mean ± SEM. Ctrl clones, n = 47 cells (LGE), 13 cells (CGE), 
38 cells (MGE), 19 cells (POA), 6 embryos per group; shEn2 clones, n = 26 cells 
(LGE), 12 cells (CGE), 28 cells (MGE), 13 cells (POA), 5 embryos per group. 
Chi-square test, *p < 0.05. LGE, lateral ganglionic eminence; MGE, medial 
ganglionic eminence; CGE, caudal ganglionic eminence; POA, pre-optic area; 
RGC, radial glial cell; MP, multipolar cell; VZ, ventricular zone; MtZ, mantle zone. 
Dotted lines delineate the ventricular border. (Panel A performed by M. Cogswell, 
Panels B-D was performed in the Borrell laboratory in collaboration)  
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Figure 12. Model of Engrailed 2 function on Progenitor Cell Dynamics in the 
Lateral Ganglionic Eminence. In normal development, VZ progenitor division is 
balanced between RGC self-renewal (blue arrow), generation of neurogenic IPCs 
(red arrow), and generation of Tuj1+ neurons (green arrows). En2 knockdown 
biases the VZ progenitor fate towards the generation of neurons over self-
renewal. (Performed in the Borrell laboratory in collaboration) 
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Identification of human En2 Target Genes with ChIP-sequencing. 
As a first step to identify the molecular determinants that underlie the 
changes in the GE upon En2 shRNA electroporation, we used chromatin 
immunoprecipitation followed by deep sequencing (ChIP-seq) to determine 
potential DNA binding sites for En2 in living cells. Unfortunately, the commercially 
available En2-Abs that we tested display high non-specific binding in neuronal 
extracts; and, therefore, cannot be used for ChIP analysis of endogenous 
transcription factors in neurons. A similar issue exists with the custom Abs 
generously supplied to us from the Joyner laboratory (Memorial Sloan Kettering 
Cancer Center, New York, NY) (Data not shown). To get around this 
methodological problem, we generated DNA expression constructs to deliver an 
En2-V5 fusion protein in HEK293 cells by sub-cloning mouse En2 cDNA (a 
generous gift from Dr. Alexandra Joyner) into a C-terminal V5-His fusion 
expression vector (Life Technologies). DNA constructs of wild type (WT) En2 and 
V5-tagged En2 (En2-V5) were expressed in these cells and protein extracts 
containing recombinant protein were analyzed by Western blot to confirm 
successful tagging and identification of the predicted WT and fusion proteins. A 
single band was observed at the expected size of approximately 40 kD for WT 
En2 detected with an anti-En2 Ab (Santa Cruz) (Fig. 13A, upper right panel, lane 
2). As expected, En2-V5 fusion proteins were also detected by the same anti-
En2 Ab (Fig. 13A, upper right panel, lane 3) as well as an anti-V5 Ab (Life 
Technologies) (Fig. 13A, upper right panel, lane 6. Note the small increase in 
		 122	
molecular weight of recombinant En2-V5 fusion proteins as a result of the 
addition of the 20 amino-acid V5-His epitope tag.)  
The 60 amino-acid DNA-binding homeobox domain of En2 is highly 
conserved across species, with 100% homology at the protein level between 
mouse and human, making the HEK293 expression system an especially 
favorable model for our initial studies. Protein-DNA complexes of transfected HEK 
cells were fixed with formaldehyde and immunoprecipitated (IP’d) with both the 
V5-Ab and IgG-Ab to control for non-specific precipitation. ChIP-enriched DNA 
and input DNA (sonicated chromatin not subjected to IP) were purified and 
quantitated for subsequent library construction. (Note: IgG IP and V5 IP in HEK 
cells transfected with WT En2 do not yield sufficient DNA for library construction.) 
Libraries were sequenced on the Illumina platform, and 50-bp single-end reads 
were aligned to the human genome (hg19 build, UCSC) using COBWeb (Strand 
NGS v2.5).  
En2 binding sites were identified using peak calling algorithms, which 
detect sites of protein-DNA binding by identifying regions where sequence reads 
are enriched in the genome after mapping. To increase the confidence of peak 
detection, we used two different peak-finding algorithms (Model-based Analysis 
for ChIP-Seq (MACS, version 2.0; (Yong Zhang et al., 2008)) and Probabilistic 
Inference for ChIP-Seq (PICS; (Xuekui Zhang et al., 2011))). MACS, run with a p-
value cutoff of 1.0E-05, identified 17,062 ChIP-enriched peaks, and PICS 
identified 23,807 peaks. Importantly, MACS and PICS identified the same 12,154 
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peaks. To reduce the number of genes chosen for the first round of downstream 
data analysis, peaks were chosen with a fold enrichment of 7 and above over 
input (3,326 peaks; See Appendix). Most of the peaks are located in the 
upstream regions of genes or their introns. Some are also found in the 5’UTR, 
with significantly fewer in the 3’ UTR and coding region (Fig. 13B), consistent 
with what would be expected for a transcriptional regulatory factor. 
 
Motif Analysis 
To further refine the set of peaks (3,326) to those with the greatest 
relevance for functional En2 regulation, the set was further analyzed for the 
presence of the canonical En2 binding motif (JASPAR database, Fig. 13C) using 
the scan motif tool of the analysis toolkit available from Strand NGS. A motif p-
value cut-off of 0.0035 was chosen, which represents the probability that the 
match between the En2 motif and the DNA sequence of the reference genome is 
most likely not due to chance. Remarkably, 2,728 out of 3,326 peaks contain the 
En2 motif (See Appendix), which were subsequently annotated to 1970 genes 
that lie within a 5kb distance from the proposed binding site (UCSC gene 
database).  
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Many En2 target genes are in the SFARI database and are expressed in the 
GE at E12.5. 
Interestingly, 87 out of the 1970 En2 targets identified above are in the 
SFARI database (Fig. 13D,) suggesting that En2 may be a master regulator of 
multiple ASD genes. This finding is in concordance with the results of a previous 
study that show many of the ASD genes in the SFARI database have transcripts 
that are differentially expressed in the hippocampus and/or cerebellum of the En2 
knockout mouse, (Sgado, 2013). Similarly, our results suggest that at least a 
subset of these genes may be direct targets of En2. Of the 87 potential targets in 
the SFARI database identified by En2-V5 ChIP-seq, all but four are expressed in 
the embryonic GE where interneurons are born (Table 15), suggesting a potential 
role for En2 in this region of the developing brain that may have been overlooked 
in previous studies. 
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Figure 13: Identification of human En2 target genes with En2-V5 ChIP-
sequencing. (A) Schematic representation of the strategy used to detect 
potential En2 target genes in the human genome. Top panel: synthesis of En2-
V5 fusion constructs that produce fusion proteins detected with En2 antibody 
(Santa Cruz) and V5 antibody (Life Technologies). Bottom panel: chromatin 
immunoprecipitation of genomic DNA fragments with bound En2-V5 fusion 
proteins identified by deep sequencing (ChIP-seq) and validated with qPCR 
analysis. (B) Pie chart depicts the proportion of genomic regions bound by En2 
(C) Mouse En2 motif obtained from the JASPAR database used for motif 
analysis in ChIP-seq. (D) Venn diagram showing that 87 of 1970 putative En2 
targets are located in the SFARI database of 703 known autism-associated 
genes. (Performed by M. Cogswell) 
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Table 15: Multiple En2 target genes that are in the SFARI database are 
expressed in the GE at E12.5. 87 out of the 1970 putative En2 targets are found 
in the SFARI database (www.sfari.org), and all but four are expressed in the 
medial ganglionic eminence (MGE, red) and lateral ganglionic eminence (LGE, 
green) as determined by RNA-seq analysis. Data analysis was performed using 
the Avadis NGS software platform. Chr: chromosome; P Score: -log10(p-value); 
Q Score: -log10(FDR); FDR: False discovery rate; FC: fold change between V5 
IP sample and Input sample; SFARI: Simons Foundation Autism Research 
Initiative database. Values in MGE and LGE columns represent normalized 
expression values using the DESeq algorithm. (Performed by M. Cogswell) 
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Validation of select ChIP-seq targets with ChIP RT-qPCR. 
Five En2 target genes of interest were chosen for further study by 
traditional ChIP with qRT-PCR analysis to test the validity of targets identified by 
ChIP-sequencing: lysine demethylase 5C (KDM5C), empty spiracles homeobox 
2 (EMX2), tuberous sclerosis 1 (TSC1), protein kinase C beta (PRKCB), and 
neurofibromin 1 (NF1). All genes are annotated in the SFARI database except for 
EMX2, which is a homeobox gene known to promote symmetrical, proliferative 
divisions of radial glial progenitor cells (Götz & Huttner, 2005), and control brain 
development (Zhao & Westphal, 2002). EMX2 is associated with ASD (Wall et 
al., 2009), and mutations in human EMX2 are associated with schizencephaly, a 
rare congenital brain malformation (Brunelli et al., 1996). All 5 genes showed a 
significant enrichment signal over IgG control (or V5 IP in HEK cells transfected 
with WT En2 expression constructs)(Figure 14B), consistent with their 
identification in the En2-V5 ChIP-seq dataset of Figure 14A. Representative En2-
V5 ChIP-seq tracks of the five validated En2 target genes are shown in Figure 
14C-G for comparison.  
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Figure 14. Validation of select ChIP-seq En2 target genes with ChIP RT-
qPCR. (A) Table containing the En2-V5 ChIP-seq dataset of five target genes 
chosen for validation with traditional ChIP. (B) Quantification of ChIP followed by 
qPCR analysis. Data is graphed as percent Input, error bars represent mean ± 
SEM of 4 replicates.(C-G) Representative ChIP-seq tracks from the Strand NGS 
software platform for KDM5C (C), EMX2 (D), TSC1 (E), PRKCB (F), and NF1 
(G). Read density profile plots of forward reads (blue) and reverse reads (red) 
aligned to the UCSC transcript model; each brown box represents a single 50-bp 
sequencing read. Exons are depicted by blue boxes, introns shown by lines 
connecting exons, shaded light blue area represents coding region. The En2 
motif sequence (and its corresponding p-value) is shown in black with the core 
sequence highlighted in red. Chr: chromosome; P Score: -log10(p-value); Q 
Score: -log10(FDR); FDR: False discovery rate; FC: fold change in peak of V5 IP 
to Input sample; SFARI: Simons Foundation Autism Research Initiative 
database. (Performed by M. Cogswell) 
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Systems Biology of En2 target genes. 
We interrogated whether there might be a functional relationship between 
subsets of the 1970 potential En2 target genes of the En2-V5 ChIP-seq dataset 
using Ingenuity Pathway Analysis (IPA, Qiagen). As expected from the 
identification of En2 as an ASD candidate gene, the top network enriched in the 
dataset is “Developmental Disorder, Neurological Disease, and Organismal Injury 
and Abnormalities” (Fig. 15A and 15B).  Additional top networks from the IPA 
analysis include cancer (Fig. 15A), where En2 has also been identified (McGrath 
et al., 2013). Top diseases and functions are all cancer-related (Fig. 15C, upper 
panel) and the top 5 molecular and cellular functions are gene expression, cell 
death and survival, cellular assembly and organization, cellular function and 
maintenance, and cellular growth and proliferation (Fig. 15C, middle panel), all 
consistent with the proposed role of En2 in brain development and in adult 
neuroprotection, especially in the basal ganglia. The proliferation of neuronal 
cells pathway is also significantly enriched in the En2-V5 ChIP-seq dataset and is 
depicted in Fig. 15D. Lastly, the top 5 physiological systems of development and 
function are: organismal survival, embryonic development, nervous system 
development and function, tissue morphology, and organ development (Fig. 15C, 
bottom panel). See Appendix for all significantly enriched pathways and their 
associated p-values and genes in the dataset from IPA analysis. 
 The top canonical signaling pathways significantly enriched in the En2-V5 
ChIP-seq dataset are shown in Table 16. The highest statistically ranked 
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pathway is that of protein kinase A (PKA) (p-value 6.82E-05), which regulates 
processes as diverse as growth, development, memory, and metabolism. The 
G2/M (growth phase 2/mitosis) cell cycle DNA damage checkpoint signaling 
pathway is also significantly enriched in the dataset (Fig. 16A and 16B, p-value 
2.83E-04). This enrichment is especially interesting as the G2/M checkpoint is 
the second checkpoint within the cell cycle which prevents cells with damaged 
DNA from entering mitosis, while also pausing so that DNA repair can occur. 
Regulation of the G2/M checkpoint can maintain genomic stability and prevent 
cells from undergoing malignant transformation.  
 Also in enrichment was the Wnt signaling pathway (Fig. 17A, p-value 
1.35E-03) with 25 En2-V5 target genes identified in key positions (Fig. 17B), 
including the Wnt receptors Frizzled 1 (FZD1) and Frizzled 6 (FZD6). This 
positioning of putative En2 targets is in concordance with a previous ChIP study 
in drosophila that identified frizzled2 (FZD2) as a target of endogenous En2 
(Solano et al., 2003). We believe the identification of En2 as a potential regulator 
of Wnt signaling could be especially important for further study as the Wnt 
pathway plays a major role in early brain development with regulation over cell 
proliferation, dendritic growth and arborization (Kalkman, 2012). It has also been 
implicated in ASD pathogenesis (Yinghua Zhang, Yuan, Wang, & Li, 2014) and 
modulation of Wnts in carcinogenesis is currently being investigated as a 
therapeutic strategy for cancer drugs (Anastas & Moon, 2013).  
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 In addition, the molecular mechanisms of cancer pathway (as described 
by IPA) is significantly enriched in the En2-V5 dataset (Table 16, p-value 1.3.7E-
03), consistent with a recent role for En2 in prostate cancer. In fact, En2 
overexpression has been identified in breast, prostate, and ovarian cancers 
(McGrath et al., 2013). In summary, all of the top canonical pathways significantly 
enriched in the En2-V5 dataset are involved in major developmental cellular 
processes that include cell proliferation, differentiation, survival and apoptosis 
and are consistent with the molecular phenotype that we now report occurs upon 
removal of En2 in GE by delivery of En2-specific shRNAs using mouse in utero 
electroporation. 
To explore further the functional relationship between potential En2 gene 
targets, we used the Gene ontology (GO) enrichment analysis tool of the Strand 
NGS software platform with 1970 En2 target genes, employing an adjusted p-
value threshold set to 0.1. A total of 224 GO terms were found significantly 
enriched in the En2-V5 dataset, indicating that En2 may regulate numerous 
pathways important in the developmental process (chromatin modification, cell 
cycle, neurogenesis, proliferation, and axon development) (Fig. 18, See 
Appendix) consistent with the IPA analysis described above. 
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Figure 15: Systems biology of En2 target genes. (A) List of the top 5 networks 
enriched in the En2-V5 ChIP-seq dataset from Ingenuity Pathway Analysis. (B) 
Pathway view of the top network, “Developmental disorder, neurological disease, 
and organismal injury and abnormalities”. (C) List of the top 5 diseases and 
functions, molecular and cellular functions, and physiological system 
development and function. The p-value range represents the range of p-values 
within each category. (D) Network view of “proliferation of neuronal cells” 
pathway (p-value 1.03E-03) located within the cellular growth and proliferation 
category show in (C). (Performed by M. Cogswell) 
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Table 16: Top canonical pathways of En2 target genes. Ingenuity Pathway 
Analysis reveals the top canonical pathways enriched in the En2 ChIP-seq 
dataset along with their associated p-values. Performed by M. Cogswell. 
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Figure 16: G2/M cell cycle DNA damage checkpoint signaling pathway. (A) 
Network view of the G2/M (growth phase 2/mitosis) cell cycle DNA damage 
checkpoint signaling pathway from IPA analysis with putative En2 target genes 
identified by En2-V5 ChIP-seq highlighted in purple (p-value 2.83E-04). (B) List 
of 12 En2 target genes in the Wnt pathway shown in panel (A). (Performed by M. 
Cogswell) 
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Figure 17. Wnt signaling pathway. (A) Network view of the Wnt signaling 
pathway from IPA analysis with En2 target genes identified by En2-V5 ChIP-seq 
highlighted in purple. (p-value=1.35E-03). (B) List of 25 En2 target genes in the 
Wnt pathway shown in panel (A). (Performed by M. Cogswell) 
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Figure 18: Overrepresented gene ontology categories for putative En2 
target genes. En2 target genes identified by En2-V5 ChIP-seq were analyzed for 
enrichment in gene ontology (GO) categories using the Strand NGS software 
platform with a Benjamini adjusted p-value cut-off of 0.1. Representative GO 
categories are reported in order of most significant as log (adjusted p-value). 
(Performed by M. Cogswell) 
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DISCUSSION 
The high co-morbidity rate between autism and epilepsy suggests they 
share common neuropathological mechanisms. En2 has been proposed to be 
the link between autism and epilepsy (Sgadò, Dunleavy, Genovesi, Provenzano, 
& Bozzi, 2011; Tripathi et al., 2009). The results of our in utero electroporation 
studies provide the first evidence to support a role for En2 in the proliferation of 
neural precursor cells in the ganglionic eminence, a region not previously 
associated with En2 function. Using gene expression analysis, we demonstrate 
that En2 mRNA is expressed at low levels in all regions of the GE, suggesting 
that it may play a general role in the ontogeny of cell types originating from this 
brain region. In utero electroporation and single progenitor clonal analysis also 
demonstrate that En2 expression in the GE may be biologically relevant as 
shRNA-targeted knockdown alters the balance between self-renewal and 
neurogenesis of radial glia progenitor cells, specifically in the LGE. Whether En2 
also plays a role in CGE, remains to be described in future studies; but, our 
results suggest that it may orchestrate a complex regulatory program that is 
important for the fate of certain radial glial progenitor cells in this transient 
structure of the brain.   
 Little is known regarding the gene targets of En2 that may underlie the 
molecular phenotype seen upon En2 shRNA-delivery. We employed a En2-V5 
ChIP-seq strategy to identify potential En2 targets in the human genome whose 
homologs may be active in mouse GE to control cell proliferation, differentiation, 
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and migration. Network analysis of these newly identified En2 targets reveals a 
significant enrichment in neurodevelopmental pathways and cellular processes 
including neurogenesis, and tumorigenesis, which is consistent with previously 
identified functions of En2 that have been studied predominantly in areas of 
abundant En2 expression (developing midbrain and cerebellum). However, 
recent studies have reported En2 expression at low levels in several regions of 
the telencephalon including the cortex and hippocampus and new techniques in 
parallel transcriptome and proteome analysis suggest that such levels have the 
potential to produce large amounts of protein (Schwanhäusser et al., 2011). This 
possibility is supported by the fact that the phenotype of the En2 knockout mouse 
suggests that En2 is active in these structures, as its removal leads to increased 
susceptibility to kainic acid-induced seizures and a decrease in specific 
interneuron populations.  
 The transcriptomic profiling of the GE that was used to verify the integrity 
of our microdissections, for downstream RT-PCR analysis, can also be used to 
identify transcripts that are specifically expressed in neural precursor cells and 
may be relevant to their developmental trajectory. Disruption in GABAergic 
signaling is one of the most consistent neuropathological findings in ASD and 
epilepsy. Ambient GABA works as a trophic factor in early brain development. 
GABA, acting at GABARs, has been shown to regulate tangential migration in the 
developing mouse brain (Cuzon et al., 2006). Migrating interneurons from the 
MGE to the cortex express functional GABARs (Cuzon Carlson & Yeh, 2011), 
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suggesting that regulation of GABAR number or kind might play an important role 
in interneuron development, even in the absence of functional synapses. In the 
developing brain, GABA acts as an excitatory neurotransmitter due to the 
delayed expression of the chloride exporter, KCC2. GABAR subunit composition 
determines the pharmacological activity of the receptor. Profiling of GABR 
subunit genes in our hands revealed an equal presence or absence of almost all 
GABAR subunit transcripts in MGE and LGE with the exception of Gabra5, which 
is higher in the MGE. Gabra5 is critical for learning and memory, as well as 
cognition. Transcripts specific to Gabra6 and Gabrd were not detected in the 
MGE or LGE, which is to be expected as Gabra6 is expressed solely in granule 
cells of the cerebellum and Gabrd is an extrasynaptic subunit that turns on later 
in development after the formation of synapses. Although out of the scope of our 
original study, future research will address the role that En2 may play in the later 
development of GABAR subunit specific expression, including its role at Gabra5, 
along the time course of embryonic development. 
 Surprisingly, we found that removal of En2 affected the LGE and not the 
MGE even though low levels of En2 are found in both regions of GE.  Again, 
whether the CGE is affected remains to be determined as we did report a 
significant and marked decrease in the self-renewal of radial glia cells even 
though the trend towards an increase in number of neurons is not significant at 
this time. The CGE is especially of interest because it is the birthplace of the VIP-
expressing cortical interneurons, and also contributes interneurons to multiple 
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structures of the limbic system including the hippocampus and amygdala (Nery et 
al., 2002).  
 The LGE generates the medium spiny neurons of the striatum, which is 
the major (95%) cell type of the striatum, and the sole output projection neurons. 
The LGE also contributes to cortical interneuron populations in later stages of 
development (T. Ma et al., 2012; Marin & Rubenstein, 2001). Thus, disruption of 
inhibitory neurons from LGE and CGE could explain some of the symptoms 
experienced by ASD-patients, as well as contribute to the hyperexcitabiliy of 
cortical networks resulting in epilepsy. The striatum is affected in ASD patients, 
and correlates with repetitive, stereotyped behaviors (Langen et al., 2014). These 
repetitive symptoms and the insistence on sameness is a debilitating symptom of 
ASD, and often requires pharmacological intervention with the use of respiridone. 
The striatum also coordinates multiple aspects of cognition, including motor and 
action planning, decision-making, motivation, reinforcement, and reward 
perception. 
Regulated proliferation of neural precursor cells is necessary to produce 
an adequate pool of neurons. Dysfunction of genes that control the balance 
between proliferation and differentiation of neural precursor cells can result in the 
generation of too many neurons and brain overgrowth or, premature cell cycle 
exit which may reduce the total number of neurons generated. Gain of function 
mutations in En2 have been associated with ASD in multiple pedigrees, which 
result in increased En2 expression (Benayed et al., 2009; J. Choi et al., 2012). 
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Increased En2 expression has been detected in post-mortem cerebellar tissue of 
ASD patients. Proper levels of En2 have been shown to be critical to its normal 
function. Knockout of En2 and overexpression of En2 in purkinje cells results in 
similar cerebellar phenotypes consisting of cerebellar hypoplasia and Purkinje 
cell loss, suggesting that the proper levels of En2 are critical for the normal 
development of the cerebellum.  
 Determining the molecular mechanisms that occur after GE delivery of 
En2 shRNAs has been hampered by the lack of information regarding the targets 
of En2 in the mammalian genome. To identify potential downstream gene 
networks regulated by En2, ChIP-seq analysis using En2-V5 fusion proteins 
expressed in HEK293 cells was used as a strategy and identified almost 2000 
En2-V5 targets in the human genome. While this analysis was performed in an in 
vitro system, the presence of an En2 motif in most ChIP-seq peaks and the 
enrichment of target genes involved in known pathways previously associated 
with En2 function suggests that the identified target genes are relevant. 
Furthermore, validation of En2 target genes using traditional ChIP followed by 
qPCR analysis confirms the accurate identification of En2 binding sites by ChIP-
seq.  
Most of the En2 targets identified by ChIP-seq are expressed in the GE at 
E12.5, suggesting that En2 may regulate the expression of critical 
neurodevelopmental networks relevant to the birth of cells from this brain region. 
Eighty-seven of the En2 targets are reported ASD-candidate genes listed in the 
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SFARI repository, suggesting that En2 may act as a master regulator of ASD 
candidate genes previously unappreciated. Earlier studies have identified 
significant changes in gene expression of multiple ASD candidate genes in the 
En2 knockout mouse using microarray analysis. Our results support this finding, 
and suggest that some of the identified genes could be actual targets of En2 in 
the genome. 
The confidence of the En2-V5 ChIP-seq dataset we report is validated by 
the significant enrichment of known pathways involved in neuronal development 
and cancer. All of the top canonical pathways enriched in the En2-V5 ChIP-seq 
dataset are involved in cellular developmental processes, including neurogenesis, 
proliferation, and cell survival. GO analysis supports this finding with a significant 
enrichment of terms related to chromatin modification, cell cycle and 
neurogenesis of the identified En2 target genes.  
En2 expression is restricted to the central nervous system (CNS) in the 
adult. Ectopic expression of En2 outside of the CNS is associated with tumor 
development, suggesting it may be involved in cancer pathogenesis. En2 has 
been implicated as a potential oncogene due to its ectopic expression in breast, 
prostate, melanoma and ovarian cancers (McGrath et al., 2013). In fact, En2 
expression has been detected in several breast cancer cell lines, and 
downregulation of En2 was shown to significantly reduce cellular proliferation. 
Ectopic overexpression of En2 in non-cancerous mammary cell lines increased 
their malignant features and caused mammary tumors when transplanted into 
		 167	
mammary glands in mice (N. L. Martin et al., 2005). En2 expression has also 
been detected in several prostate cancer cell lines, and downregulation of En2 
was shown to decrease cellular proliferation (Bose et al., 2008). 
 In conclusion, our results are the first to suggest that En2 may act as an 
anti-neurogenic factor in neural precursor cells of the LGE (and possibly CGE) to 
sustain the progenitor pool. Discovery of new En2 targets using En2-V5 ChIP-
seq suggests that En2 may have a more profound role in the developing brain 
that links it directly to the future generation of neurons that play a key role in the 
maintenance of brain inhibition. They also point to genomic sites where treatment 
of cancer and brain disorders may overlap.  Future studies will use genetic 
mouse models to follow the fate of selectively removing En2 expression in GE 
and will examine the impact that this has on the total number of neurons and glia 
that reside in key areas of the brain most vulnerable in developmental disorders. 
.
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CHAPTER IV: CHANGES IN GABAR SUBUNIT EXPRESSION RELEVANT TO 
THE DEVELOPMENT OF EPILEPSY. 
 
SECTION I: Effect of spontaneous seizures on GABAR subunit expression 
in an animal model of temporal lobe epilepsy. 
 
ABSTRACT 
 In this section, I present the work of studies done in collaboration with the 
Brooks-Kayal laboratory at the University of Colorado, Denver. The signaling 
mechanisms that mediate GABAR subunit plasticity in the dentate gyrus of the 
hippocampus after SE have been well defined. Increases in levels of α4 GABAR 
subunits are transcriptionally regulated by BDNF activation of the TrkB receptor, 
its downstream signaling cascades (PKC and MAPK), as well as upregulation of 
its target gene Egr3 (Roberts et al., 2006). Moreover, levels of both BDNF and 
Egr3 increase (Lund et al., 2008; Roberts et al., 2005; 2006), as does binding of 
Egr3 to the ERE site in the Gabra4 promoter following SE (Roberts et al., 2005). 
In parallel, BDNF-mediated activation of the JAK-STAT pathway precedes ICER 
and pCREB binding to the CRE site in the Gabra1 promoter, which mediates 
decreased transcription of Gabra1 after SE (Lund et al., 2008). The following 
studies test the hypothesis that changes in GABAR subunit gene expression that 
occur during the latent period following SE also occur in chronically epileptic rats, 
and that these changes are mediated by the activation of similar signal 
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transduction pathways. This work is partially adapted from the following 
publication: (Grabenstatter, H.L., Cogswell, M., Cruz Del Angel, Y., Carlsen, J., 
Gonzalez, M.I., Raol, Y.H., Russek, S.J., & Brooks-Kayal, A.R., 2014). 
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RESULTS 
Regulation of GABAR α4 subunit levels by spontaneous seizure activity. 
 Previous experiments have demonstrated that increased transcription of 
Gabra4 following prolonged pilocarpine-induced seizures (SE) is mediated by 
binding of Egr3 to the Gabra4 ERE site in the core promoter region 24 h following 
SE (Roberts et al., 2005). For the first time, we evaluated whether increased 
GABAR α4 expression may also occur during secondary epileptogenesis in 
response to acute spontaneous seizures (SS). Rats with a recent SS had 
significantly higher levels of Gabra4 mRNAs in the DG than controls (Fig. 19), 
whereas epileptic rats with no seizures for > 24 h had Gabra4 mRNA levels 
similar to controls. Western blot analysis was performed to determine if the 
increase in Gabra4 mRNA levels was paralleled by a similar increase in GABAR 
α4 protein levels. Animals sacrificed with 3 h of a recent SS had significantly 
higher α4 protein levels than control rats, yet epileptic rats having an SS within 
the last 3 h also had significantly higher α4 protein levels when compared to 
epileptic rats without a seizure for > 24 h, suggesting that recent SS activity 
induces increased α4 protein expression in chronically epileptic animals (Fig. 20). 
Continuous video-EEG collected from the same animals for 7 days prior to 
sacrifice was analyzed to determine whether there was a difference in overall 
seizure frequency between the two groups. Video-EEG data demonstrated that 
rats sacrificed < 3 h after SS, which had higher levels of GABAR α4 expression, 
also had significantly higher daily seizure frequency than the rats sacrificed > 24 
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h after the last seizure (Fig. 21). These results suggest that spontaneous 
seizures may induce a cascade of events that increase α4 on a relatively short 
time-scale, and that animals with frequent SS (i.e., more severe epilepsy) may 
have higher overall GABAR α4 subunit levels.  
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Figure 19. Spontaneous seizures increase Gabra4 mRNA expression in DG. 
Quantification of RT-PCR analysis of Gabra4 mRNA expression in DG < 3 and > 
24 h after SS (controls, n=4; SS 3H, n=5; SS 24H, n=4) demonstrates a 
significant (p<0.05) increase in Gabra4 mRNA levels following a recent 
spontaneous seizure activity (within 3 h) relative to control rats. Epileptic rats that 
had not had a seizure for > 24 h have Gabra4 mRNA levels similar to controls. 
Gabra4 mRNA expression was normalized to cyclophilin and expressed as fold 
change compared to controls (defined as 1). Statistically significant differences in 
mRNA levels were determined using a one-way ANOVA with Tukey’s test for 
multiple comparisons. For all graphs, error bars, mean ± SEM. (Performed by M. 
Cogswell.) 
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Figure 20: Spontaneous seizures increase GABAR α4 protein expression in 
DG. Western blots of DG protein homogenates of control rats or epileptic rats 
sacrificed within 3 h of a spontaneous seizure (top left panel; n=6 controls, n=6 
SS) or > 24 h after last spontaneous seizure  (top right panel; n=3 controls, n=4 
No SS) reacted with an anti-α4 and anti-Actin antibodies. Densitometry analysis 
demonstrates that rats with recent seizure activity show ~23% increase in 
GABAR α4 expression relative to controls (p<0.01) and ~20% increase relative to 
epileptic rats without recent spontaneous seizures (p<0.05) using a one-way 
ANOVA with Tukey’s test for multiple comparisons. Normalized data are 
presented as mean ± standard error of the mean (SEM) and expressed as 
percent change. (This work was performed in the Brooks-Kayal laboratory in 
collaboration) 
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Figure 21: Seizure frequency is increased in epileptic animals with 
increased GABAR α4 levels following recent spontaneous seizure. The 
same rats that express increased α4 subunit mRNA and protein levels in DG 
following a recent SS (i.e., < 3 h SS; SS 3H, n=6) demonstrate a significantly 
higher seizure frequency (i.e., seizures/day) during the 7-day monitoring period 
prior to sacrifice relative to the > 24 h SS group (SS 24H, n=4; *p=0.0139). 
Significant differences in seizure frequency were detected using a Mann-Whitney 
test. For all graphs, error bars, mean ± SEM. (This work was performed in the 
Brooks-Kayal laboratory in collaboration) 
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Spontaneous seizures increase BDNF, and Egr3 mRNA levels.  
 Evaluation of the mechanisms leading to increased GABAR α4 subunit 
levels demonstrated that rats with a recent SS had a greater than sixfold 
increase in BDNF mRNA levels in the DG relative to control rats (Fig. 22). BDNF 
mRNA levels in epileptic rats with no SS within 24 h of sacrifice were similar to 
controls, suggesting changes in BDNF expression may be driven by recent 
seizure activity rather than being a residual effect of SE, or inherent to the 
epileptic state. Because BDNF has been shown previously to regulate Gabra4 
expression via its control over Egr3 levels, and the binding of Egr3 to the Gabra4 
core promoter after SE (Roberts et al., 2006), we examined whether Egr3 mRNA 
levels also change following a recent SS. Levels of Egr3 mRNAs increased by 
greater than eightfold following a recent (< 3 h) spontaneous seizure and were 
significantly higher than in epileptic rats with no seizures for > 24 h (Fig. 23). 
Chromatin immunoprecipitation was used to examine whether increased binding 
of Egr3 protein to the promoter of the Gabra4 subunit gene occurred within 3 h of 
a spontaneous seizure and might account for the increased Gabra4 mRNA 
levels. Although Egr3 protein binding to the ERE promoter of the Gabra4 subunit 
gene was observed in the DG following recent spontaneous seizures, the levels 
were not significantly different from those seen in controls (Fig. 24). 
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Figure 22. Spontaneous seizures increase BDNF mRNA expression in DG. 
DG from epileptic rats with recent SS (within 3 h) showed significant (p < 0.01) 
increases in BDNF mRNA expression compared to controls, and compared to 
rats that had not had an SS for > 24 h (p < 0.05) (controls, n=7, SS 3H, n=8; SS 
24H, n=6). BDNF mRNA expression was normalized to cyclophilin and 
expressed as fold change compared to controls (defined as 1). Statistically 
significant differences in mRNA levels was determined using a one-way ANOVA 
with Tukey’s test for multiple comparisons. For all graphs, error bars, mean ± 
SEM. (Performed by M. Cogswell) 
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Figure 23. Spontaneous seizures increase Egr3 mRNA expression in DG. 
DG from epileptic rats with recent SS (within 3 h) showed significant (p < 0.01) 
increases in Egr3 mRNA expression compared to controls, and compared to rats 
that had not had an SS for > 24 h (p < 0.05) (controls, n=4, SS 3H, n=8; SS 24H, 
n=4). Egr3 mRNA expression was normalized to cyclophilin and expressed as 
fold change compared to controls (defined as 1). Statistically significant 
differences in mRNA levels was determined using a one-way ANOVA with 
Tukey’s test for multiple comparisons. For all graphs, error bars, mean ± SEM. 
(Performed by M. Cogswell) 
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Figure 24. Egr3 binding to the Gabra4 promoter was not different between 
groups. Quantification of protein-DNA binding in DG < 3 h after SS (controls, 
n=3; SS 3H, n=4) demonstrates no difference in Egr3 protein binding to the ERE 
promoter of Gabra4 following a recent spontaneous seizure activity (within 3 h) 
relative to control rats. Data were normalized to input signal (Egr3/Input) and 
expressed as fold change with respect to control (defined as 1). Input represents 
the DNA signal from sample preparation prior to immunoprecipitation. Potential 
significant differences in protein-DNA binding was determined using an unpaired, 
Student’s t-test. Error bars, mean ± SEM. (Performed by M. Cogswell) 
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Spontaneous seizures increase ICER and CREM mRNA levels, and 
decreases Gabra1 mRNA levels.  
 Previous experiments in our lab have demonstrated that decreased 
transcription of Gabra1 following prolonged pilocarpine-induced seizures (SE) is 
mediated by activation of the JAK-STAT pathway and binding of ICER and 
pCREB to the Gabra1 CRE site in the core promoter region 24 h following SE 
(Lund et al., 2008). For the first time, we evaluated whether activation of the JAK-
STAT pathway and decreased Gabra1 expression may also occur during 
secondary epileptogenesis in response to acute SS. Epileptic rats without a 
seizure for > 24 h had significantly lower levels of Gabra1 mRNAs in the DG than 
controls, whereas epileptic rats with recent seizure activity (< 3 h SS) had 
Gabra1 mRNA levels similar to controls (Fig. 25). Levels of ICER mRNAs 
significantly increased following a recent (< 3 h) spontaneous seizure as 
compared to controls, and were significantly higher than in epileptic rats with no 
seizures for > 24 h (Fig. 26). In order to detect whether there might be an 
associated change in ICER protein levels, and given that ICER is synthesized 
from an internal promoter in the CREM gene, we next examined whether levels 
of CREM mRNAs also change following a recent SS. Levels of CREM mRNAs 
significantly increased following a recent (< 3 h) SS as compared to controls, and 
were significantly higher than in epileptic rats without a seizure for > 24 h (Fig. 
27).  
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Figure 25. Spontaneous seizures decrease Gabra1 mRNA expression in 
DG. Quantification of RT-PCR analysis of Gabra1 mRNA expression in DG < 3 
and > 24 h after SS (controls, n=4; SS 3H, n=7; SS 24H, n=4) demonstrates a 
significant (p<0.05) decrease in Gabra1 mRNA levels in epileptic rats without a 
seizure for > 24 h relative to control rats. Epileptic rats with recent seizure activity 
(< 3 h) have Gabra1 mRNA levels similar to controls. Gabra1 mRNA expression 
was normalized to cyclophilin and expressed as fold change compared to 
controls (defined as 1). Statistically significant differences in mRNA levels was 
determined using a one-way ANOVA with Tukey’s test for multiple comparisons. 
For all graphs, error bars, mean ± SEM. (Performed by M. Cogswell) 
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Figure 26. Spontaneous seizures increase ICER mRNA expression in DG. 
DG from epileptic rats with recent SS (within 3 h) showed significant (p < 0.05) 
increases in ICER mRNA expression compared to controls, and compared to rats 
that had not had an SS for > 24 h (p < 0.01) (controls, n=7, SS 3H, n=8; SS 24H, 
n=8). ICER mRNA expression was normalized to cyclophilin and expressed as 
fold change compared to controls (defined as 1). Statistically significant 
differences in mRNA levels was determined using a one-way ANOVA with 
Tukey’s test for multiple comparisons. For all graphs, error bars, mean ± SEM. 
(Performed by M. Cogswell) 
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Figure 27. Spontaneous seizures increase CREM mRNA expression in DG. 
DG from epileptic rats with recent SS (within 3 h) showed significant (p < 0.05) 
increases in CREM mRNA expression compared to controls, and compared to 
rats that had not had an SS for > 24 h (p < 0.05) (controls, n=4, SS 3H, n=8; SS 
24H, n=4). CREM mRNA expression was normalized to cyclophilin and 
expressed as fold change compared to controls (defined as 1). Statistically 
significant differences in mRNA levels was determined using a one-way ANOVA 
with Tukey’s test for multiple comparisons. For all graphs, error bars, mean ± 
SEM. (Performed by M. Cogswell) 
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Changes in seizure semiology related to GABAR differences. 
 Continuous video-EEG monitoring was used to characterize seizure 
frequency, seizure type, and temporal distribution for 7 days before sacrifice. 
Rats sacrificed within 3 h of a recent seizure had significantly higher seizure 
frequencies overall than rats sacrificed > 24 h after the last spontaneous seizure 
(Fig. 28), suggesting they had more severe epilepsy in general. However, despite 
the difference in seizure frequency between the < 3 h SS and > 24 h SS groups, 
each group had similar seizure durations (Fig. 29) and severity (i.e., convulsive 
vs. nonconvulsive [Fig. 30]). Of interest, rats sacrificed > 24 h after SS, had 
technically more prolonged interictal intervals (defined as > 300 min or ~6 h) than 
animals sacrificed < 3 h after SS (Fig. 31). Increases in Gabra4 mRNA and 
protein levels occurred following high frequency seizure clusters with or without 
prolonged intercluster intervals (Fig. 32, top panel), suggesting that spontaneous 
seizure clusters can induce Gabra4 plasticity even when they occur infrequently. 
High frequency seizure clusters were more common in < 3 h SS animals, but 
were present in some of the > 24 h group; however, the group consistently had 
Gabra4 mRNA, and protein, levels similar to control rats when sacrificed 
following long periods of seizure freedom (i.e., long interictal interval; Fig. 32, 
bottom panel). This suggests that Gabra4 mRNA levels are plastic, increasing 
transiently following a spontaneous seizure and then falling again after a long 
period of seizure freedom.  
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Figure 28. Rats with recent spontaneous seizure demonstrate a higher 
seizure frequency. EEG data across all rats used for above experiments for < 3 
h SS group (n=16) demonstrate a significantly higher seizure frequency (i.e., 
seizures/day) during the 7-day monitoring period prior to sacrifice relative to the > 
24 h SS group (n=6; **p=0.0019). Statistically significant differences were 
determined using the Mann-Whitney test. (This work was performed in the 
Brooks-Kayal laboratory in collaboration) 
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Figure 29. Mean seizure duration was not different between groups. During 
the same 7-day period, continuous EEG monitoring demonstrated no significant 
difference in seizure duration in the < 3 h SS group or the > 24 h SS group. 
Statistically significant differences were determined using an unpaired Student’s 
t-test. (This work was performed in the Brooks-Kayal laboratory in collaboration) 
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Figure 30. Seizure severity was not different between groups. During the 
same 7-day period, continuous EEG monitoring demonstrated no significant 
difference in the proportion of convulsive seizures to nonconvulsive seizures 
present in the < 3 h SS group or the > 24 h SS group. Statistically significant 
differences were determined using a Fisher’s exact test. (This work was 
performed in the Brooks-Kayal laboratory in collaboration) 
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Figure 31. The 24 h SS group had more long interseizure intervals. 
Frequency histograms of the interseizure intervals for the group of epileptic rats 
sacrificed within 3 h of last spontaneous seizure and > 24 h after last 
spontaneous seizure. The first bin (< 60 min or > 1 seizure/h) had a high number 
of interseizure intervals for both groups, suggesting the presence of seizure 
clusters. A significant difference between the two groups was found in < 300 (or 
~6 h) bin demonstrating the SS 24 h group had more long interseizure intervals 
(or intercluster intervals). Statistically significant differences were determined 
using a one-way ANOVA with a Newman-Keuls test for multiple comparisons. 
(This work was performed in the Brooks-Kayal laboratory in collaboration) 
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Figure 32. High frequency seizure clusters were more common in < 3 h SS 
animals. Representative raster plots depicting the time of previous seizure 
occurrence under the conditions of increased Gabra4 mRNA and protein 
expression within 3 h of a spontaneous seizure (top panels) or unchanged 
Gabra4 mRNA and protein (bottom panels) in DG of rats without seizures for > 
24 h. (This work was performed in the Brooks-Kayal laboratory in collaboration) 
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DISCUSSION 
 The results of these studies are the first demonstration that spontaneous 
seizures may acutely regulate Gabra4 RNA, and protein, expression, suggesting 
that spontaneous seizures (regardless of whether convulsive or non-convulsive) 
result in acute transcriptional upregulation of the Gabra4 gene in the DG of 
epileptic rats. Increased levels of Gabra4 RNAs and protein were associated with 
higher overall seizure frequencies in epileptic rats sacrificed within 3 h of an SS. 
These data could support two different, but not mutually exclusive, 
interpretations. One interpretation is that in chronic epilepsy the spontaneous, 
recurrent seizures drive Gabra4 increases via acute activation of cellular 
signaling pathways after each epileptic event (i.e., reactive plasticity of Gabr 
subunit genes). Long periods of seizure freedom allow the system to “reset” and 
GABAR subunit levels to return to control levels until an SS again induces Gabr 
increases. In addition, it is possible that the increased seizure frequency 
observed in these animals may, in part, be a consequence of long-term changes 
in GABAR subunit expression. The most parsimonious explanation of our data is 
that these scenarios exist together, with spontaneous seizures themselves 
stimulating the change in GABAR α4 subunit expression, and that these 
alterations, in turn, may contribute to higher overall seizure frequencies that then 
perpetuate and/or exacerbate the GABAR alterations. 
 Increases in Gabra4 expression have been demonstrated in epileptic 
animals in several TLE models (Brooks-Kayal, Jin, Price, & Dichter, 1998a; 
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Nishimura et al., 2005; Peng, Huang, Stell, Mody, & Houser, 2004; Nianhui 
Zhang, Wei, Mody, & Houser, 2007). The functional consequences of these 
increases in GABAR α4 levels depend in large part on what other subunits it 
pairs with to compose a receptor. Immunoprecipitation and immunogold labeling 
studies suggest that α4 subunits can assemble with either δ or γ2 subunits (Jia et 
al., 2005; Lund et al., 2008; Sur et al., 1999), with α4δ-containing receptors 
predominating in normal DG and α4γ-containing receptors becoming more 
abundant in epileptic tissue (Lund et al., 2008; Peng et al., 2004; Nianhui Zhang 
et al., 2007). Delta-containing GABARs are located primarily at extrasynaptic 
sites and have traditionally been thought to mediate tonic inhibition, whereas 
phasic inhibition is governed by γ-containing GABARs located at synaptic or 
perisynaptic regions (Chandra et al., 2006; Mody, 2001; Nusser & Mody, 2002; 
Wisden et al., 2002). Despite a diminished expression of δ subunit mRNA 
(Nishimura et al., 2005; Nianhui Zhang et al., 2007) and a reduction in functional 
α4δ-containing GABARs in the hippocampus of epileptic animals (Rajasekaran, 
Joshi, Sun, Mtchedlishvilli, & Kapur, 2010), tonic GABAergic inhibition is 
maintained or increased in epileptic animals (Zhan & Nadler, 2009). Some 
studies in chronically epileptic animals suggest that the novel α4γ2-containing 
receptors are responsible for maintaining tonic inhibition (Rajasekaran et al., 
2010), whereas others find that an increase in such receptors in synaptic and/or 
perisynaptic locations are responsible for altered phasic GABA currents in 
epileptic hippocampus (Nianhui Zhang et al., 2007). Thus, alterations in α4-
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containing GABARs may be associated with changes in both tonic and phasic 
GABAR-mediated inhibition. 
 Alterations in α-subunit subtype can result in differences in GABAR 
modulation by benzodiazepines, neurosteroids, and zinc (Buhl, Otis, & Mody, 
1996; Cohen, Lin, Quirk, & Coulter, 2003; J. W. Gibbs, Shumate, & Coulter, 
1997; Sun, Mtchedlishvili, Erisir, & Kapur, 2007). Pharmacologic experiments 
suggest that increased levels of α4γ-containing receptors in epileptic brain may 
contribute to an altered response of GABARs to GABA and to GABAergic drugs. 
Lagrange et al., 2007 reported that α4γ-containing receptors are more rapidly 
desensitized and recover more slowly from desensitization. They further found 
that exposure to prolonged low levels of GABA greatly suppressed the response 
of α4γ-containing receptor currents to higher concentrations of GABA. Overall, 
these receptors appeared less efficacious when exposed to prolonged low levels 
of GABA or during repetitive stimulation, as may occur during seizures. These 
results are consistent with the observation that, in epileptic animals, GABARs 
become largely insensitive to higher GABA concentrations (Overstreet, Jones, & 
Westbrook, 2000). Thus, drug treatments that increase the level of extrasynaptic 
GABA may negatively modulate the ability of extrasynaptic α4γ-containing 
receptors to respond to variations in ambient GABA that may occur following SS, 
as well as during SE (Naylor & Wasterlain, 2005). In addition, because α4-
containing GABARs are more sensitive to zinc blockade, a shift to more α4-
containing GABARs may be associated with the enhanced blockade of the GABA 
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response by zinc in the DG, seen both acutely after SE and in chronic epilepsy in 
both animals (Buhl et al., 1996; Cohen et al., 2003; J. W. Gibbs et al., 1997; 
Leroy, Poisbeau, Keller, & Nehlig, 2004), and in humans with TLE (Shumate, Lin, 
Gibbs, Holloway, & Coulter, 1998). Zinc is distributed by aberrant mossy fiber 
axons of DG cells that innervate the inner molecular layer of the DG in late 
stages of epileptogenesis (i.e., after the onset of SS). The α4-containing 
GABARs present on dendrites of epileptic DG neurons are exquisitely sensitive 
to blockade by zinc, and thus may contribute to loss of inhibitory function and 
increased excitability (Cohen et al., 2003; Shumate et al., 1998). The 
transcriptional upregulation of Gabra4 gene expression seen in association with 
spontaneous seizures may thus result in changes in both tonic and phasic 
GABAR-mediated inhibition that could impact seizure susceptibility in chronically 
epileptic rats. 
 The increases in BDNF levels following recent spontaneous seizure 
activity (i.e., within 3 h) suggest that SS may recurrently “reactivate” signaling 
pathways that could contribute to the perpetuation and progression of epilepsy. 
However, although there was a marked and significant increase in levels of Egr3 
mRNA, as well as BDNF, following recent SS, we did not detect an associated 
increase in Egr3 binding to the Gabra4 promoter. Without this evidence, we 
cannot definitively conclude that BDNF-induced increases in Egr3 are driving the 
induction of Gabra4 transcription following SS. Our evidence does allow us to 
conclude, however, that Egr3 is present at the promoter region and is part of the 
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transcriptional complex that most likely underlies increased rates of transcription 
in our studies. Little is known about the mechanism of Egr3-directed gene 
regulation in neurons, and research in this area has been hampered by the lack 
of antibodies with which to probe the expression of its many variants, an active 
area of investigation in our laboratories. 
 The decrease in Gabra4 mRNA levels in rats without recent spontaneous 
seizure activity (i.e., > 24 h) is consistent with our previous findings during the 
latent period demonstrating a decrease in α1 subunit levels that occurs 
subsequent to the increase in α4 levels. Increases in ICER and CREM mRNA 
levels were observed in animals with recent seizure activity (i.e., < 3 h) 
suggesting that spontaneous seizures reactivate the JAK-STAT signaling 
pathway to promote a subsequent reduction in the expression of Gabra1 in the 
DG of the hippocampus.  
 In conclusion, these studies provide the first evidence of acute molecular 
regulation of GABAR subunit expression in association with spontaneous 
seizures during chronic epilepsy. Better understanding of the molecular changes 
induced by SS and their functional consequences could contribute to the 
development of disease-modifying therapies that do not just symptomatically 
treat seizures but potentially inhibit their progression and long-term adverse 
consequences. 
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SECTION II: CHANGES IN GABAR SUBUNIT EXPRESSION ACROSS THE 
MENSTRUAL CYCLE 
 
INTRODUCTION 
 In this section, I present the work of studies done in collaboration with the 
Sharfman laboratory at NYU School of Medicine, New York. Catamenial epilepsy 
is characterized by the exacerbation of seizures in females during menstruation 
when levels of progesterone and its metabolite allopregnanolone decrease 
(Scharfman, 2003). Allopregnanolone, a neuroactive steroid, is a potent positive 
allosteric modulator of the GABAR (Herzog & Frye, 2003; Macdonald & Olsen, 
1994). The following studies test the hypothesis that changes in GABAR subunit 
gene expression that occur during the latent period following SE also occur in the 
DG of female rats across the menstrual cycle when females are more susceptible 
to seizures, and that these changes are mediated by the activation of similar 
signal transduction pathways. The dentate gyrus of the hippocampus was 
dissected from adult female rats during the four different phases of the estrus 
cycle; proestrus, estrus, diestrus 1 and diestrus 2 for protein expression assays 
using Western blot analysis.  
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Figure 33. Changes in GABRA4 protein levels across the estrus cycle. DG 
tissue was collected from adult rats during proestrus (P, n=4), estrus (E, n=5), 
diestrus 1 (D1, n=5), and diestrus 2 (D2, n=5). Changes in protein were 
measured using Western blot. Data was normalized to β-actin. Representative 
Western blots are shown. Protein levels are expressed as fold change relative to 
proestrus set to 1. Significant changes are indicated (*p<0.05; mean ± SEM, one-
way ANOVA with post hoc analysis by Tukey’s Multiple Comparisons test). 
(Performed by M. Cogswell) 
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Figure 34. Changes in GABRA1 protein levels across the estrus cycle. DG 
tissue was collected from adult rats during proestrus (P, n=4), estrus (E, n=5), 
diestrus 1 (D1, n=5), and diestrus 2 (D2, n=5). Changes in protein were 
measured using Western blot. Data was normalized to β-actin. Representative 
Western blots are shown. Protein levels are expressed as fold change relative to 
proestrus set to 1. Significant changes are indicated (*p<0.05; mean ± SEM, one-
way ANOVA with post hoc analysis by Tukey’s Multiple Comparisons test). 
(Performed by M. Cogswell) 
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Figure 35. Changes in Egr3 protein levels across the estrus cycle. DG tissue 
was collected from adult rats during proestrus (P, n=4), estrus (E, n=5), diestrus 
1 (D1, n=5), and diestrus 2 (D2, n=5). Changes in protein were measured using 
Western blot. Data was normalized to β-actin. Representative Western blots are 
shown. Protein levels are expressed as fold change relative to proestrus set to 1. 
Significant changes are indicated (*p<0.05; mean ± SEM, one-way ANOVA with 
post hoc analysis by Tukey’s Multiple Comparisons test). (Performed by M. 
Cogswell) 
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DISCUSSION 
 These studies demonstrate that there are changes in GABAR subunit 
protein levels across the menstrual cycle. Specifically, increased levels of 
GABRA4 subunits are observed during proestrus, accompanied by decreased 
levels of GABRA1 subunits during estrus. These findings suggest that similar 
changes in GABAR subunit genes that occur during the latent period of SE also 
occur across the menstrual cycle. The increase in GABRA4 subunit levels may 
be mediated by Egr3, as evidenced by the parallel increase in Egr3 protein levels 
during proestrus. Importantly, we demonstrate that increases in GABRA4 subunit 
expression occurs when females are more susceptible to seizures as 
progesterone decreases during proestrus. The question that remains to be 
determined is whether the increase in GABRA4 subunit levels results in more 
extrasynaptic receptors, or a replacement of α1-containing receptors at the 
synapse as occurs in the TLE model. These pro-epileptic changes that occur in 
the healthy female brain may explain the underlying pathophysiology of 
catamenial epilepsy. Future studies will measure activation of the JAK-STAT 
pathway (ICER and pSTAT3) using Western blot analysis and qPCR, and Egr3 
binding to the Gabra4 promoter along with ICER binding to the Gabra1 promoter 
using ChIP assays across the menstrual cycle to establish a model for seizure 
susceptibility and increased anxiety during the premenstrual cycle. 
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CHAPTER V: SUMMARY AND FUTURE DIRECTIONS 
In my thesis I have presented the research that encompasses two different 
stories, the first which I originated in the laboratory that reflects my personal 
desire to better understand the etiology of autism spectrum disorders and the 
second, which is an outgrowth of my laboratory’s previous projects that 
specifically address the etiology of spontaneous seizures as they relate to 
chronic epilepsy and occur as a consequence of a change in the subunit 
composition of GABARs. In this last chapter of my thesis I will address what I 
believe would be a key set of experiments that could follow up on my discoveries 
for Chapter III and move my work forward towards directly testing the 
overarching hypothesis that: expression of the ASD candidate gene Engrailed 2 
in the ganglionic eminence is critical for the development of neuronal populations 
that originate from this brain region and the subsequent formation of key 
inhibitory neural circuitry that is disrupted in brain disorders. 
 
As I discussed in Chapter 1, an emerging feature of multiple 
neuropsychiatric disorders is a disruption in the development of GABAergic 
interneurons that originate in the transitory structure called the ganglionic 
eminence of the embryonic brain, although the mechanism behind such 
disruption remains to be identified. A plethora of genes associated with mental 
disorders have appeared since the discovery of En2 mutations in autistic human 
patients; yet, En2-/- mice remain an important model displaying many of the 
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behavioral, anatomical, and neuropathological features (including loss of specific 
GABAergic interneuron populations and increased seizure susceptibility) 
associated with the disease. How removal of a homeobox transcription factor 
specifically responsible for development of the midbrain and cerebellum 
produces a full spectrum of anatomic and behavioral changes is a mystery that is 
made more elusive by the lack of knowledge regarding specific En2 targets in the 
genome.  
When we began our studies on En2 we were surprised to find that so little 
is known regarding the targets of this transcription factor in the genome. The lack 
of a specific antibody to En2, i.e. one that resolves to a single band upon 
Western blot, also makes it difficult to interpret results of any chromatin 
immunoprecipitation (ChIP) studies in the literature, as all of the available 
antibodies (including those of A. Joyner) produce multiple strong bands, in 
addition to En1 and En2 detection, that are non-specific. To get around the 
antibody specificity issue, we generated an En2 expression construct that fuses 
the V5 tag as a means to precipitate a single gene product using a V5-specific 
antibody in transfected HEK293 cells. To our surprise we found, using ChIP 
sequencing (ChIP-seq), that overexpressed En2-V5 bound to 87 target genes 
found in the SFARI database, a repository of all known human genes associated 
with ASD. Many of these genes are also expressed in the GE at E12.5 along with 
low levels of En2, as seen previously in the hippocampus. Based on these 
findings, En2 shRNAs were delivered into the GE using mouse in utero 
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electroporation and we now report that specific En2 knockdown decreases the 
number of apical progenitors residing in the VZ of the LGE. Single progenitor 
clonal analysis using retroviral En2 shRNA delivery supports this finding and 
demonstrates that En2 can promote self-renewal in interneuron progenitor cells; 
and, that its absence, or decrease, triggers premature cell cycle exit and 
detachment from the VZ to promote neurogenesis. We also report a significant 
decrease in progenitor cells in CGE, but the consequence of this finding remains 
unknown. Taken together our findings in Chapter 3 demonstrate a novel role for 
En2 in the GE, a region not previously associated with En2 function and one that 
may be critical to the development of GABAergic neurons. Based on these 
findings I propose that to directly assess the role of En2 expression in GE the 
laboratory should make a new mouse model and directly characterize its 
anatomic and genomic phenotype in the developing mouse brain. The following 
specific Aims would be used to accomplish this goal: 
 
Aim 1. Develop a mouse model in which mice expressing codon optimized iCre 
directed by the endogenous Gsx2 (GS homeobox 2) promoter/enhancer region 
(Kessaris et al., 2006) is crossed with a floxed En2 gene to produce a removal of 
functional En2 in the ganglionic eminence of the developing brain. 
 
Aim 2. Develop a mouse model by crossing the mouse line of Aim 1 with a floxed 
dual reporter line from Jackson labs that expresses membrane bound green 
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fluorescence, instead of tomato, in all cells expressing Gsx2-iCre and floxed En2. 
The resulting line will contain green fluorescence only in cells of the ganglionic 
eminence (and septum) where Gsx2-iCre is expressed and where En2 has been 
functionally deleted.  
 
Working closely with the transgenic core at Boston University School of Medicine 
(and Jackson Labs), I would obtain mice that express iCre recombinase (codon-
improved Cre recombinase) under the control of the Gsx2 (GS homeobox 2) 
promoter/enhancer region, which is expressed in all regions of the GE. This line 
would then be crossed with a floxed En2 line, and later we will cross the resulting 
line with a dual reporter line, supplied again by Jackson labs, in order to identify 
the cells where En2 has been functionally deleted. The floxed En2 mice were 
created by Alexandra Joyner’s lab and are viable and fertile, as well as used 
previously to generate region-specific knockout by crossing with a region specific 
CRE line (Fox and Deneris, 2012). The loxp sites flank the coding region of Exon 
2 and upon CRE recombinase expression will lose the homeodomain for the 
protein. The dual reporter mouse expresses tomato when Cre is absent but 
expresses membrane bound green fluorescence upon Cre excision. This will 
enable us to identify the cells where En2 is removed so that they can be followed 
over time and genotyped via RNA-seq and ChIP-seq using laser capture and/or 
microdissection.  
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 Future studies could use these genetic mouse models to follow the fate of 
selectively removing En2 expression in GE and would examine the impact that 
this has on the total number of neurons and glia that reside in key areas of the 
brain that are most vulnerable in developmental disorders. These studies would 
be the first of their kind to determine whether targeted deletion of En2 in GE has 
a molecular phenotype that mimics some of the features of the global En2 
knockout and would have the promise of providing important new tools for the 
study of neuropsychiatric disorders. 
 
Additional areas for further clarification: 
Low levels of En2 mRNAs: In my thesis research, En2 expression was detected 
at low levels in all regions of the GE, consistent with several other reports in the 
literature. The question that remains is how much protein is translated from these 
low copy number transcripts. The lack of a specific En2 antibody prevents the 
measurement of protein abundance. One possibility is that En2 protein 
expression levels parallel the low transcript abundance, which may dictate the 
biological function of En2. Homeobox genes are expressed in gradients during 
development, and strings of binding sites have been detected in the genome. It is 
possible that the targets of En2 change with varying levels of En2 expression. 
Another possibility is that En2 transcripts produce high amounts of protein. 
Reports in the literature have demonstrated that a single transcript can generate 
as many as 2,500 proteins. At this time I cannot propose a clear strategy to 
		 221	
interrogate the role of rare En2 to brain function, outside of the knockout model 
discussed above, given that ChIP-seq cannot be performed in single cells and 
still requires a lot of precipitated DNA and a highly selective antibody. The Joyner 
laboratory did make a mouse with a knock-in fusion protein in the endogenous 
En2 allele for selective pull down but this model has issues because it is lethal to 
the animal, suggesting a loss of function in and of itself. 
 
Region-specific phenotype: An additional area for further clarification is that En2 
mRNA was detected in all regions of the GE, but we only observed a phenotype 
in the LGE, and possibly the CGE, using both IUE and clonal analysis. We only 
had time to quantitate the IUE phenotype in LGE, not in any other regions. What 
would CGE have looked like? As CGE is the birthplace of fast spiking 
interneurons that express VIP, and as these neurons have been implicated in 
mental disorders, future studies from the laboratory could study this region 
directly, and the genetic model discussed above would be a good place to start.  
My results also show that there is a potential consequence of premature 
neurogenesis in the GE that could possibly reduce the total number of 
interneurons originating from these structures in the adult brain and result in 
hyperexcitable networks. This hypothesis is supported by the finding that En2 
knockout mice are more susceptible to seizures. LGE contributes interneuron 
populations to the cortex and olfactory bulb, and projection neurons to the 
striatum. The striatum has been shown to be disturbed in ASD patients. Future 
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studies using the new genetic model described above will allow us to follow the 
effect of GE specific En2 knockout on interneuron populations into postnatal 
development. We will determine if the total number of interneurons is changed 
(GAD65/67) and follow specific interneuron populations using 
immunohistochemistry (PV, SOM, CR, NPY, etc.).  
 
Limitations of ChIP-seq: Lack of an En2-specific Ab has also hindered the 
identification of En2 targets in the mammalian genome. As a first step, we 
generated a V5-tagged En2 fusion protein and overexpressed it in HEK cells. 
This model system has some drawbacks, however. Overexpression of En2 at 
non-physiological levels may affect whether certain genes bind En2 in the 
absence of known En2 co-activators and so skew our results suggesting that 
these target genes may be primed but not En2 regulated unless the relevant 
associated proteins are expressed. HEK cells may also have different chromatin 
structure that is relevant to gene repression and I know the laboratory is very 
interested in determining whether this is the case for En2 as the major mode of 
its regulation is gene repression.  
  
So in summary, my research in this area has given us a roadmap to pursue what 
may be a novel role for En2 in the ganglionic eminence. Our research has 
identified what may be a specific regulatory network that links En2 to many ASD 
genes and the strategy that I pursued enabled us to make these early 
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connections that could have far-reaching effects on how we view the role of En2 
in brain disorders and in cancer. 
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CHAPTER VI: APPENDIX 
I have organized the appendix to contain experiments that I conducted during my 
dissertation research but never had the time to complete. Because they were 
interesting findings, I felt they should be included in the appendix in case other 
members of my laboratory would like to build upon these insights. 
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A1. In my dissertation, I show that En2 mRNA is expressed in tissue of the 
mouse ganglionic eminence. Here, I demonstrate that En2 is also present in 
dissociated primary cells that are kept in culture. This work further emphasizes 
that the expression of En2 studied in IUE is most likely relevant to neurons, as 
these primary cultures only contain neuronal populations, and do not contain glia. 
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Figure A1. En2 is expressed in rat primary cultures. Primary midbrain, 
hippocampal, and neocortical neurons were dissected from E18 Sprague-Dawley 
rats (Charles River Laboratories). RNA was collected, and En2 mRNA 
abundance was measured using RT-PCR. Data were normalized to cyclophilin 
expression in the same sample, and expressed as the En2/cyclophilin ratio. 
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A2-3. A previous member of our laboratory Daniel Roberts and I identified that 
SNPs in GABRA4 that are associated with ASD alter the consensus site for the 
transcription factor En2. Additionally, patients diagnosed with ASD have been 
identified to have an additional copy of GABRA4. To test the role of GABRA4 in 
neural precursor cell development and mimic the GABRA4 duplication 
documented in ASD patients, we overexpressed GABRA4 cDNAs in the GE in 
collaboration with Dr. Victor Borrell (Figure A2). Although these results are very 
preliminary, this initial study suggests that overexpression of GABRA4 alters the 
proliferation and/or migration of precursor cells in the VZ of the mouse GE. To 
test the role of endogenous GABRA4 in GE and its potential regulation by En2, I 
developed shRNA constructs for use in future IUE studies that will determine the 
effects of silencing in the background of EN2 loss (Figure A3). 
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Figure A2. Overexpression of GABRA4 in the GE results in a potential 
proliferation and/or migration defect. A. GABRA4 cDNA was cloned into the 
pCAX vector for over-expression studies in vivo. Expression was confirmed with 
western blot analysis. B. Delivery of GABRA4 to the GE (top panels) results in a 
dramatic increase in GFP+ cells in close proximity to the VZ as compared to 
control (bottom panels), with a concurrent decrease in cells that have migrated 
away from the VZ. A representative brain slice shown at both 20x (Left) and 10x 
(Right) magnification.  
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Figure A3. GABRA4 shRNA screening in HEK293 cells. A. Four GABRA4 
shRNAs (1-4) and random sequence (RS) shRNAs were designed and cloned 
into the pSilencer vector and co-transfected with GABRA4 cDNA in HEK293 
cells. Empty vector (EV) control transfection reveals A4 protein is not 
endogenously expressed in HEK293 cells (lane 1).  A4 protein expression was 
normalized to B-actin. B. A4 knockdown efficiency was quantified by 
normalization to RS-shRNA and expressed as percent control. 
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A4. Pilocarpine-induced status epilepticus (SE), which results in temporal lobe 
epilepsy (TLE) in rodents, activates the JAK/STAT pathway. In the current study, 
we evaluate whether brief exposure to a selective inhibitor of the JAK/STAT 
pathway (WP1066) early after the onset of SE affects the severity of SE or 
reduces later spontaneous seizure frequency via inhibition of STAT3-regulated 
gene transcription. Rats that received systemic WP1066 or vehicle at the onset 
of SE were continuously video-EEG monitored during SE and for one month to 
assess seizure frequency over time. Protein and/or mRNA levels for pSTAT3, 
and STAT3-regulated genes including: ICER, Gabra1, c-myc, mcl-1, cyclin D1, 
and bcl-xl were evaluated in WP1066 and vehicle-treated rats during stages of 
epileptogenesis to determine the acute effects of WP1066 administration on SE 
and chronic epilepsy. WP1066 (two 50 mg/kg doses) administered within the first 
hour after onset of SE results in transient inhibition of pSTAT3 and long-term 
reduction in spontaneous seizure frequency. WP1066 alters the severity of 
chronic epilepsy without affecting SE or cell death. Early WP1066 administration 
reduces known downstream targets of STAT3 transcription 24 h after SE 
including cyclin D1 and mcl-1 levels, known for their roles in cell-cycle 
progression and cell survival, respectively. These findings uncover a potential 
effect of the JAK/STAT pathway after brain injury that is physiologically important 
and may provide a new therapeutic target that can be harnessed for the 
prevention of epilepsy development and/or progression. This work is partially 
adapted from the following publication: (Grabenstatter, H.L., Cruz Del Angel, Y., 
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Carlsen, J., Wempe, M.F., White, A.M., Cogswell, M., Russek, S.J., & Brooks-
Kayal, A.R., 2014). 
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Figure A4. SE induces increases in STAT3-target genes. (A) Quantification of 
RT-PCR analysis of c-myc (CTRL, n = 3; SE, n = 4), cyclin D1 (CTRL, n = 3; SE, 
n = 4), bcl-2 (CTRL, n = 3; SE, n = 4), bcl-xl (CTRL, n = 3; SE,n = 4), mcl-1 
(CTRL, n = 3; SE, n = 4), VEGF (CTRL, n = 3; SE, n = 4), and ICER (CTRL, n = 
5; SE, n = 5) mRNA expression in DG 6 h after SE and (B) 24 h after SE (all 
genes, CTRL, n = 3; SE, n = 4). For RT-PCR reactions, each sample was run in 
triplicate. (A) SE caused a significant increase in ICER (p < 0.001), c-myc (p < 
0.001), and mcl-1 (p < 0.01) mRNA expression in DG of rats 6 h compared to 
CTRL. (B) SE induced significant increases in ICER (p < 0.01), c-myc (p < 0.01), 
cyclin D1 (p < 0.01), bcl-xl (p < 0.05), and mcl-1 (p < 0.01) 24 h after SE. No 
significant difference in Bcl-2 or VEGF mRNA was observed at 6 h or 24 h after 
SE relative to levels in control rats, although a trend towards an increase was 
present. Expression of mRNA was normalized to cyclophilin and expressed as 
fold change compared to controls (CTRL, defined as 1). Significant differences 
were determined using an unpaired, Student's t-test. (This work was performed in 
the Brooks-Kayal laboratory in collaboration, panel A performed by M. Cogswell)  
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